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Ab  antibody
ABMR   antibody mediated rejections 
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DSA   donor specifi c antibodies
EAE  experimental autoimmune encephalomyelitis
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EM  e# ector memory
FBS  fetal bovine serum
FDA  Food and Drug Administration
FDC  follicular dendritic cells
FOXP3  forkhead box P3 
HD  hemodialysis
HLA  human leukocyte antigens 
HPS    human pooled serum
IFNγ  interferon-γ
Ig  Immunoglobulin
8IL  interleukin
IVIG  intravenous immunoglobulin
LN  lymph nodes
mAb  monoclonal antibody
MALT  mucosa-associated lymphoid tissues
MFI  median fl uorescence intensity
MHC  major histocompatibility complex
MMF  mycophenolate mofetil
MPA  mycophenolic acid
N  naive
N  number
NA  not available
NFAT  nuclear factor of activated T cells 
NHL  non-Hodgkin’s lymphoma
NK  natural killer cell
PB  peripheral blood
PBMCs  peripheral blood mononuclear cells
PD  peritoneal dialysis
PI  propidium iodide
PRA  panel reactive antibody
pro-B  progenitor B cells
RA   rheumatoid arthritis
RAG  recombinant-activating genes
RORγt   retinoid-related orphan receptor-γt
RTX  rituximab
SD  standard diviation
SHM  somatic hypermutation
SNP  single nucleotide polymorphism
SPL  spleen cells
TACI  transmembrane activator and calcium-modulator and cytophilin  
  ligand interactor
T
CM
   central memory T cells
T
EM
   e# ector memory T cells
T
EMRA  
highly di# erentiated memory T cells
T
FH
   follicular helper T cells
Th  T helper cell
TLR  toll-like receptors
T
N  
naive T cells
TNFα  tumor necrosis factor-α
T
REGS  
regulatory T cells
Tx  transplantation
W/O  without
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General introduction and outline of the thesis 1
General introduction
The immune system is a complex interplay of cells, tissues and molecules that 
protects us from foreign invaders, such as bacteria, viruses, as well as foreign 
antigens. The immune system can be divided into two arms, the innate and the 
adaptive immune system. The innate immune system, which is present from birth, 
forms the fi rst line of defense and is designed to keep invaders out by physical 
barriers such as skin and mucosa. It consists of soluble proteins (e.g. complement) 
and a variety of cells including neutrophils, macrophages, monocytes, dendritic 
cells (DCs), and natural killer (NK) cells. Adaptive immunity refers to a specifi c 
immune response, which is acquired after exposure to a specifi c invader. Upon 
antigen exposure, an antigen-presenting cell (APC) displays the antigen to T helper 
(Th) cells which upon recognition of the antigen become activated and will initiate 
an immune response thereby activating also other immune cells, such as B cells 
and cytotoxic T cells. Activated B cells will mature to antibody-secreting plasma 
cells and activated antigen-specifi c cytotoxic T cells will directly kill the pathogens. 
This response takes a few days to develop completely. However, after exposure to 
the same antigen for a second time, this immune response will develop faster and 
be stronger due to the development of memory cells. Communication between 
the di# erent types of immune cells critically depends on production of soluble 
mediators called cytokines and chemokines.
When functioning properly, our immune system is able to identify potential 
threats, and distinguish them from the body’s own (self) healthy tissue. In renal 
transplantation, the immune system will respond to the foreign donor antigens 
present on the kidney leading to graft rejection.
Renal transplantation
In the 20th century, transplantation medicine has overcome many limitations to 
become as successful as it is today. The fi rst experimental organ transplantations 
were performed with animal organs and organs from deceased humans in the early 
1900s. After the improvement of surgical techniques, the fi rst kidney transplantation 
in humans was performed in 1950’s in the United States on a 44-year-old woman 
who received a kidney from an unrelated deceased donor (1). The donated kidney 
was rejected because no immunosuppressive therapy was available at that time. 
In 1954, the fi rst successful kidney transplantation was performed between two 
monozygotic twin brothers (2). The need for immunosuppressive therapy was 
circumvented by the genetic identity between the donor and recipient. Studies on 
the mechanisms of rejection and the use of immunosuppressive drugs resulted in 
the fi rst successful kidney transplantations between unrelated donors a few years 
later (3). 
Nowadays, kidney transplantation is the most optimal treatment for 
patients with end stage renal failure. The discovery and development of potent 
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immunosuppressive drugs that are able to prevent or treat rejection of the 
transplanted graft has greatly improved the short-term graft survival after 
transplantation, however the long-term results have lagged behind (4). The 1-year 
graft survival is over 90%, but after 10 years this is only about 60% (5). The causes 
of graft loss will be discussed in the next sections.
Transplantation immunology
Transplantation of an organ from a genetically identical individual (monozygotic 
twin) does not lead to a detrimental immune response. In contrast, transplantation 
between genetically di# erent (allogeneic) individuals will lead to rejection of the 
graft if no immunosuppressive treatment is given (6-8). Immune responses are 
triggered after recognition of the mismatched allogeneic major histocompatibility 
complex (MHC) antigens, which are also called human leukocyte antigens (HLA) (9). 
T cells play an important role in the pathogenesis of rejection via the recognition of 
these alloantigens on antigen-presenting cells (APCs). After transplantation, donor 
and recipient APCs migrate to the T-cell areas of secondary lymphoid organs. 
There, they activate naive and central memory T cells that recirculate between 
di# erent lymphoid tissues (10).
Recognition of foreign HLA by T cells can take place via three pathways: direct, 
indirect or semidirect allorecognition. In the direct pathway, intact MHC on donor 
APCs is recognized by CD4+ and CD8+ T cells of the recipient (11). The indirect 
pathway is characterized by recipient APC uptake of allogeneic donor MHC that 
has been shed through apoptosis or necrosis. This is then processed, resulting 
in presentation of donor antigens via recipient MHC class II to recipient CD4+ T 
cells (12). Semidirect recognition results from the transfer of cellular membrane 
components, including intact donor MHC, from donor APCs to recipient APCs 
through cell-cell contact or the transfer of donor exosomes that fuse with recipient 
APC cell membranes (13). Recipient APCs are then chimeric for MHC and are able 
to stimulate recipient CD4+ and CD8+ T cells. Activated antigen-specifi c T cells 
undergo clonal expansion and di# erentiation to express e# ector functions. 
The ability of our immune system to distinguish between self-antigens and 
foreign (non-self) antigens, and between harmful and harmless invaders, is critical 
to the maintenance of immune homeostasis. Failure to maintain tolerance to self- 
or harmless antigens results in te development of autoimmune or allergic diseases, 
respectively. Following organ transplantation, it is essential to control both the 
innate immune response triggered by the injured tissue and the adaptive immune 
response stimulated by mismatched donor and recipient MHC to enable long-term 
graft survival. The ultimate goal in transplantation is to achieve transplant tolerance, 
where the recipients’ immune system is unresponsive to donor alloantigens, but is 
able to response to all other antigens. 
15
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Graft rejection
In general, there are three forms of rejection: hyperacute, acute and chronic. 
Hyperacute rejection occurs within minutes after transplantation due to pre-
existing antibodies, either toward blood group antigens (ABO) (14) or foreign HLA 
(15) present on the donor kidney (donor specifi c antibodies, DSAs). This rejection 
will result in organ failure within hours after transplantation. The pre-existing 
antibodies against non-self HLA can be formed after a previous transplantation, 
blood transfusion or pregnancy (16-20). To determine if the patient has pre-existing 
antibodies against foreign HLA, several techniques are currently in use: both solid 
phase methodology as well as the classic cytotoxicity method help in defi ning the 
so-called virtual panel reactive antibody (PRA) value, based on allele frequencies in 
the population (21). To determine whether the patient has detrimental pre-existing 
DSAs, serum from the patient is incubated with lymphocytes from the donor. 
When the test is positive, the transplantation will not be performed. Due to the 
introduction of these tests, hyperacute rejection is very uncommon (22). 
Acute rejections can be classifi ed as predominantly T-cell mediated (cellular), 
mainly antibody-mediated (humoral), or mixed types of rejection. Acute cellular 
rejection can occur at any time after transplantation, although it is most commonly 
seen within the fi rst six months after transplantation. T cells play a central role 
in acute cellular rejection and the magnitude of the immune response is likely 
dependent on the frequency of e# ector T-cell precursors that recognize donor 
HLA molecules via the direct pathway of allorecognition (23, 24). Patients can 
also experience an acute humoral rejection in case they have been sensitized to 
a certain antigen but have undetectable DSAs levels at time of transplantation 
(25). After transplantation, donor-specifi c memory B cells can rapidly transform to 
plasma cells that produce antibodies against the donor kidney leading to rejection 
(26). Accordingly, patients with a high PRA value, referred to as sensitized, have a 
higher risk of developing rejection (27, 28). To reduce the incidence of antibody-
mediated rejection in sensitized patients there are nowadays di# erent treatment 
options (29).
Finally, chronic rejection or chronic allograft dysfunction (CAD) limits the long-
term success of renal transplantation (30). It occurs years after transplantation, 
particularly by repeated infl ammation and can be caused by a number of processes, 
both immunological and non-immunological (4, 31, 32). The origin and quality of the 
kidney, the degree of ischemia-reperfusion injury, but also the use of calcineurin-
inhibitors are examples of non-immunological factors that might contribute 
to CAD. On the other hand, recipients’ T cells can recognize the alloantigen via 
the indirect pathway and initiate an immune responses associated with antibody 
formation against the kidney leading to a chronic type of humoral rejection (33). 
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T-cell di! erentiation and regulation
To achieve a state of immunological tolerance, the immune system has a variety 
of built-in mechanisms. The fi rst line of self-tolerance is the elimination of self-
reactive T-cell clones in the thymus, referred to as central tolerance induction 
(34). However, some self-reactive T cells escape this negative selection process 
and appear in the periphery. There are at least three mechanisms of peripheral 
tolerance: death of self-reactive T cells via negative selection, induction of anergy 
(unresponsiveness) and the induction of regulatory T cells (T
REGS
). There are 
naturally occurring and acquired T
REGS
, which regulate e# ector T-cell responses 
either directly through cell-cell contact, the production of immunosuppressive 
cytokines, or cytokine deprivation and/or indirectly by targeting dendritic cells 
(DCs) (35). Naturally occurring CD4+ T
REGS
 can be characterized by the constitutive 
expression of the IL-2 receptor -chain (CD25), the transcription factor forkhead 
box P3 (FOXP3), and the absence of the IL-7 receptor α-chain (CD127) (36). In 
contrast, conventional CD4+ T cells have a low expression of CD25, are negative 
for FOXP3, and show high expression of CD127. However, upon activation CD4+ 
T cells resemble the phenotype of T
REGS
, which complicates the identifi cation of 
T
REGS
 (37). 
T-cell subsets
Once naive T cells (T
N
) have left the thymus, they recirculate through the blood 
and secondary lymphoid organs in search of antigens presented by APCs. T
N
 cells 
are defi ned by the co-expression of CD45RA, the lymph node homing markers 
L-selectin (CD62L) and CCR7, and the co-stimulatory receptors CD27 and CD28 
(38, 39). When T
N
 cells encounter their specifi c antigen, they get activated and 
subsequently proliferate and di# erentiate into e# ector and memory T cells (40). 
E# ector T cells can enter peripheral tissues where they recognize antigens and 
generate infl ammatory reactions. Protective memory is mediated by e# ector 
memory T cells (T
EM
) that are able to migrate to infl amed peripheral tissues and 
display immediate e# ector function. In contrast, central memory T cells (T
CM
) home 
to T-cell areas of secondary lymphoid organs, where antigenic stimulation leads 
to rapid proliferation and di# erentiation into e# ector cells. T
CM
 cells, like T
N
 cells 
co-express CD62L, CCR7, and CD27, but they have become CD45RO-positive 
and CD45RA-negative. The expression of CD45RA and CD45RO are regulated 
in a reciprocal manner: in the thymus T cells express CD45RO, which is converted 
to CD45RA at time of emigration to the periphery, and then switched back to 
CD45RO after antigen stimulation (41). T
EM
 cells have lost their expression of CCR7 
and CD27, and are heterogeneous for CD62L expression (42). 
CD4+ T
N
 can di# erentiate into a variety of e# ector subsets, including T helper 
1 (Th1), Th2, Th17, and follicular helper T (T
FH
) cells, which have di# erent roles in 
further activation of the immune system and the protection against pathogens 
(43). After activation of T
N
 by APCs, their di# erentiation is regulated predominantly 
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by the cytokines in the microenvironment (44). IL-12 produced by innate immune 
cells as well as IFNγ produced by both NK and T cells polarize cells toward Th1 
di# erentiation through activation of T box transcription factor T-bet (45). Th1 cells 
are characterized by the production of IFNγ and IL-2, and are involved in cellular 
immunity against intracellular microorganisms. Th2 cells produce IL-4, IL-5 and IL-
13 and are required for humoral immunity to control infections with helminths and 
other extracellular pathogens. Th2 cell di# erentiation requires the activation of 
the transcription factor GATA3 downstream of IL-4 (46). Th17 cells produce IL-17 
and IL-22 and are needed to protect against extracellular microbes. In addition, 
they are associated with many infl ammatory disorders. Th17 cell di# erentiation 
requires retinoid-related orphan receptor (ROR)γt, a transcription factor that is 
induced by the proinfl ammatory cytokines IL-6, IL-21, and IL-23 (47). T
FH
 cells are 
a subset of helper T cells that regulate the maturation of B cells in the germinal 
centers through the expression of CD40 ligand (CD40L) and the production of 
IL-21 (48). The various subsets of e# ector T cells can also be characterized by the 
expression of di# erent chemokine receptors. The B cell-follicle-homing receptor 
CXCR5 identifi es T
FH 
cells, whereas CXCR3 is mainly expressed on Th1 cells. In 
addition, CCR4 is expressed on Th2 cells, whereas Th17 cells are found within the 
CCR6+  memory T cells (49). The ligands for these receptors are infl ammatory 
chemokines, which are expressed in infl amed tissues and mediate the selective 
recruitment of di# erent types of e# ector cells (50). 
B cells in renal transplantation
For years, the pathogenic role of B cells was thought to be limited to antibody 
production. The deleterious e# ects of pre-existing antibodies directed against 
HLA are well known. The presence of donor-specifi c anti-HLA antibodies before 
transplantation is associated with poorer allograft survival (28). However, additional 
functions of B cells have been shown in the pathogenesis of autoimmune diseases 
(51, 52), and are also increasingly recognized in the rejection of organ grafts (53, 
54). After transplantation, B cells play a central role in humoral immunity via the 
production of antibodies, but they can also induce an immune response by acting 
as professional APCs (55), or by the production of various cytokines (Figure 1). As 
professional APCs, B cells can e"  ciently stimulate T cells and allow the optimal 
development of memory CD4+ T cells (56, 57). Studies in mice showed that B cells 
are required for systemic T-cell responses when antigen concentrations are low 
(58). Furthermore, B cells produce cytokines such as IL-6, IL-10 and IFNγ, which 
have regulatory e# ects on DCs and other lymphocytes (59). In animal models, 
cytokines produced by B cells are known to guide the di# erentiation of naive CD4+ 
T cells into Th1 or Th2 subsets (60), suggesting that the production of cytokines 
by B cells can regulate immune responses. B cells can both generate and respond 
to chemotactic factors responsible for leukocyte migration and therefore play a 
major role in mediating infl ammatory cell-infi ltration processes (61). In addition, 
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B cells with regulatory functions have been described (62, 63). Evidence for a 
regulatory e# ect of B cells in autoimmune diseases was fi rst provided by Wolf et 
al. (64) who observed that mice lacking B cells su# ered from a severe and chronic 
form of experimental autoimmune encephalomyelitis (EAE). Research on the 
underlying mechanism revealed that B cells regulate this autoimmune disease via 
the production of IL-10 (65). A suppressive function of IL-10 producing B cells has 
also been demonstrated in mouse models for infl ammatory bowel disease (66) 
and collagen-induced arthritis (67). Therefore, they were named regulatory B cells 
(B
REGS
) (66). More recently, regulatory B cells have been identifi ed in humans too 
(68). Their regulatory function appears to be mainly mediated by the production 
of IL-10, which inhibits proinfl ammatory cytokines and supports T
REG
 di# erentiation 
(69). There is controversy regarding the surface markers used to characterize B
REGS
. 
Blair et al. describe CD24hiCD38hi B cells with regulatory capacities, which are 
functionally impaired in patients with systemic lupus erythematosus (70). Others 
indentify B
REGS
 as CD24hiCD27+ (71) or as CD1dhi with or without co-expression of 
CD5 (72, 73). Interestingly, operationally tolerant renal transplant patients, who 
T cell
Antigen 
presentation
Antibody
production
Costimulation
Activation
Expansion
Memory
Cytokines
T
REG
IL-10
IL-10
B cellT cell
DC
plasma
cell
Figure 1. B-cell functions.
B cells can induce immune responses by producing antibodies, secreting cytokines, or 
presenting antigens to T cells. In addition, they can regulate immune responses by secreting 
IL-10 which directly suppresses the activation and expansion of T cells, and indirectly via the 
di# erentiation of regulatory T cells (T
REGS
) and suppression of dendritic cells (DCs).
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have stable graft function despite receiving no immunosuppression for at least 1 
year, have more B cells, including CD24hiCD38hi B cells, compared to patients on 
immunosuppression (74-76). 
B-cell development
It is a long and hard way for a B-cell precursor to become a mature B cell. Only a 
small percentage of the B-cell precursors survive the maturation process. B-cell 
development takes places in several stages which are localized in di# erent tissues: 
B-cell precursors di# erentiate from common lymphoid progenitors (CLP) to naive 
mature B cells in the bone marrow (77, 78) and the subsequent maturation to 
memory/e# ector cells takes place in secondary lymphoid tissues (lymph nodes, 
spleen, mucosa-associated lymphoid tissues (MALT)), and bone marrow (79, 80) 
(Figure 2). B cells constantly circulate in blood and lymphoid tissue until they 
encounter an antigen. Activated naive B cells generate antibody secreting plasma 
cells and memory B cells in response to a specifi c antigen. 
B-cell di! erentiation and maturation
B cells di# erentiate from CLPs through various precursor stages in the bone 
marrow (81). Pre-B cells arise from progenitor (pro-B) cells that express neither 
the pre-BCR nor surface Immunoglobulin (Ig) (Figure 2). During the development 
of the pre-B-cell, the assembly of a correct BCR takes place in the bone marrow. 
The stromal cells in the bone marrow, which are crucial for the development of 
the pro- to pre-B cells, provide adhesive contacts and soluble factors like stem 
cell factor, CXCL12 and the cytokine BAFF (B cell-activating factor belonging to 
the TNF family) (82). Recombinant-activating genes-1 (RAG-1) and RAG-2 are 
enzymes crucial for the development of the BCR, and without these enzymes 
no lymphocytes can develop. If the B-cell fails to express the receptor, the cell is 
forced to undergo apoptosis. However, the cell can save itself by performing VDJ 
gene rearrangement of the BCR and if this is successful the B-cell can continue 
its development to become an immature B-cell. The receptor on the cell surface 
of the immature B-cell is a complete IgM molecule, which is important for the 
negative selection. An immature B cell that expresses an IgM, which strongly binds 
self-molecules, is eliminated via apoptosis. If that is the case, the cell gets a second 
chance to change its IgM molecule via a process called receptor editing, and if 
this is successful the cell survives. Besides apoptosis and gene rearrangement, 
the developing B cell has two other potential fates: a soluble self-molecule can 
induce anergy in the cell that eventually dies, and low-a"  nity non-crosslinking 
self-molecules can induce a clonally ignorant cell (which means that the antigen 
is present, but it will not be able to activate the cell). The B-cell that does not bind 
self-molecules continues its development as a transitional B-cell into a naive mature 
B-cell. The transitional B-cell expresses both IgM and IgD (83) on its cell surface 
and migrates through the blood to peripheral secondary lymphoid organs where 
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Figure 2. B-cell di! erentiation.
Cell-surface expression during B-cell development in the bone marrow, periphery, lymph 
nodes, spleen and mucosa-associated lymphoid tissues (MALT). B cells develop from 
common lymphocyte progenitors (CLP) through various precursor stages in the bone 
marrow. After obtaining a functional B-cell receptor (BCR) they migrate to the periphery 
and become transitional B cells. Upon antigen encounter they mature and migrate to 
lymphoid tissues. Depending on the type of antigen, a T-cell dependent (TD) or T-cell 
independent (TI) B-cell response is initiated, resulting in the development of memory B 
cells and plasma cells with high a"  nity BCR due to somatic hypermutation (SHM) and class 
switch recombination (CSR).Adapted from Perez-Andres et al. (100)  and van den Burg et 
al. (177).
CLP pro-B pre-B-I pre-B-II immature
B-cell
transitional
B-cell
naive
mature
B-cell
Bone marrow Periphery
VDJ recombination
CD19
CD20
IgD
CD27
IgM
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the fi nal maturation occurs. Once again, the B-cell is tested for self-reactivity and 
binding of self-antigens will lead to cell death. If the B-cell survives this fi nal test, 
it has become a mature naive B-cell, which is ready to enter the circulation in the 
search of pathogens. Similar to the early stages in the bone marrow, this phase of 
development in the spleen also requires the presence of a functional BCR and of a 
supporting microenvironment. 
B-cell activation
As described in the previous section, transitional B cells are the earliest bone 
marrow emigrants. They rapidly di# erentiate into naive mature B cells in the 
periphery, which form the majority of B cells in peripheral blood. Naive mature B 
centroblast centrocyte
Lymphoid tissues
germinal center
Periphery Bone marrow
MALT
Spleen
memory
B-cell
plasmablast/
plasma cell
plasma cell
SHM
CSR
marginal zone
B-cell
TI
TD
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cells are short-lived and their survival is dependent on the interaction of BAFF and 
its receptor (BAFF-R) (84, 85). During B-cell maturation BAFF-R is expressed fi rst 
by immature B cells in the bone marrow (86). 
Most B-cell responses are T-cell dependent (87, 88). Upon antigen recognition 
with their specifi c BCR, naive mature B cells internalize the antigen which enters 
the MHC class II presentation pathway (89). After a subsequent co-stimulatory 
signal by T helper cells that recognize a MHC-peptide complex on the B-cell 
surface, the B cell is activated resulting in immunoglobulin class switch, memory 
B-cell and plasma cell formation, and antibody production (90, 91). This activation 
usually occurs in the T-cell zone of lymphoid organs by interaction with T helper 
cells. Next, B cells migrate into B-cell follicles, proliferate and establish germinal 
centers (92, 93). In these germinal centers, centroblasts form a network with 
follicular dendritic cells (FDCs), which present antigen to stimulate proliferation 
and survival of antigen-specifi c B cells (94). The proliferating centroblasts undergo 
somatic hypermutation (SHM), which involves random mutations in the genes 
encoding for Ig, giving rise to B cells with slightly di# erent antigen-a"  nities 
(95). The centroblasts become resting centrocytes and can undergo class switch 
recombination (CSR). Only B cells that have gained an increased a"  nity for the 
antigen will survive after interaction with FDCs and germinal center T cells, the T
FH
 
(96). CSR recombination is dependent on the enzyme activation-induced cytidine 
deaminase (AID), which introduces single-strand DNA mutations in Ig genes (97, 
98). Finally, B cells develop into memory B cells and plasma cells. Plasma cells 
are fully di# erentiated B cells that have lost their BCR and are only capable of 
producing large amounts of antibodies (99). Plasma cells are found mainly in the 
bone marrow, spleen and MALT (100). 
B-cell responses can also occur independently of T cells in the marginal zone of 
the spleen or in the lamina propria of the gut (101, 102). T-cell independent antigens, 
which are represented predominantly by polysaccharide antigens, induce antibody 
responses in the absence of T-cell help (103). Alternatively, B cells can recognize 
antigens on pathogens, via toll-like receptors (TLRs) (104). 
B-cell subsets and their surface markers
B cells can be characterized using a variety of molecules. Committed B cells 
induce the expression of the pan-B-cell marker CD19, which regulates intracellular 
signal transduction and is predominantly important in B-cell development (105, 
106). CD20 is expressed on the majority of B cells from pre-B-cell stage, but is 
lost after di# erentiation into plasma cells (107). CD24 and CD38 are associated 
with intracellular signaling and upregulated during B-cell development in the bone 
marrow and the germinal center. CD24 is a cell-adhesion molecule and seems to 
be associated with B-cell activation via pattern recognition receptors, such as TLRs 
(108), while CD38 is a transmembrane glycoprotein that catalyzes the synthesis and 
hydrolysis of cyclic ADP-ribose involved in calcium signaling and signal transduction 
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(109). CD27 is a glycoprotein and a member of the tumor necrosis factor (TNF) 
receptor family (110), and was found to be a useful marker for B cells that have 
undergone somatic hypermutation and therefore a marker for memory B cells (111).
B-cell subsets can be identifi ed using fl ow cytometry using various classifi cation 
schemes, of which the IgD/CD27 (112) and the IgD/CD38 (113) classifi cation are 
most commonly used. Using the IgD/CD27 classifi cation, B cells can be divided 
into four subsets: naïve (IgD+CD27-); unswitched memory (IgD+CD27+); switched 
memory (IgD-CD27+) and double-negative (IgD-CD27-). The expression level of 
IgD and CD38 distinguishes mature B (Bm) cells into sequential stages from Bm1 
through Bm5 and was fi rst used to characterize B cells in secondary lymphoid 
organs. Once activated in secondary lymphoid organs, naive Bm1 (IgD+CD38-) 
cells become Bm2 (IgD+CD38+), and di# erentiate into germinal center Bm2’ cells 
(IgD+CD38++). There they evolve into Bm3 centroblasts and Bm4 centrocytes 
(together IgD-CD38++), which di# erentiate into either plasma cells (early Bm5; IgD-
CD38+) or memory B cells (late Bm5; IgD-CD38-). Inside the germinal centers, a 
few cells of each subset escape into the circulation (114). Finally, CD24 and CD38 
are especially used to characterize B
REGS
, which are believed to be part of the 
transitional B-cell population (CD24++CD38++) (70), while mature and memory B 
cells are defi ned as CD24+CD38+ and CD24++CD38-, respectively. Depending on 
the situation a di# erent B-cell classifi cation scheme might be used to characterize 
B cells.
B-cell cytokines
The cytokines that regulate human B-cell development are incompletely 
understood (115). The most important cytokines for B cells are BAFF, IL-2, IL-4, IL-
6, IL-10 and IL-21. BAFF is a cell survival and maturation factor for B cells (116, 117), 
and overproduction is associated with systemic autoimmune disease (118). BAFF is 
also known as BLys (119) and also binds to 2 other receptors on B cells, namely the 
transmembrane activator and calcium-modulator and cytophilin ligand interactor 
(TACI) and the B-cell maturation antigen (BCMA) (120). Activated B cells express 
CD25 (IL-2 receptor α-chain) and IL-2 is involved in the di# erentiation of B cells but 
it does not infl uence the isotype switch (121). IL-2 is mainly produced by activated 
T cells. IL-4 is produced mainly by Th2 cells, which are the biologically most active 
helper cells for B cells and also secrete IL-6. IL-4 promotes the proliferation and 
di# erentiation of activated B cells as wells as the expression of MHC class II antigens 
and low a"  nity IgE receptors on resting B cells. IL-4 predominantly directs naive 
B cells to express surface IgG1, with fewer cells expressing IgG2 and IgG3, but 
is unable to induce secretion of any IgG subclasses (122). IL-6 stimulates B cells 
to proliferate, di# erentiate, and to secrete immunoglobulin. However, it does not 
infl uence the isotype switch. The main sources of IL-6 production are macrophages, 
fi broblasts and endothelial cells, although B and T cells also can produce IL-6. IL-10 
enhances B-cell survival, proliferation and di# erentiation. It also drives the isotype 
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switch to IgG1-3 and IgA, and together with IL-4 to IgG4 and IgE. IL-10 is produced 
by T cells, NK cells, B cells, and monocytes. IL-21 provides co-stimulation to B cells, 
induces plasma cell di# erentiation, immunoglobulin secretion and class switch 
(123, 124). IL-21 is produced by activated peripheral T cells and spontaneously by 
CXCR5+ follicular helper T cells (48, 125, 126). Furthermore, at least 10 distinct 
transcription factors regulate the early stages of B-cell development (127). The 
transcriptional factor Pax5 is important for commitment of lymphoid progenitors 
to the B lymphocyte lineage. It fulfi lls a dual role by inhibiting non-B lineage genes 
and simultaneously activating B-cell lineage-specifi c genes (128). 
Immunosuppressive drugs
Every transplant recipient is treated with immunosuppressive drugs to reduce the 
chance of rejection. Generally, these immunosuppressive drugs must be taken for 
the rest of the patients’ life. Today, a wide variety of immunosuppressive drugs is 
available, each interfering with di# erent steps in the immune response (10, 129). 
The initial immunosuppressive therapy after transplantation usually consists of a 
combination of a calcineurin-inhibitor, a proliferation inhibitor, and corticosteroids 
(Figure 3). Depending on the transplant center, patients also receive induction 
therapy in the form of T-cell depleting antibodies (e.g. anti-thymocyte globulin, ATG) 
or antibodies against CD25 (130, 131). Most immunosuppressive drugs mainly target 
the T-cell response, while B-cell activation and subsequent antibody formation is 
more di"  cult to suppress. About 15-20% of renal transplant recipients undergo 
one or more acute rejection episodes, which can usually e# ectively be treated with 
additional immunosuppressive drugs. Cellular rejection is mostly treated with high 
dose of corticosteroids. In case of unresponsiveness to corticosteroids, ATG is 
given, which reduces the number of T cells. Treatment of humoral rejection is more 
di"  cult. Protocols using plasmapheresis, intravenous immunoglobulin (IVIG) (132), 
B-cell (133, 134) and plasma cell depleting (135) agents have all been described. 
The use of powerful immunosuppressive drugs in organ transplantation has 
greatly improved the outcome, but is associated with the occurrence of many 
side e# ects such as increased susceptibility to infections (136), increased tumor 
incidence (137) drug toxicity (138) and cardiovascular disease (139). Therefore, 
minimizing the dose of immunosuppressive drugs is essential and more specifi c 
agents are needed (140, 141). 
Calcineurin-inhibitors
Cyclosporin and tacrolimus (FK506) are powerful immunosuppressive drugs which 
inhibit T-cell activation via the inhibition of calcineurin. Upon T-cell activation via 
the TCR, the intracellular Ca2+ levels are increased and the phosphatase calcineurin 
gets activated. Subsequently, calcineurin dephosphorylates the nuclear factor of 
activated T cells (NFAT) enabling it to enter the nucleus and to bind to the promotor 
of several genes, including the IL-2 gene. Cyclosporin binds to cyclophilin (142), 
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and tacrolimus to FK506-binding protein (FKBP-12) (143) thereby preventing the 
activation of calcineurin and the downstream signal transduction. The blockade of 
cytokine gene transcription impairs the activation and proliferation of T cells. 
Tacrolimus has been associated with a lower incidence of acute rejection 
compared to cyclosporin, but one year graft survival rates are comparable with 
both drugs (144). An advantage of tacrolimus over cyclosporin is that is associated 
with a lower incidence of hypertention and hyperliopidemia (145). An important 
disadvantage of tacrolimus is its diabetogenic potential.
Corticosteroids
Corticosteroids, such as prednisolone, are used in transplantation as maintenance 
therapy as well as in the treatment of acute rejection (146). Upon binding to 
intracellular glucocorticoid receptors, the complex is translocated to the nucleus 
where it inhibits the transcription of several genes (147), including proinfl ammatory 
cytokines (148). Corticosteroids are widely used due to their anti-infl ammatory 
e# ects. 
Targets of commonly used immunosuppressive drugs in renal 
transplantation.
Antigen-specifi c T-cell receptor activation results in calcineurin activation, which can 
be inhibited by cyclosporin and tacrolimus. Calcineurin dephosphorylates nuclear factor 
of activated T cells (NFAT) enabling it to enter the nucleus binding to the promotor of 
several genes, including the IL-2 gene. Corticosteroids inhibit the transcription of di# erent 
cytokines. Sirolimus acts on cytokine-signal transduction. The anti-proliferative agents 
mycophenolate mofetil (MMF) and azathioproine interrupt DNA replication by inhibiting 
purine synthesis.
T cell
Antigen Costimulation
Calcineurin
Nucleus
NFAT IL-2 gene
promotor
IL-2
IL-2R
G1 S
G2M
cell
cycle
purine
syntesis
Tacrolimus
Cyclosporin
Steroids
MMF
Azathioprine
Sirolimus
Antigen presenting cell
Figure 3.
26
Chapter 1
Proliferation inhibitors 
Anti-proliferative immunosuppressive drugs include mycophenolate mofetil 
(MMF) and azathioprine. MMF is converted to the active form mycophenolic acid 
(MPA), which inhibits an enzyme essential for de novo purine synthesis (149). This 
e# ect is rather specifi c for lymphocytes because other cells can obtain purines 
by the salvage pathway (150). Azathioprine is metabolized to 6-mercaptopurine 
(6-MP) and then converted to 6-thioguanine (6TG) (151). These compounds are 
incorporated in the DNA and prevent replication. 
Monoclonal antibodies
The development of monoclonal antibodies (mAbs), directed against specifi c cell 
types or markers, has allowed more specifi c targeting of cells and their signaling 
pathways. MAbs are widely used in the treatment of malignancies, transplant 
rejections, as well as a range of autoimmune diseases such as rheumatoid arthritis. 
In transplantation, mAbs used include basiliximab, alemtuzumab and rituximab. 
Basiliximab is a chimeric mouse-human monoclonal antibody directed against 
the α-chain of the IL-2 receptor (CD25). Treatment with this agent does not 
result in depletion of CD25-positive cells but prevents full T-cell activation (152). 
Alemtuzumab (Campath-1H) is a humanized monoclonal depleting antibody directed 
against CD52 expressed on T cells, B cells, NK cells, monocytes, macrophages and 
DCs (153, 154). 
Although treatment with mAbs is usually well tolerated, administration with 
some mAbs can be associated with acute infusion reactions, caused by various 
mechanisms including cytokine release syndrome (CRS) (155). Treatment with 
alemtuzumab leads to a fi rst-dose CRS with elevated levels of IL-6, TNFα, and IFNγ, 
which appeared to be dependent on Fc-receptor (CD16) ligation on NK cells (156). 
After treatment with rituximab, especially patients with high B-cell counts such 
as those with a B-cell lymphoma, can develop a CRS (157). It is unknown which 
cells are responsible for this cytokine release and whether the cytokine release 
infl uences clinical outcome in terms of rejection or graft survival. 
Rituximab
Rituximab (RTX) is a chimeric IgG1 monoclonal antibody that recognizes CD20 
expressed on human B cells. This molecule is expressed throughout di# erentiation, 
but is lost during the fi nal maturation of B cells into plasma cells (107; Figure 4). The 
antibody is constructed in such a way that the binding regions from a murine anti-
human CD20 antibody, consisting of variable regions of immunoglobulin heavy and 
light chains, are fused to human IgG1 heavy-chain and human kappa light-chain 
constant regions. The Fc portion from human IgG1 was selected for its ability 
to fi x complement and activate antibody-dependent cellular cytotoxicity (107). 
RTX was the fi rst monoclonal antibody that was approved by the Food and Drug 
Administration (FDA) for the treatment of cancer, specifi cally B-cell non-Hodgkin’s 
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lymphoma (NHL) (158, 159). Since then it has been widely used in the treatment 
of malignancies, autoimmune diseases and in renal transplantation. RTX depletes 
B cells in three ways: through antibody-dependent cellular cytotoxicity (ADCC), 
complement-dependent cytotoxicity (CDC) and apoptosis (160). Although the 
clinical e# ectiveness of RTX is no longer in question, the exact contribution of 
each of these processes in vivo remains unclear. It is assumed that ADCC is the 
most dominant player, followed by CDC. Cell death through apoptosis is thought to 
be minimally involved (160-163). Recently, the mechanism of anti-CD20-mediated 
B-cell depletion was described in mice (164). Using intravital imaging, the authors 
revealed that after treatment of MAFIA mice with mouse anti-CD20 Ab, the 
Kup# er cells in the liver are responsible for the abrupt arrest and engulfment of 
B cells.
CD20 is a non-glycosylated transmembrane protein of 35 kDa (165) without 
a known ligand. It is expressed on the surface of human B cells and also weakly on 
a small subset of T cells (166). The CD20 protein is expressed at high levels, is not 
shed from the cell surface, and does not internalize upon antibody binding (167), 
which makes it an ideal target for the recruitment of e# ector cells expressing Fcγ 
receptors (168). In vitro studies suggest that CD20 is involved in the regulation of 
Ca2+ infl uxes across the plasma membrane (169) and in the regulation of B-cell 
activation and proliferation (170). Although treatment with CD20 mAbs depletes 
normal and malignant B cells in vivo, mAb crosslinking of CD20 alters Ca2+ 
B cell
cell
membrane
CD20 protein
Antigen binding site
Rituximab
Figure 4. Rituximab.
Rituximab targets B cells by binding specifi cally to CD20 on the cell surface.
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homeostasis and could lead to apoptosis in vitro (171). The CD20 gene is strongly 
conserved between mouse and human. CD20-defi cient mice were found to have 
normal B cells, however the CD19-induced calcium responses were reduced 
(172). More recently, Kuijpers et al. described that CD20 has a central role in the 
generation of T-cell-independent antibody responses (173). The observed CD20 
defi ciency in a 4 year old girl did not a# ect the di# erentiation of precursor B cells 
in the bone marrow, but did reveal a severe reduction of class-switched memory 
(IgD-CD27+) B cells. 
Aim and outline of this thesis 
Short-term allograft loss due to acute rejection has almost been eliminated by the 
use of e# ective immunosuppressive drugs, while long-term allograft survival can 
still be improved. Chronic rejection is one of the major causes of long-term allograft 
loss. T cells play a central role in the pathogenesis of rejection and therefore most 
immunosuppressive drugs are directed against alloreactive T cells. However, B cells 
can also play a major role in allograft rejection. Increased attention for the role 
of antibodies and B cells in the pathogenesis of rejection has been elicited by the 
association between the presence of pre-transplant anti-HLA antibodies in serum 
and B-cell clusters in renal allografts during acute rejection on the one hand and 
an increased risk for allograft failure on the other hand (28; 174). It is currently well 
recognized that B cells are not only involved in antibody production, but can also 
act as professional antigen presenting cells or produce of various cytokines leading 
to an increased immune response. Accordingly, anti-B-cell therapy has been shown 
to be e# ective in chronic infl ammatory diseases mediated by T and B cells, such as 
rheumatoid arthritis (175) and multiple sclerosis (176). Consequently, depletion of 
B cells might be an important novel strategy to reduce the incidence of allograft 
rejection in renal transplant patients. The aim of this thesis is to investigate the 
e# ectiveness of the B-cell depleting agent RTX as induction therapy after renal 
transplantation and to explore the e# ects of RTX beyond peripheral B-cell 
depletion.
In chapter 2, we evaluated the e"  cacy and safety of RTX when added to 
standard triple immunosuppressive therapy after renal transplantation in a double-
blind, placebo-controlled study. The peripheral depletion of B cells induced by RTX 
is followed by a repopulation phase during which a change in the subset distribution 
of B cells may occur. In addition, given the close interaction between B and T cells, 
B-cell depletion might also change the T-cell repertoire. Our study population 
provided the unique opportunity to perform a detailed study on the e# ects of 
RTX on the time course of phenotype and function of peripheral B and T cells 
in a homogeneous group of renal transplant patients who did not experience a 
rejection episode or CMV infection (chapter 3). 
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RTX has been used since 1993 to treat patients with malignant B-cells 
lymphoma, however still little is known about its e# ects on primary human B cells. 
Therefore, we studied the direct e# ects of RTX on the proliferation, activation and 
di# erentiation of purifi ed peripheral blood B cells of healthy donors (chapter 4). 
From other studies, we learned that a single dose of RTX induces a nearly complete 
B-cell depletion in peripheral blood, however there often remains a residual B-cell 
population in secondary lymphoid organs. To study the functional properties of this 
non-depleted, but potentially modulated B cells that remain present in secondary 
lymphoid organs after treatment with RTX, we collected lymph nodes during renal 
transplant surgery in patients who received RTX 4 weeks earlier in preparation 
for an ABO-incompatible renal transplantation. In chapter 5 we compared the 
phenotypic and functional properties of B cells isolated from lymph nodes of 
RTX-treated patients to B cells isolated from lymph nodes collected from renal 
transplant patients not treated with RTX. In chapter 6, we focused on cytokine 
release which is known to be associated with anti-T-cell therapy and might also 
accompany the administration of RTX when given as induction therapy during renal 
transplantation. We examined the levels of various pro- and anti-infl ammatory 
cytokines and chemokines after the start of the RTX infusion and compared this 
to levels in placebo-treated patients. Moreover, we performed in vitro studies to 
decipher the source of the cytokines that were released.
Finally, in chapter 7 the fi ndings reported in this thesis are summarized and 
discussed, and future perspectives are outlined.
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Abstract
Background. A variety of data indicates a role for B cells in acute renal allograft 
rejection. We evaluated the e"  cacy and safety of the anti-B-cell antibody rituximab 
when added to standard immunosuppression.
Methods. In a single centre, double-blind, placebo-controlled study, 280 adult 
renal transplant patients were randomized between a single dose of rituximab (375 
mg/m2) or placebo during transplant surgery. Patients were stratifi ed according 
to panel-reactive antibody (PRA) value and rank number of transplantation. 
Maintenance immunosuppression consisted of tacrolimus, mycophenolate 
mofetil, and steroids. The primary end point was the incidence of biopsy proven 
acute rejection (BPAR) within six months after transplantation. Secondary end 
points included the incidence of infections and malignancies within 24 months, 
graft function, and patient and graft survival. The study is registered with the 
ClinicalTrials.gov Register, number NCT00565331.
Findings. The incidence of BPAR was comparable between rituximab-treated 
(23/138, 16.7%) and placebo-treated patients (30/142, 21.2%, P=0.25 by log-rank 
test). Immunologically high risk patients (PRA >6% or re-transplant) receiving 
placebo had a signifi cantly higher incidence of rejection (13/34, 38.2%) compared 
to other treatment groups (rituximab-treated immunologically high risk patients, 
and rituximab- or placebo treated immunologically low risk (PRA ≤6% or fi rst 
transplant) patients (17.9%, 16.4%, and 15.7%, P=0.004 by log-rank test). Severity 
of rejection, patient and graft survival, and graft function, were not infl uenced by 
rituximab. Neutropenia (<1.5 x 109/L) occurred more frequently in rituximab-treated 
patients (24.3% vs. 2.2%, P<0.001). After 24 months, the cumulative incidence of 
infections and malignancies was comparable. 
Interpretation. A single dose of rituximab added to standard immunosuppression 
may reduce the incidence of BPAR in immunologically high risk patients. Treatment 
with rituximab is safe; the association with a higher incidence of neutropenia did 
not lead to more infections. 
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Introduction
With the current immunosuppressive treatment consisting of a calcineurin inhibitor, 
mycophenolate mofetil, and prednisolone, the incidence of acute rejection after 
renal transplantation is acceptably low. Since acute rejection is one of the main 
predictors of chronic transplant glomerulopathy (1).  Further lowering of incidence 
of acute rejection, e.g. by the additional use of IL-2 receptor antagonists  or 
polyclonal anti-T-cell antibodies, might improve long term outcome (2, 3). Increased 
attention for the role of antibodies and B cells in acute rejection has been elicited 
by the negative prognostic impact of donor-specifi c anti-HLA antibodies (4), the 
presence of B-cell clusters in biopsies of patients with severe rejection (5), as well as 
the frequent fi nding of capillary deposition of C4d in patients with acute rejection. 
In addition, anti-B-cell therapy has been shown to be e# ective in diseases that were 
considered to be mainly T-cell driven, like rheumatoid arthritis (6, 7).
Based on these considerations, we chose to investigate the e# ectiveness of 
the anti-B-cell monoclonal antibody rituximab (RTX) as induction therapy after 
renal transplantation. RTX induces long-lasting B-cell depletion in peripheral blood 
with limited short- and long-term toxicity (8, 9). Most experience with RTX in renal 
transplantation stems from its use in ABO-incompatible transplantation, where low 
rates of acute rejection were observed (10). At time of initiation of the current 
study, no data were available on the e# ect of RTX on acute rejection in ABO-
compatible transplantation. We tested the hypothesis that adding a single dose of 
RTX to an immunosuppressive regimen consisting of tacrolimus, mycophenolate 
mofetil and steroids would reduce the incidence of biopsy proven acute renal 
allograft rejection (BPAR). 
Methods
Study design and patients 
We performed a single centre, randomized, stratifi ed, double-blind, placebo-
controlled study at the Radboud University Medical Centre, Nijmegen, The 
Netherlands, from December 2007 to June 2012. All patients of 18 years or older 
who were scheduled to receive a renal allograft from either a living or deceased 
ABO compatible donor were screened for eligibility by the nephrologist on call. 
To be included, the immunosuppressive treatment had to consist of a combination 
of tacrolimus, mycophenolate mofetil, and prednisolone. Induction therapy with 
IL-2 receptor antagonists or anti T-cell antibodies was not part of our standard 
therapy, and was not allowed for this study. Other exclusion criteria were: a HLA-
identical living donor; haemolytic uremic syndrome as original kidney disease; 
focal segmental glomerulosclerosis that had recurred in a previous graft; three or 
more previously failed grafts; a current or historic panel-reactive antibody (PRA) 
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value ≥85%; total white blood cell count <3.0 x 109/L; platelet count <75 x 109/L; 
active infection with hepatitis B, hepatitis C, or HIV; a history of tuberculosis; and 
previous treatment with RTX. Female patients at risk for pregnancy had a negative 
serum pregnancy test before randomisation and agreed to use contraception 
for 12 months. The PRA value was defi ned as the percentage of panel cells that 
reacts with patient serum in the complement-dependant cytotoxicity screening. 
The panel cells consisted of lymphocyte suspensions obtained from 60 di# erent 
healthy individuals selected for HLA A, B, DR, and DQ as to achieve a maximum 
ability to detect anti-HLA antibodies (11).
All patients provided written informed consent before study entry. The study 
was approved by the Committee on Human-Related Research Arnhem–Nijmegen, 
conducted according to the Declaration of Helsinki and good clinical practice 
guidelines, and reported according to CONSORT guidelines (12).
Randomisation and study medication
Patients were randomized in a 1:1 ratio to treatment with RTX or placebo. Since 
we hypothesised that the e# ects of RTX could be unequal in immunologically 
high- and low- risk patients, we stratifi ed for PRA according to the Eurotransplant 
cut-o#  value of 6% for allo-sensitization and history of prior transplantations (fi rst 
vs. re-transplant). For allocation, a computer-generated list of random numbers 
was used for each of the four strata, prepared by an independent investigator. 
This list containing study number and treatment allocation was only accessible for 
authorised nurses, who signed confi dentiality statements. For every new included 
patient, the lowest available study number was handled to one of the authorised 
nurses, who prepared study medication according to the randomisation list. 
Patients randomized to RTX were treated with a single dose of 375 mg/m2 
intravenously during surgery. The required dose was diluted in a 500 ml bag of 0.9% 
sodium chloride. In placebo-treated patients infusion consisted of an identical 500 
ml bag. Both bags had an identical appearance and were labelled ‘study medication’.
At the start of the operation both groups received standard antibiotic prophylaxis 
next to 100 mg prednisolone and 2 mg clemastin intravenously to prevent allergic 
reactions to RTX. Infusion of study medication was started 30 minutes thereafter 
at a rate of 60 ml/hour,  increased every 30 minutes to a maximum rate of 200 
ml/hour After the operation prednisolone was continued intravenously for three 
days at 100 mg/day, followed by 15–25 mg/day prednisolone orally, according 
to bodyweight, and tapered to 0.1 mg/kg/day. Tacrolimus (Prograft, Astellas 
Pharma) was given in a dose of 0.2 mg/kg/day, divided in two doses. The target 
trough levels were 15–20 ng/ml in the fi rst two weeks post transplant, 10–15 ng/ml 
during weeks 3–6, and 5–10 ng/ml thereafter. Mycophenolate mofetil (CellCept, 
Ho# man-La Roche) was started at 2000 mg/day, divided in two doses, and 
reduced to 1500 mg/day after two weeks unless patients weighed more than 90 
kg. Additional treatment consisted of trimethoprim/sulfamethoxazole 480 mg/day 
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for the fi rst 3 months, and thrice weekly thereafter until one year post-transplant. 
Cytomegalovirus (CMV) seronegative patients who received a kidney from a CMV 
seropositive donor were treated prophylactically with valganciclovir during the fi rst 
three months. Additionally, valganciclovir prophylaxis was given for two months 
after treatment with anti-T-cell antibodies when either the donor or recipient was 
CMV seropositive.
First-line anti-rejection therapy consisted of methylprednisolone for three 
consecutive days in a dose of 500-1000 mg/day intravenously. Steroid-resistant 
rejections were treated with anti-T-cell antibodies (Rabbit anti-thymocyte 
globulin [Thymoglobulin], Genzyme; Muromonab-CD3 [OKT3], Janssen-Cilag; 
alemtuzumab [Campath], Genzyme) according to local practice. Rejection was 
considered steroid-resistant if no stabilization or improvement of graft function 
occurred within fi ve days after the fi rst methylprednisolone dose.
E"  cacy and safety
The primary end point was the incidence and severity of BPAR within the fi rst six 
months after transplantation. For patients with more than one biopsy available 
during a single rejection episode, the biopsy score with the highest Ban#  grade 
was used for analysis. Borderline rejections were excluded. Biopsies were scored 
independently by two blinded pathologists according to the updated Ban#  07 
criteria (13). In case of di# erent conclusions, biopsies were re-evaluated collectively. 
Protocol graft biopsies were not performed.
Secondary end points included the estimated glomerular fi ltration rate (eGFR) 
at six months (graft failure was recorded as 0 ml/min), cumulative incidence of 
infections and malignancies at six and 24 months, and patient and graft survival 
at six months and at end of follow-up. All serious adverse events were recorded 
during 24 months. 
Number and phenotype of B cells
Blood was taken before and at several time points up to 60 months after 
transplantation. Peripheral blood mononuclear cells (PBMCs) were isolated by 
gradient centrifugation using Lymphoprep (Lucron, Dieren, The Netherlands) 
and stored in liquid nitrogen until further use. Cell phenotypes were analyzed by 
10-color fl ow cytometry (Navios, Beckman-Coulter, Fullerton, USA). The following 
fl uorochrome-conjugated monoclonal antibodies were used to study B cells: 
CD19(J3-119)-APC Alexa Fluor 750, CD27(1A4-CD27)-PeCy5.5, CD45(J.33)-
Krome Orange and IgD(IADB6)-FITC (Beckman-Coulter). Isotype controls or 
unstained cells were used for gate settings. Data were analyzed using Kaluza 
software (Beckman-Coulter).
The B-cell phenotype at time of transplantation was analyzed in 26 
immunologically high risk patients (for defi nition see below), based on availability 
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of the samples. For comparison  we selected 28 immunologically low risk patients 
matched for age, gender, type of dialysis, and CMV status.
Statistical analysis
To detect a decrease in rejection incidence from 15% to 5% with a two-sided 5% 
signifi cance level and a power of 80%, the required sample size was 140 patients 
per treatment arm. The trial was not powered to test superiority in the di# erent 
strata. After 70 patients had reached a follow-up of six months, a planned interim 
safety analysis was performed to test the cumulative incidence of infections and 
malignancies (14). This interim analysis was not performed with the intention to test 
e"  cacy or futility.
Statistical testing was performed according to distribution and type of data 
(unpaired T test, Mann-Whitney U, or Fisher’s exact tests). Time to fi rst BPAR, 
allograft loss, and death were analyzed with the Kaplan–Meier method, and 
di# erences were assessed by the log-rank test. 
In a secondary analysis, the four strata were grouped as follows: patients with a 
re-transplant or PRA value >6% were considered to be immunologically high risk, and 
those with a  fi rst transplant and PRA value ≤6% were regarded as immunologically 
low risk. Comparison of subgroups was performed by one-way ANOVA, Kruskal-
Wallis, and chi-square tests. All data were analyzed on an intention-to-treat basis. 
Analyses were performed with IBM SPSS Advanced Statistics 20.0. This study is 
registered with ClinicalTrials.gov register, number NCT00565331.
Role of the funding source
Funding for the clinical trial was provided by Ho# mann–La Roche and Astellas 
Pharma. RTX (MabThera, Ho# man-La Roche) was donated. Both companies were 
informed of the results and had no role in study design, data collection, analysis, 
interpretation, or writing of the report. The Dutch Kidney Foundation supported 
the ex vivo study of B cells.
Results
Between December 2007 and June 2012, 488 adult renal transplant candidates 
were evaluated for eligibility and 281 patients were included, of whom 139 patients 
were randomized to RTX and 142 to placebo (Figure 1). One patient did not undergo 
transplantation and was therefore excluded from all analyses. Overall, the groups 
were well balanced with respect to demographic, clinical, and donor characteristics 
(Table 1). 
Infusion with RTX was well tolerated and all but six patients received the full 
dose (Figure 1). One patient experienced an anaphylactic reaction during surgery, 
which was attributed to RTX. She recovered uneventfully. Temporary interruption 
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Table 1. Baseline characteristics of the patients*
Variable
All patients
rituximab
(n=138)
placebo
(n=142)
Age (yr) 50.8 ± 13.2 49.8 ± 12.3
Male sex (%)† 69.6 63.4
White race (%)‡ 94.9 96.5
Cause of end-stage renal disease (%)
Glomerulonephritis 29.0 34.5
Diabetes mellitus 4.3 6.3
Urological disorder 7.2 7.0
Hypertension / vascular damage 6.5 7.0
Polycystic kidney disease 22.5 22.5
Uncertain 15.9 14.8
Other 14.5 7.7
Type of donor (%)
Living 58.7 57.0
Deceased – donation after cardiac death 10.1 13.4
Deceased – donation after brain death 31.2 29.6
Donor age (yr) 54.1 ± 11.6 52.8 ± 10.2
Antigen mismatches — A, B, and DR (no.) 3.30 ± 1.62 3.15 ± 1.46
Panel-reactive antibody titre — highest assessment§ 0 (0 – 83) 0 (0 – 71)
Patients with re-transplant (%) 8.7 10.6
Cold-ischemia time — deceased donors only (hr) 17.2 ± 5.1 17.4 ± 5.5
Cytomegalovirus serologic status — donor positive, recipient 
negative (%)
21.7 23.2
* Values are presented as mean ± standard deviation or median (range). Overall group 
di# erences were not signifi cant.
† P =0.02 for all strata calculated with the chi-square test.
‡ Race was determined by the investigator.
§ P <0.01 for all strata calculated with the chi-square test.
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2Immunologically low risk patients Immunologically high risk patients
rituximab
(n=110)
placebo
(n=108)
rituximab
(n=28)
placebo
(n=34)
51.0 ± 13.6 50.6 ± 11.8 49.8 ± 11.7 47.3 ± 13.6
71.8 69.4 60.7 44.1
94.5 96.3 96.4 97.1
28.2 33.3 32.1 38.2
4.5 5.6 3.6 8.8
7.3 5.6 7.1 11.8
6.4 7.4 7.1 5.9
22.7 26.9 21.4 8.8
16.4 13.0 14.3 20.6
14.5 8.4 14.3 5.9
60.9 61.1 50.0 44.1
10.0 11.1 10.7 20.6
29.1 27.8 39.3 35.3
54.7 ± 11.4 53.4 ± 9.1 51.6 ± 12.1 50.7 ± 13.0
3.26 ± 1.60 3.21 ± 1.49 3.43 ± 1.77 2.94 ± 1.37
0 (0 – 6) 0 (0 – 5) 17 (2 – 83) 15 (0 – 71)
- - 42.9 44.1
16.7 ± 5.2 17.0 ± 5.3 18.8 ± 4.7 18.3 ± 6.0
21.8 26.9 21.4 11.8
of the infusion,  mainly due to hypotension, occurred in seven RTX-treated patients 
(5.1%) compared to fi ve placebo-treated patients (3.5%, P =0.57 by Fisher’s exact 
test).
Analysis of B cells in peripheral blood in 20 CMV-negative patients without 
BPAR, confi rmed nearly complete depletion in RTX-treated patients as compared 
to placebo-treated patients at six months after transplantation (median CD19+ B 
cells and range; 0.6/µl (0/µl – 16.4/µl) vs. 141/µl (31/µl – 458/µl); P<0.001).
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 488 Patients were assessed for eligibility 
141 Were ineligible 
 18 Received a HLA identical kidney   
9 Had HUS as primary renal disease 
1 Had a history of primary FSGS with recurrence 
6 Had a PRA >85%    
3 Had received  ≥ three previous transplants 
7 Were previously treated with rituximab or had 
participated in the current trial before 
10 Received cyclosporine instead of tacrolimus  
5 Had a history of HIV, Hepatitis B, or Hepatitis C 
7 Had a history of tuberculosis  
30 Participated in another clinical trial 
11 Underwent an ABO-incompatible transplantation
    27 Were unable to give informed consent
 (either due to language problems or impaired 
cognition)
 7 Were started on an incompatible 
immunosuppressive regimen (mostly basiliximab
induction) 
132 Received 
the full dose 
142 Underwent transplantation 138 Underwent transplantation 
0 Did not undergo 
transplantation 
1 Did not undergo 
transplantation 
142 Were assigned to receive placebo 139 Were assigned to receive rituximab 
281 Underwent randomization 
1 Did not receive the full 
dose 
   1 Had side-eZects
   during infusion 
141 Received 
the full dose 
6 Did not receive the full 
dose 
   3 Had side eZects-  
   during infusion 
   2 Had problems with  
   anesthesia before    
   infusion 
   In 1 infusion was    
   stopped after finding  
   a mass in the caecum 
142 Were included in the analysis 
0 Were lost to follow-up-  
 
138 Were included in the analysis 
0 Were lost to follow-up-  
66 Were eligible but were excluded 
 59 Did not provide informed consent 
 5 Were overlooked for inclusion
2 Were withdrawn by the treating clinician
Figure 1. Trial profi le of all patients.
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The primary outcome, BPAR within six months after transplantation, occurred in 
23 of the 138 RTX-treated patients (16.7%), compared to 30 of 142 placebo-treated 
patients (21.1%, P=0.25 by log-rank test, Figure 2A). Based on the stratifi cation 
according to PRA value and rank number of transplantation, we grouped the four 
strata to form a immunologically low risk group (n=218) and an immunologically 
Number at Risk
Immunologically low risk, rituximab
Immunologically low risk, placebo
110 98 96 95 95 95 92
28 23 22 22 22 21 21
108 94 91 89 86 83 81
34 22 18 18 18 18 18
Number at Risk
Rituximab
Placebo
142 116 109 107 104 101 99
138 121 118 117 117 116 113
A
B
Immunologically high risk, rituximab
Immunologically high risk, placebo
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Figure 2. 
(A) Cumulative probability of biopsy proven acute rejection (BPAR) in all patients. 
(B) Cumulative probability of BPAR in immunologically low vs. high risk patients.
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high risk group (n=62). Immunologically high risk patients receiving placebo had 
a signifi cantly higher incidence of acute rejection compared to immunologically 
low risk patients (RTX- or placebo-treated) and RTX-treated immunologically high 
risk patients (38.2% vs. 16.4%, 15.7%, and 17.9%, P =0.004 by log-rank test, Figure 
2B). When the group of immunologically high risk patients was analyzed separately, 
there was a clear trend towards a lower incidence of BPAR with RTX treatment 
(17.9% vs. 38.2%, P =0.06 by log-rank test).
Since RTX appeared to be more e# ective in immunologically high risk 
patients, we studied B-cell number and phenotype in a peripheral blood sample 
of immunologically high risk and immunologically low risk patients obtained 
immediately before transplantation. The number of CD19+ B cells, especially CD27+ 
memory B cells, was higher in the immunologically high risk patients (CD19+CD27+ 
memory B cells 35 cells/µl [12-152] vs. 24 cells/µl [5-78], P =0.02 by Mann-Whitney 
U test, Figure 3).
Most rejections were T-cell mediated according to the Ban#  classifi cation 
(Table 2). RTX-treated patients tended to have less antibody mediated rejections 
(ABMR), compared to placebo-treated patients (4/138, 2.9% vs. 11/142, 7.7% P =0.11 
by Fisher’s exact test). At six months, there were small but signifi cant di# erences 
in maintenance immunosuppression between RTX and placebo-treated patients 
(Table 3).
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and 28 matched immunologically low risk patients. P values are calculated with the Mann-
Whitney U test.
Figure 3.
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Patient and graft survival (at six months, and after a median duration of follow-
up of 3.2 years, range 1.3–5.7 years) as well as graft function were comparable 
between the RTX and placebo group (Table 4). One RTX-treated patient was 
diagnosed with progressive multifocal leukoencephalopathy and died shortly 
thereafter. The overall incidence of infections or malignancies was not higher after 
treatment with RTX compared to placebo.
During the fi rst six months after transplantation, treatment with RTX was 
associated with a signifi cantly higher cumulative incidence of grade 2 or more 
severe leucopenia (19.0% vs. 1.4%, P<0.001 by Fisher’s exact test) and neutropenia 
(24.3% vs. 2.2%, P<0.001 by Fisher’s exact test, Table 4).
Discussion
Our data show that induction therapy with a single dose of RTX at the time of renal 
transplantation is safe but ine# ective to reduce the incidence of BPAR in the general 
population of renal transplant patients. The stratifi cation of our patients according 
to re-transplantation and PRA, enabled comparison of immunologically high and 
low risk patients. We observed that within the whole population, immunologically 
high risk patients who did not receive RTX had the highest incidence of BPAR. 
Furthermore, a separate analysis of the immunologically high risk patients showed 
a clear trend towards a lower incidence of BPAR in RTX-treated patients. Notably, 
the study was not su"  ciently powered for this secondary analysis within a subgroup 
of 62 patients. Interestingly, the incidence of ABMR tended to be lower after RTX, 
especially in immunologically high risk patients. Altogether, these results suggest a 
protective e# ect of RTX against acute rejection in this specifi c group of transplant 
recipients. With the current median duration of follow-up of 3.2 years, this has not 
resulted in improved graft function or graft survival.
In a recent study with 140 patients, Tydén et al. showed no signifi cant e# ect 
of RTX on the incidence of BPAR within six months after transplantation, although 
a tendency toward fewer and milder rejection episodes in the RTX group was 
observed (11.8% vs. 17.6%, P =0.32) (15). In the current study, we included twice as 
many patients and stratifi ed for immunological risk.
It is tempting to speculate that a protective e# ect of RTX in immunologically 
high risk patients could be explained by reducing the relatively high pre-transplant 
levels of memory B cells in our immunologically high risk patients. Indeed, an 
increase in circulating memory B cells has been associated with acute rejection 
in paediatric renal transplant recipients (16), while heart transplant recipients with 
higher percentages of naive B cells had a lower risk of  acute rejection (17). However, 
we and others have previously shown that memory B cells are more resistant to 
depletion by RTX than naive B cells (18, 19). Interestingly we have noticed that 
RTX can a# ect B-cell phenotype and function, resulting in an altered outcome of 
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Table  4. Secondary end points*.
Variable
Rituximab
(n=138)
Placebo
(n=142)
Calculated GFR at six months – ml/min† 48.7 ± 20.0 45.6 ± 22.1
Proteinuria at six months – g/10 mmol creatinine
0.16 
(0.10 – 6.5)
0.18 
(0.10 – 6.7)
Allograft survival at six months (%)
Censored for death of patients with functioning graft 96.4 93.0
Uncensored for death of patients with functioning graft 94.9 90.1
Allograft survival at end of follow-up (%)
Censored for death of patients with functioning graft 92.0 88.0
Uncensored for death of patients with functioning graft 81.2 82.4
Patient survival at six months (%) 97.8 95.8
Patient survival at end of follow-up (%) 88.4 89.4
Cause of death (no.) number of patients
Infection related 7 5
Malignancy related 4 3
Other causes 5 7
Patients with ≥ 1 infection within six months (%) 63.8 62.0
Patients with CMV disease within six months (%) 14.5 11.3
Patients with ≥ 1 infection within 24 months (%) 79.0 76.1
Patients with CMV disease within 24 months (%) 15.9 12.7
Patients with ≥ 1 malignancies within 24 months (%) 5.8 5.6
Type of malignancies (no.) number of patients
Skin 2 5
Non-skin 6 3
Patients with ≥1 serious adverse event (SAE) 
within 24 months (%)
70.3 64.8
Incidence of grade ≥ 2 leucopenia within six months
(leucocytes < 3.0 x 109/L) (%)‡
19.0 1.4
Incidence of grade ≥ 2 neutropenia within six months 
(neutrophils < 1.5 x 109/L) (%)‡
24.3 2.2
Haemoglobin level at six months (mmol/L) 7.6 ± 1.0 7.6 ± 1.0
Thrombocyte count at six months (x109/L) 220 ± 69 222 ± 72
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B-T-cell interaction (20). Moreover, after treatment with one dose of RTX a B-cell 
population remains in secondary lymphoid organs, despite complete depletion in 
peripheral blood (19). These remaining B cells mainly consist of switched memory 
(IgD-CD27+) B cells, and have di# erent functional capacities as compared to B cells 
obtained from lymph nodes of patients not treated with RTX. Taken together, these 
data indicate that RTX can have e# ects beyond B-cell depletion.
Our study confi rmed previous observations of a high incidence of leucopenia 
and neutropenia after treatment with RTX (21). The cause of this so called late-
onset neutropenia remains incompletely understood. The higher incidence of 
neutropenia did not lead to more infections, which is in accordance with  the results 
of other studies (22-27). Potentially worrisome are the recently published 3-year 
follow-up data from Tydén’s study, suggesting an increased mortality in RTX-
treated patients (25). We could not confi rm these results in our study.
In conclusion, our study has demonstrated that addition of RTX induction 
therapy to a standard immunosuppressive triple drug regimen does not reduce the 
incidence of acute rejection in immunologically low risk patients. Therefore, we do 
not recommend the use of RTX induction therapy in a population of unselected 
renal transplant recipients. However, our data suggest that treatment with RTX 
may reduce the incidence of BPAR in immunologically high risk patients to a level 
comparable to that in immunologically low risk patients, thereby representing a 
further step in improving the treatment of this specifi c group of patients. The results 
need to be confi rmed in a multicenter clinical trial focused on immunologically high 
risk patients, with special attention for the combination or comparison with other 
induction agents, like basiliximab and anti-thymocyte globulin.
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Abstract 
Background. Prevention of rejection after renal transplantation requires treatment 
with immunosuppressive drugs. Data on their in vivo e# ects on T- and B-cell 
phenotype and function are limited. 
Methods. In a randomized double-blind placebo-controlled study to prevent renal 
allograft rejection, patients were treated with tacrolimus, mycophenolate mofetil 
(MMF), steroids, and a single dose of rituximab or placebo during transplant 
surgery. We analyzed the number and phenotype of peripheral T and B cells by 
multiparameter fl ow cytometry before transplantation, and at 3, 6, 12, and 24 
months after transplantation.
Results. In patients treated with tacrolimus/MMF/steroids the proportion of central 
memory CD4+ and CD8+ T cells was higher at 3 months post-transplant compared 
to pre-transplant levels. In addition, the ratio between the percentage of central 
memory CD4+ and CD4+ regulatory T cells was signifi cantly higher up to 24 months 
post-transplant compared to pre-transplant levels. Interestingly, treatment with 
tacrolimus/MMF/steroids resulted in a shift toward a more memory-like B-cell 
phenotype post-transplant. Addition of a single dose of rituximab resulted in a 
long-lasting B-cell depletion. At 12 months post-transplant, the small fraction of 
repopulated B cells consisted of a high percentage of transitional B cells. Rituximab 
treatment had no e# ect on the T-cell phenotype and function post-transplant.
Conclusions. Renal transplant recipients treated with tacrolimus/MMF/steroids 
show an altered memory T and B-cell compartment post-transplant. Additional 
B-cell depletion by rituximab leads to a relative increase of transitional and memory-
like B cells, without a# ecting T-cell phenotype and function.
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Introduction
Life-long use of immunosuppressive drugs is required to prevent rejection after 
renal transplantation. Nevertheless, the continuous use of immunosuppressive 
drugs does not preclude the development of chronic rejection, which is a 
major cause of long-term allograft loss (1). T cells play an important role in the 
pathogenesis of rejection via the recognition of alloantigens, resulting in T-cell 
activation, proliferation, and di# erentiation into CD8+ cytotoxic T cells and CD4+ 
T helper cells (2). Therefore, the most commonly used immunosuppressive drugs 
in transplantation are directed against T cells to inhibit these processes (3). On 
the other hand, regulatory T cells are able to suppress the immune response and 
prevent allograft rejection (4). The balance between memory and regulatory T 
cells during the course after transplantation can be used to predict renal graft 
rejection following the reduction of immunosuppressive therapy (5). Next to T 
cells, B cells can be involved in graft rejection (6). The presence of B-cell clusters in 
renal grafts during acute rejection or the presence of anti-HLA antibodies before 
transplantation is associated with poorer graft survival (7-9). Notably, B cells can 
induce alloimmune responses by acting as professional antigen presenting cells, or 
by the production of various (pro-)infl ammatory cytokines (10). Therefore, depletion 
of B cells in renal transplant recipients might help to prevent allograft rejection. 
Current immunosuppressive regimens consisting of steroids, a calcineurin-inhibitor, 
and mycophenolate mofetil (MMF) inhibit B-cell function directly due to inhibition 
of their proliferation and indirectly via the inhibition of T-cell help. B cells can also 
be selectively depleted by rituximab (RTX), an anti-CD20 monoclonal antibody. 
RTX is successfully used in the treatment of B-cell malignancies and autoimmune 
disorders mediated by T and B cells (11, 12). 
Although the major target of RTX-based treatment was to reduce the levels 
of circulating autoantibodies, additional B-cell functions may be a# ected, such 
as antigen presentation and cytokine production (13). Furthermore induction of 
regulatory T cells (T
REGS
) was reported after RTX treatment in patients with lupus 
nephritis (14). Therefore, next to its e# ect on B cells, RTX might decrease the chance 
of rejection after transplantation by a# ecting the T-cell compartment. Remarkably 
little is known about the e# ects of the currently used immunosuppressive strategies 
on the phenotype and function of T and B cells during the course after renal 
transplantation. Advancements in multiparameter fl ow cytometry have made it 
possible to analyze the e# ects of immunosuppressive agents on various T- and B-cell 
subsets in more detail. We had the opportunity to study the e# ects of standard 
immunosuppression (tacrolimus, MMF and steroids), with or without the addition 
of RTX induction therapy on the phenotype and function of T and B cells over time 
in renal transplant recipients participating in a randomized placebo-controlled trial, 
studying the e"  cacy and safety of RTX added to standard immunosuppression. To 
avoid bias by other immunological events as much as possible, we analyzed only 
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Cytomegalovirus (CMV) seronegative patients who received a kidney from a CMV 
seronegative donor, did not experience a rejection episode, and were not treated 
with additional immunosuppressive drugs during the follow-up period.
Materials and Methods
Patients
Patients were selected from a clinical trial with RTX in renal transplantation 
at our hospital (ClinicalTrials.gov, NCT00565331). This study investigated the 
e# ectiveness and safety of RTX for prophylaxis of acute rejection after renal 
transplantation. Patients were randomized between treatment with a single 
dose of RTX (375 mg/m2) or placebo during transplant surgery. Concomitant 
immunosuppression consisted of tacrolimus, MMF, and steroids. Patients received 
100 mg of prednisolone intravenously during the fi rst 3 days after transplantation 
and subsequently an oral dose of 15-25 mg/day, tapered to a maintenance dose 
of 0.1 mg/kg/day. Tacrolimus was started at 0.2 mg/kg/day and the dose was 
subsequently adjusted to achieve whole-blood trough levels of 15-20 ng/ml during 
the fi rst 2 weeks, 10-15 ng/ml during weeks 3-6, and 5-10 ng/ml from week 7. MMF 
was administered at 1000 mg twice daily with a dose reduction to 750 mg twice 
daily at 2 weeks after transplantation, and discontinued after 6 months.
To avoid bias by other immunological events as much as possible, we 
investigated only Cytomegalovirus (CMV) seronegative patients who received 
a kidney from a CMV seronegative donor (and thus did not develop CMV 
infection), did not experience a rejection episode, and were not treated with other 
immunosuppressive drugs during the follow-up period. 14 patients were included 
in the group treated with tacrolimus, MMF and steroids, and 12 patients in the 
group additionally treated with RTX. Peripheral blood mononuclear cells (PBMCs) 
of 4 standard-treated patients and 3 RTX-treated patients were not available at 24 
months after transplantation. Table 1 summarizes the characteristics of all patients. 
The study was approved by the Institutional review board of the Radboudumc 
Nijmegen. Written informed consent was obtained from all participants.
Cells
Peripheral blood samples were obtained before transplantation, and up to 24 
months after transplantation. Whole blood counts were performed and PBMCs 
were isolated by density gradient centrifugation using Lymphoprep (Lucron, Dieren, 
The Netherlands). PBMCs were cryopreserved in liquid nitrogen until analysis. For 
each patient longitudinal fl ow cytometric analysis was performed for all available 
samples at the same time.
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Flow cytometry
For cell surface staining, the following fl uorochrome-conjugated monoclonal 
antibodies were used CD3(UCHT1), CD4(13B8.2), CD8(B9.11), CD19(J3-119), 
CD24(ALB9), CD38(LS198-4-3), CD45(J.33), CD45RO(UCHL1), CD127(R34.34) 
and IgD(IADB6) (all from Beckman-Coulter, Mijdrecht, The Netherlands), 
CD25(M-A251), CCR4(1G1), CCR6(11A9) and CXCR3(1C6/CXR3) (BD Biosciences, 
Erembodegem, Belgium), and BAFF-R(11C1) (BioLegend, Uithoorn, The 
Netherlands). Intracellular analysis of IL-2(MQ1-17H12) (BD Biosciences), IL-
4(8D4-8), IL-17(EBIO64CAP17), IFNγ(4S.B3) (eBioscience, San Diego, CA, USA), 
and TNFα(Mab11) (Dako, Glostrup, Denmark) was performed after fi xation and 
permeabilization, using Fix and Perm reagent (eBioscience). Before intracellular 
cytokine measurement, the cells were stimulated for 4 hours with PMA (12.5 ng/
ml), ionomycin (500 ng/ml) and Brefeldin A (5 μg/ml; Sigma-Aldrich, Zwijndrecht, 
The Netherlands).
The cell phenotype was analyzed by fi ve-color (FC500) or ten-color fl ow 
cytometry (NaviosTM), and data were analyzed using Kaluza® software (all from 
Beckman-Coulter). Isotype controls or unstained cells were used for gate settings. 
Cell populations >0.1% of the CD45+ lymphocyte population with a threshold of 
more than 50 cells were considered reliable.
Table 1. Patient characteristics.
Triple immunosuppression
+ rituximab P value
N 14 12
Median age at Tx, years (range) 50 (20-73) 57 (25-66) 0.440
Sex, no. male (%) 11 (79%) 7 (58%) 0.288
Type of dialysis 0.236
Hemodialysis 6 5
Peritoneal dialysis 2 4
None 6 3
Median PRA, % (range) 0 (0-58) 0 (0-10) 0.852
Living donor, no. (%) 13 (93%) 8 (67%) 0.100
HLA mismatches total, median (range) 4 (2-6) 3 (1-5) 0.224
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Statistical analysis 
 Continuous data are expressed as mean ± SD. Nonparametric tests were used 
to compare variables. One-way ANOVA was used to test di# erences within the 
triple immunosuppression-treated group over time. To test the di# erence between 
RTX- and placebo-treated patients a Mann-Whitney U-test was performed. P<0.05 
was considered statistically signifi cant. Statistical analysis was performed using 
GraphPad Prism 5.03 (GraphPad Software Inc., La Jolla, CA, USA).
Results
Phenotype and function of T cells in renal transplant recipients after 
treatment with tacrolimus, MMF and steroids
CD4+ and CD8+ T cells can be divided into naive, central and e# ector memory, and 
highly di# erentiated memory cells based on CD27 and CD45RO expression. (15).
The absolute numbers of CD4+ and CD8+ T cells in peripheral blood did not change 
during the use of triple drug immunosuppression after transplantation (Figure 1A-
C). However, the percentages of central memory (T
CM
; CD27+CD45RO+) CD4+ and 
CD8+ T cells were signifi cantly higher at 3 months after transplantation compared 
to before transplantation, while the percentages of e# ector memory (T
EM
; CD27-
CD45RO+) CD4+ and CD8+ T cells, and regulatory (T
REGS
; CD25hiFOXP3+) CD4+ T 
cells were signifi cantly decreased. The percentages of naive (T
N
; CD27+CD45RO-) 
and highly di# erentiated memory (T
EMRA
; CD27-CD45RO-) CD4+ and CD8+ T cells 
were comparable to pre-transplant levels. Next to the T-cell subset distribution, the 
ratio between memory and regulatory T cells might be an important determinant of 
the risk of rejection (16). Interestingly, the CD4+ T
CM
 / CD4+ T
REGS
 ratio signifi cantly 
increased from 3 months after transplantation and remained elevated compared 
to the pre-transplant ratio (Figure 1D). The CD4+ T
EM 
/ CD4+ T
REGS
 ratio after 
transplantation was comparable to pre-transplant levels. Finally, we determined the 
expression of chemokine receptors associated with T helper (Th) 1 (CXCR3), Th2 
(CCR4), and Th17 (CCR6) cells (Figure 1E). The percentage of CXCR3+ and CCR6+ 
CD4+ T cells increased during immunosuppressive treatment, whereas triple drug 
immunosuppression did not a# ect the percentage of CCR4+ CD4+ T cells. Also, the 
percentage of CD4+ T cells expressing co-stimulatory (CD28) or co-inhibitory (PD-
1) receptors was comparable to before transplantation (data not shown).
Although triple drug immunosuppression had minimal e# ects on the phenotype 
of peripheral T cells, this did not preclude an e# ect on functional capacities. To 
assess the cytokine producing capacity of circulating T cells, PBMCs were ex vivo 
stimulated for 4 hours with PMA, ionomycin and Brefeldin A. E# ector cytokine 
production was assessed using intracellular cytokine staining in both CD4+ and 
CD8+ T cells. The percentage of IL-2, IL-4, IL-17, and TNFα producing CD4+ cells 
decreased at 3 months after transplantation compared to pre-transplant levels. 
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Subset distribution of circulating T cells in renal transplant recipients 
after treatment with tacrolimus, MMF and steroids over time. 
(A) Representative dot plots for a renal transplant recipient showing CD3+CD4+ and 
CD3+CD8+ T cells within the CD45+ lymphocyte population. Circulating CD4+ and 
CD8+ T cells can be characterized as naive (T
N
; CD27+CD45RO-), central memory (T
CM
; 
CD27+CD45RO+), e# ector memory (T
EM
; CD27-CD45RO+) and highly di# erentiated 
memory (T
EMRA
; CD27+CD45RO-) cells. Furthermore, CD4+ T cells can be characterized as 
regulatory T cells (T
REGS
; CD25hiFOXP3+). (B) Shown are the absolute numbers of CD4+ T 
cells and the percentages of T
N
, T
CM
 and T
EM
 within the CD4+ T-cell population for 14 triple 
immunosuppression-treated patients before transplantation (t=0) and at 3, 6, 12 and 24 
months after transplantation (n=10 at 24 m). (C) As described under B, for CD8+ T cells. 
(D) The ratio between the percentage of CD4+ T
CM
 or T
EM
 and the percentage of T
REGS
. (E) 
Longitudinal analysis of the percentages of CCR4+, CCR6+, and CXCR3+ cells within the 
CD4+ T-cell population of 14 triple immunosuppression-treated patients (n=10 at 24 m). 
Bars show standard deviation (SD). Signifi cant di# erences are indicated compared to pre-
transplant levels: *P<0.05, **P<0.01, ***P<0.001.
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Hereafter, the production of all cytokines but TNFα returned to baseline levels 
within 24 months after transplantation (Figure 2). Ex vivo IFNγ production was not 
a# ected by triple drug immunosuppression, nor was cytokine producing capacity 
of CD8+ T cells. Taken together, within the T-cell compartment, the most notable 
changes were found in the e# ector CD4+ T-cell pool.
Under treatment with tacrolimus, MMF and steroids, renal transplant 
recipients develop a memory-like B-cell phenotype 
During immunosuppressive treatment, the absolute B-cell numbers in peripheral 
blood were comparable to pre-transplant levels up to 24 months after 
transplantation (Figure 3A). To defi ne whether the composition of the peripheral 
B-cell compartment was a# ected, we characterized CD19+ B cells using the 
Bm1-Bm5 classifi cation (17). Compared to pre-transplant levels, the percentages 
of naive Bm2 (IgD+CD38+) and transitional Bm2’ (IgD+CD38++) CD19+ cells were 
lower, and the percentage of late memory Bm5 (IgD-CD38-) cells was higher after 
transplantation (Figure 3B-C). This shift to a more memory-like phenotype was 
accompanied by an increase in the percentage of virgin naive Bm1 cells, probably 
needed for B-cell renewal. Accordingly, using an alternative terminology for B 
cells, the percentages of transitional CD24++CD38++, mature CD24+CD38+, and 
naive IgD+CD27- B cells were decreased, while there was a relative increase in 
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Ex vivo cytokine production by circulating T cells in renal transplant 
recipients after treatment with tacrolimus, MMF and steroids. 
Peripheral blood mononuclear cells (PBMCs) were stimulated for 4 hours in the presence of 
PMA, ionomycin and Brefeldin A. Shown are the percentages IL-2, IL-4, IL-17, IFNγ or TNFα-
producing cells within the CD4+ or CD8+ T-cell population of 14 triple immunosuppression-
treated patients before transplantation (t=0) and at 3, 6, 12, and 24 months after 
transplantation (n=10 at 24 m). Bars show standard deviation (SD). Signifi cant di# erences 
are indicated compared to pre-transplant levels: *P<0.05, **P<0.01, ***P<0.001.
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CD24++CD38- memory and IgD-CD27+ switched memory B cells (data not shown). 
At 12 and 24 months after transplantation, there was a higher percentage of CD80+ 
and CD95+ B cells as compared to before transplantation, supporting the more 
complete di# erentiation towards memory cells within the B-cell compartment 
BA
Bm3+4 Bm2’
Bm2
Bm1
Early
Bm5
Late 
Bm5
IgD
C
D
3
8
pre-Tx 3 m 6 mCD19+
IgD
C
D
3
8
12 m 24 m
6
15
15
0
49
15
9 70
4
92
6
1
6
5
1
81
6
3
9
7
0
67
13
0
4
4
0
82
10
D
C
CD19+
CD19+ CD19+
BAFF-R
E
pre-Tx 24 m
F
CD19+ B cells
0 3 6 12 24
0
500
months after Tx
c
e
lls
/µ
l
Bm1
0 3 6 12 24
0
20
100
* ** *** **
months after Tx
%
Bm2
0 3 6 12 24
0
100
* *
months after Tx
*******
Bm2'
0 3 6 12 24
0
10
100
***
months after Tx
Bm3+4
0 3 6 12 24
0
10
100
* **
months after Tx
Early Bm5
0 3 6 12 24
0
20
100
months after Tx
Late Bm5
0 3 6 12 24
0
20
100
months after Tx
CD80+
0 3 6 12 24
0
20
*
**
months after Tx
%
BAFF-R+
0 3 6 12 24
0
100 **
months after Tx
CD95+
0 3 6 12 24
0
30
*
**
months after Tx
BAFF-R
0 3 6 12 24
0
5
**
*****
***
months after Tx
M
F
I
Longitudinal analysis of circulating B cells in renal transplant recipients 
after treatment with tacrolimus, MMF and steroids. 
(A) Shown are the absolute numbers of CD19+ B cells of 14 triple immunosuppression-treated 
patients before transplantation (t=0) and at 3, 6, 12, and 24 months after transplantation 
(n=10 at 24 m). (B) Representative dot plots for a renal transplant recipient over time using 
the Bm1-Bm5 classifi cation: Bm1 (IgD+CD38-), Bm2 (IgD+CD38+), Bm2’ (IgD+CD38++), 
Bm3+4 (IgD-CD38++), Early Bm5 (IgD-CD38+) and Late Bm5 (IgD-CD38-) cells within the 
CD19+ B-cell population. (C) Shown are the percentages of the di# erent B-cell subsets using 
the Bm1-Bm5 classifi cation over time. (D) Shown are the percentages of CD80+, CD95+, and 
BAFF-receptor+ (BAFF-R) cells within the CD19+ B-cell population. (E) Overlay plot of the 
BAFF-R expression (MFI: median fl uorescence intensity) within the CD19+ B-cell population 
of one patient before transplantation (pre-Tx) and 24 months (24 m) after transplantation 
under treatment with tacrolimus, MMF and steroids. Gray line shows unstained cells. (F) 
Summary graph showing the BAFF-R MFI of 14 triple immunosuppression-treated patients 
before over time (n=10 at 24 m). Bars show standard deviation (SD). Signifi cant di# erences 
are indicated compared to pre-transplant (pre-Tx; t=0) levels: *P<0.05, **P<0.01, ***P<0.001.
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(Figure 3D and data not shown). The majority of B cells remained positive for 
B-cell activating factor receptor (BAFF-R) after transplantation. Interestingly, the 
expression level of BAFF-R increased after transplantation, as documented by an 
increase in median fl uorescence intensity (MFI; Figure 3E). Overall, renal transplant 
recipients treated with tacrolimus, MMF and steroids developed a more memory-
like B-cell phenotype.
A single dose of RTX results in a long lasting B-cell depletion in 
peripheral blood without a! ecting the T-cell compartment
The participation of renal transplant recipients in a randomized double-blind 
placebo-controlled study evaluating the e"  cacy and safety of RTX when added 
to triple drug immunosuppression gave us the opportunity to study the e# ects 
of additional B-cell depletion on the phenotype and function of T and B cells. RTX 
treatment resulted in a nearly complete depletion of B cells from the peripheral 
lymphocyte population up to 12 months after transplantation. Remarkably, the 
B-cell depletion after a single dose of RTX was long lasting. The absolute numbers 
of B cells remained quite low at 24 months after RTX treatment with a median of 9.7 
B cells/μl (range 3.0-294.8) compared to a median of 116.4 B cells/µl (range 49.7-
379.7) in patients not treated with RTX (Figure 4A-B). Interestingly, at 12 months the 
percentage of Bm2’ (IgD++CD38++) and Bm3+4 (IgD-CD38++) cells was signifi cantly 
higher in RTX-treated patients, while the percentages of Bm1 (IgD+CD38-) and Bm2 
(IgD+CD38+) cells were lower in RTX-treated patients (Figure 4C). Accordingly, the 
percentages of CD24++CD38++ transitional and IgD-CD27+ switched memory B cells 
were higher in RTX-treated patients, while the percentages of IgD+CD27- naïve B 
cells were lower in RTX-treated patients (data not shown). Fitting with the relative 
increase of Bm3+4 (IgD-CD38++) cells, there was an increase in the percentage of 
CD80+ and CD95+ B cells at 12 and/or 24 months after transplantation (Figure 4D). 
Remarkably, the percentage of BAFF-R+ B cells was lower in RTX-treated patients 
at 3 and 12 months after transplantation. In addition, the BAFF-R expression (MFI) 
on B cells of RTX-treated patients was lower up to 24 months after transplantation 
(Figure 4D). 
Next, we analyzed whether the long-lasting B-cell depletion with a relative 
increase of transitional B cells resulted in changes in the T-cell compartment. 
There was no signifi cant e# ect of RTX treatment on the absolute numbers and 
percentages of CD4+ and CD8+ T cells or on the subset distribution and phenotype 
of these cells (Figure 4E and data not shown). In addition, in vivo B-cell depletion 
with RTX had no e# ect on the production of IL-2, IL-4, IL-17, IFNγ and TNFα by ex 
vivo stimulated T cells (Figure 4F).
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Discussion
Despite the extensive clinical experience with currently used immunosuppressive 
drug regimens, there are limited data available regarding their e# ects on the 
peripheral lymphocyte compartment after kidney transplantation. One study 
describes the e# ects of cyclosporine, MMF, steroids, and anti-CD25 monoclonal 
antibody therapy on T and B cells of mainly CMV seropositive renal transplant 
recipients at 6, 24, and 60 months after transplantation (18). This therapy resulted 
in an increased percentage of CD4+CD25+ T
REGS
 and CD27+ memory B cells in 
renal transplant recipients compared to healthy donors (18), but the data were 
not compared with pre-transplant levels. In contrast, we performed a longitudinal 
analysis of T- and B-cell phenotype and function in CMV seronegative patients 
who received a kidney from a CMV seronegative donor and did not experience 
a rejection episode up to 24 months after transplantation. In this homogeneous 
patient population, not a# ected by major immunological events, we showed 
that treatment with the combination of tacrolimus, MMF and steroids had no 
e# ects on the total number of T and B cells. Nevertheless, these patients had a 
Longitudinal analysis of circulating B cells in renal transplant recipients 
after treatment with tacrolimus, MMF and steroids, and a single dose of 
rituximab (RTX) during transplant surgery. 
(A) Representative dot plots of CD19+ B cells within the CD45+ lymphocyte population for 
a RTX-treated and a triple immunosuppression (IS)-treated patient before transplantation 
(pre-Tx) and at 3, 12, and 24 months after transplantation. (B) Shown are the absolute 
numbers of CD19+ B cells for RTX-(gray, n=12) and triple IS-treated (white, n=14) patients 
before transplantation (t=0) and up to 24 months after transplantation (n=10 and n=9 at 
t=24 m, respectively). (C) Pie charts depicting the distribution the di# erent B cells subsets 
over time using the Bm1-Bm5 classifi cation as depicted in Figure 3B: Bm1 (IgD+CD38-), Bm2 
(IgD+CD38+), Bm2’ (IgD+CD38++), Bm3+4 (IgD-CD38++), Early Bm5 (IgD-CD38+) and Late 
Bm5 (IgD-CD38-) cells within the CD19+ B-cell population. Data are represented as means 
of 14 triple IS+RTX-treated and 12 IS-treated patients before transplantation (pre-Tx) and at 
3, 12, and 24 months after transplantation (n=10 and n=9 at t=24 m, respectively). (D) Shown 
are the percentages of CD80+, CD95+ and BAFF-R+ cells within the CD19+ B-cell population 
for RTX- (gray, n=12) and triple IS-treated (white, n=14) patients before transplantation (t=0) 
and up to 24 months after transplantation. (E) The percentage of regulatory T cells (T
REGS
; 
CD25hiCD127lo), central memory (T
CM
; CD27+CD45RO+), e# ector memory (T
EM
; CD27-
CD45RO+), CXCR3+ and CCR6+ within the CD4+ T-cell population in RTX- (gray, n=12) and 
triple IS-treated (white, n=14) patients before transplantation (t=0) and up to 24 months 
after transplantation. Results are shown as box plots displaying the median, 25th and 75th 
percentiles as the box, and the 5th and 95th percentiles as whiskers. Signifi cant di# erences 
are indicated by asterisks: *P<0.05, **P<0.01, ***P<0.001.
Figure 4.
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higher proportion of central memory CD4+ and CD8+ T cells at 3 months after 
transplantation compared to pre-transplant levels. Interestingly, the triple drug 
immunosuppression resulted in a shift toward a more memory-like phenotype in 
the B-cell population. Addition of a single dose of RTX resulted not only in a long-
lasting B-cell depletion, but also in a higher percentage of transitional B cells upon 
B-cell recovery at 12 months post-transplant. The additional RTX treatment had no 
e# ect on the T-cell phenotype. 
Although tacrolimus, MMF, and steroids mainly target T-cell activation, 
proliferation, and di# erentiation (3, 19), we found that treatment with a combination 
of tacrolimus, MMF, and steroids, induced only marginal changes in the peripheral 
T-cell phenotype. These changes were mainly present within the fi rst 6 months 
after transplantation, which suggests a role for MMF, as this drug was discontinued 
at 6 months after transplantation. Ex vivo, the T cells collected from patients treated 
with triple immunosuppressive therapy were functional, suggesting that they are 
only suppressed when the drug is present (during treatment). In addition, we found 
that the ratio between CD4+ central memory and T
REGS
 was increased under triple 
drug immunosuppressive therapy. Concomitantly, we observed a relative increase 
of CXCR3+ and CCR6+ CD4+ T cells, chemokine receptors associated with memory 
or activated Th1 and Th17 cells, respectively. This expression enables them to 
migrate toward infl ammatory sites that express their cognate chemokines (20), 
such as observed in the graft during rejection (21) and on activated human primary 
tubular epithelial cells (22). 
With respect to B cells, mycophenolic acid, but not tacrolimus, has been 
shown to inhibit the proliferation and immunoglobulin production in vitro (23). 
However, in patients with systemic lupus erythematosus who were treated with 
MMF, the number and phenotype of B cells were similar to that in controls without 
immunosuppressive therapy (24). In our cohort, discontinuation of MMF at 6 months 
after transplantation resulted in a relative increase of virgin naive Bm1 cells, while 
naive Bm2 cells were decreased compared to pre-transplant levels. Transitional 
Bm2 cells remained low up to 24 months after transplantation, suggesting that their 
development is mainly suppressed by treatment with tacrolimus and/or steroids. 
Finally, following the discontinuation of MMF, the percentage of memory B cells 
became comparable to levels before transplantation. Steroids were also found to 
have clear e# ects on B cells; ex vivo immunoglobulin production by PBMC was 
decreased during treatment with a high dose of prednisolone (60 mg) while a lower 
dose (30 mg) resulted in an increased production after stimulation (25). Others 
have described that steroids have an e# ect on B-cell activation, while proliferation 
and activation are less a# ected (26). Under combined treatment with tacrolimus, 
MMF, and steroids, our renal transplant recipients had a more memory-like B-cell 
phenotype compared to before transplantation. This relative increase of memory 
B cells was also found in a patient cohort treated with cyclosporine, MMF, steroids, 
and an anti-CD25 monoclonal antibody (18). The observed memory-like B-cell 
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phenotype was accompanied by an increased percentage of CD80+ and CD95+ B 
cells, which may be explained by the preferential expression of these molecules on 
memory-like B cells (17). 
Treatment with RTX provides a highly e"  cient means for the (temporary) 
depletion of B cells, with potential suppression of B cell-associated anti-graft 
responses. Adding a single dose of RTX to the combination of tacrolimus, MMF, and 
steroids in our patients indeed resulted in a long lasting B-cell depletion in peripheral 
blood. A remarkable characteristic of the returning B cells was a decreased 
expression of the receptor for B-cell activating factor (BAFF), an essential growth 
factor for B cells (27). The decreased percentage of BAFF-R+ B cells after RTX 
treatment, which was also found in patients with rheumatoid arthritis (28) may be 
due to a relative increase of memory-like B cells, which have lower or no BAFF-R 
expression (data not shown). In addition, treatment with B-cell depleting agents has 
previously been shown to elevate BAFF levels (29-31), and increased BAFF levels in 
turn were inversely correlated with BAFF-R expression during B-cell repopulation 
(30, 32). Another interesting observation was an increase in the percentage 
of transitional B cells at 12 months after treatment with RTX compared to triple 
immunosuppression therapy alone. Interestingly, BAFF-R defi ciency in patients 
with common variable immunodefi ciency (CVID) was associated with B-cell 
lymphopenia and a relative increase in the number of transitional B cells (33). Taken 
together, an increase in BAFF level, reduced BAFF-R expression, and an increase in 
the proportion of transitional B cells appear to be interrelated phenomena which 
are associated with RTX treatment.
Upon activation, B cells are able to proliferate, produce various cytokines and 
process antigen for presentation to T cells (34-36). Previously, we showed that 
in vitro RTX treatment can a# ect B-cell phenotype and function, resulting in an 
altered outcome of B-T-cell interaction upon stimulation (37). However, in contrast, 
we did not observe any changes in the T-cell compartment in our patients treated 
with RTX. It should be noted that we were only able to analyze peripheral blood 
T cells. From a previous study in renal transplant patients, we know that a single 
dose of RTX leads a to nearly complete B-cell depletion in peripheral blood, but 
not in secondary lymphoid organs, and that these remaining B cells have di# erent 
functional capacities (38). From our current data, it seems that this population of 
mostly memory type B cells residing in lymphoid organs does not noticeably a# ect 
the peripheral blood T-cell compartment as compared to transplant recipients on 
triple immunosuppression without RTX. Interestingly, several studies on patients 
with autoimmune disease revealed that the T-cell compartment was a# ected upon 
RTX treatment (12, 39, 40). However, in most of these patients the cumulative dose 
of RTX was higher than in our patients, who received only a single, relatively low 
dose (39). 
In summary, we have demonstrated that treatment of renal transplant 
recipients with tacrolimus, MMF and steroids leads to alterations in the T- and 
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B-cell compartments. This detailed longitudinal analysis provides more insight into 
the immune status of renal transplant recipients with stable graft function and may 
be used as a reference in the monitoring of renal transplant patients. 
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Abstract
Rituximab is a chimeric anti-CD20 monoclonal antibody used in B-cell malignancies, 
various autoimmune disorders, and organ transplantation. Although administration 
of a single dose of rituximab results in full B-cell depletion in peripheral blood, 
there remains a residual B-cell population in secondary lymphoid organs. These 
nondepleted B cells might be altered by exposure to rituximab, with subsequent 
immunomodulatory e# ects. Therefore, we analyzed in vitro the e# ects of 
rituximab on proliferation, activation, and di# erentiation of CD19+ B cells by means 
of  carboxyfl uorescein succinimidyl ester (CFSE)-based multiparameter fl ow 
cytometry. Rituximab inhibited the proliferation of CD27- naive, but not of CD27+ 
memory B cells. Interestingly, upon stimulation with anti-CD40 mAb and IL-21 in the 
presence of rituximab there was an enrichment of B cells that underwent only one or 
two cell divisions, and displayed an activated naive phenotype (CD27-IgD+CD38-/+). 
The potency of prestimulated B cells to induce T cell proliferation was increased 
by exposure of the B cells to rituximab. Of note, after stimulation with rituximab-
treated B cells, proliferated T cells displayed a more Th2-like phenotype. Overall, 
these results demonstrate that rituximab can a# ect human B-cell phenotype and 
function, resulting in an altered outcome of B-T cell interaction.
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Introduction
Rituximab (RTX) is a chimeric IgG1 monoclonal antibody that recognizes human 
CD20, a cell-surface glycoprotein, expressed on B cells throughout di# erentiation 
and lost during maturation to plasma cells (1, 2). RTX depletes B cells through three 
mechanisms: antibody-dependent cellular cytotoxicity (ADCC), complement-
dependent cytotoxicity (CDC), and apoptosis. Although the exact contribution of 
these mechanisms in vivo remains unclear, it is assumed that ADCC is the most 
dominant player, followed by CDC. Cell death through apoptosis is thought to be 
minimal (2-5).
Anti-B-cell therapy has an important place in the treatment of patients with 
malignant B-cell lymphoma (5). Furthermore, RTX is used to reduce the level of 
auto-antibodies in various auto-immune disorders (6, 7). However, treatment has 
also benefi cial e# ects on T-cell mediated diseases, such as rheumatoid arthritis 
(RA), multiple sclerosis, and type 1 diabetes, which suggests that the therapeutic 
e# ects cannot be solely ascribed to e# ects on antibody production (7-10). In renal 
transplantation, RTX is used in ABO-incompatible transplantation, in desensitization 
protocols, and for treatment of antibody-mediated rejection (11-13). Because the 
presence of CD20+ B cells in the graft is associated with poor outcome (14), RTX 
may be of additional value in the treatment of steroid resistant acute rejection 
with intragraft B-cell infi ltration (15, 16). The exact e# ects of RTX on B cells, and 
probably indirectly on T cells, in these various clinical conditions remains to be 
elucidated.
Following activation by antigen recognition, B cells are able to proliferate, 
produce various cytokines, and process antigen for presentation to T cells (17-
19). T follicular helper cells provide help to B cells via expression of CD40L and 
production of IL-21 (20). Depending on the activating conditions, B cells will 
eventually di# erentiate into plasma cells or will acquire a memory phenotype, 
which allows for rapid responses upon subsequent encounter of cognate antigen 
(17, 18, 21, 22). The cell surface molecules CD27 and IgD are used to identify the 
two main B-cell populations in peripheral blood: naive B cells are CD27-IgD+, while 
circulating memory B cells are CD27+IgD- (23). Recently, a regulatory B-cell subset 
has been identifi ed, which is predominantly found within the CD24highCD27+ B-cell 
population, and produces IL-10. This population is very small in healthy individuals, 
but was found to be increased in patients with autoimmune disease (24, 25).
In RTX-treated patients, the duration of B-cell depletion in the peripheral 
blood appears to depend on the disease, in combination with the number of RTX 
infusions. After a single dose of RTX there is a nearly complete B-cell depletion in 
peripheral blood. However, it should be appreciated that there remains a residual 
B-cell population in secondary and tertiary lymphoid organs (26-28). 
So far it is not clear what the exact functional capacity of these persisting, but 
potentially modulated B cells might be, and how they could infl uence the immune 
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response after treatment with RTX. To address this issue we set up an in vitro, non-
depleting B-cell stimulation model, and investigated the e# ects of RTX treatment 
on the phenotypic and functional characteristics of B cells.
Materials and methods
Cell isolation
Bu# y coats from healthy donors, who gave written informed consent for scientifi c 
use of the bu# y coats, were purchased from Sanquin Blood Bank, Nijmegen, The 
Netherlands. PBMC were isolated by density gradient centrifugation (Lymphoprep; 
Nycomed Pharma, Roskilde, Denmark). CD19+ B cells were positively selected 
using anti-CD19 magnetic microbeads (Miltenyi Biotec, Utrecht, The Netherlands). 
This resulted in a CD19+ B-cell enrichment of more than 97%. CD19+CD27- and 
CD19+CD27+ B cells were isolated by high-purity fl uorescence-activated cell 
sorting on an ALTRA cell sorter (Beckman-Coulter, Mijdrecht, The Netherlands). A 
rerun confi rmed that the purity of the sorted cells was more than 98%. 
CD4+CD25- T cells were obtained by sequential negative and positive selection 
of CD25- cells and CD4+ cells, respectively, with anti-CD25 and anti-CD4 magnetic 
microbeads (Miltenyi Biotec). This resulted in a 98% pure CD4+CD25- population.
Culture conditions
Freshly isolated B cells (5 x 104 cells per well) were cultured in 200 μl medium in 
the presence of anti-CD40 monoclonal antibody (αCD40 mAb, 1 μg/ml, Bioceros, 
Utrecht, The Netherlands) and recombinant human IL-21 (25 ng/ml, ZymoGenetics, 
Seattle, WA) for 6 days in 96-well round bottom plates (Greiner, Frickenhausen, 
Germany) in a 37°C, 95% humidity, 5% CO
2
 incubator. The culture medium consisted 
of RPMI-1640 supplemented with pyruvate (0.02 mM), glutamax (2 mM), penicillin 
(100 U/ml), streptomycin (100 μg/ml) (all from Gibco, Paisley, United Kingdom), and 
10% heat-inactivated pooled human serum (HPS). Where indicated, RTX was added 
in a concentration of 5 µg/ml.
In separate experiments, the e# ects of RTX and complement on viability of the 
B cells was assessed by incubating B cells (5 x 104 cells per well, 100 μl medium) for 
30 min at 37°C with or without RTX (5 µg/ml), and subsequently with 10-30% of 
HLA-ABC/DR rabbit complement (Invitrogen, Breda, The Netherlands) or culture 
medium only. After an additional 60 min the cell viability was assessed by fl ow 
cytometry using Annexin V-FITC (AnxV) and propidium iodide (PI, 5 µg/ml; Bender 
Medsystems, Vienna, Austria) according to the manufacturer’s instructions.
In some experiments, the cells that remained after incubation with RTX and 
complement were washed and subsequently incubated for six days with medium 
containing αCD40 mAb, IL-21 and RTX, as described above.
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Flow cytometry and CFSE labeling
For cell surface staining, the following fl uorochrome-conjugated mAbs were used: 
CD19(SJ25C1)-PeCy7, CD70(Ki-24)-PE, CD80(L307.4)-PeCy5, CD86(233-(fun-
1))-PE, IgD(IA6-2)-biotin, CCR4(1G1)-PeCy7, CCR6(11A9)-PE, HLA-DR(L243(G46-
6))-PE (BD Biosciences, Erembodegem, Belgium), CD27(1A4-CD27)-PeCy5, 
CD62L(DREG56)-ECD, CD69(TP1.55.3)-ECD (Beckman-Coulter, Mijdrecht, The 
Netherlands), CD38(HIT2)-PE (Immunotools, Friesoythe, Germany), CXCR3(1C6/
CXCR3)-PeCy5 (eBioscience, Uithoorn, The Netherlands), CD27(M-T271)-PE, 
CD95(DX2)-PE (Dako, Glostrup, Denmark), CD138(B-B4)-PeCy5 (IQ Products, 
Groningen, The Netherlands), CD25(4E3)-biotin (Miltenyi Biotec), CD27(M-T271)-
biotin (Ancell, Bayport, MN), IgM-PE (Southern Biotech, Birmingham, AL), BAFF-
R(11C1) (BioLegend, San Diego, CA). The detection of biotinylated antibodies was 
performed with streptavidin conjugated to Quantum dots (Qdot 605, Invitrogen, 
Breda, The Netherlands). Isotype-matched antibodies were used to defi ne marker 
settings. Intracellular analysis of IL-2(MQ1-17H12)-PE, IL-6(AS12)-PE, IL-10(JES3-
19F1)-PE, TNFα (Mab11)-PE (BD Biosciences), GATA3(TWAJ)-Alexa fl uor 647, 
RORγt(AFKJS-9)-PE, FOXP3(PCH101)-Alexa fl uor 647, IL-4(8D4-8)-PeCy7, IL-
17(EBIO64DEC17)-Alexa fl uor 647, IL-21(eBIO3A3-N2)-PE, IFNγ(4S.B3)-PeCy7 
(eBioscience), Tbet(4B10)-PE (Santa Cruz Biotech, Heidelberg, Germany) and 
IL-22(142928)-PE (R&D Systems, Oxon, UK) was performed after fi xation and 
permeabilization, using Fix and Perm reagent (eBioscience). Before intracellular 
cytokine measurement, the cells were stimulated for 4 hours with PMA (12.5 ng/ml) 
plus ionomycin (500 ng/ml) in the presence of Brefeldin A (5 μg/ml; Sigma-Aldrich, 
Zwijndrecht, The Netherlands).
To study cell division by fl ow cytometry, 1-10 x 106 cells of interest were labeled 
with 0.5-1 μM carboxyfl uorescein succinimidyl ester (CFSE; Molecular Probes, 
Leiden, The Netherlands) prior to stimulation. The cell phenotype was analyzed 
by fi ve-color fl ow cytometry (FC500, Beckman-Coulter), and data were analyzed 
using CXP software (Beckman-Coulter). In some experiments, cells were counted 
by fl ow cytometry using Flow-Count fl uorospheres (Beckman-Coulter). 
Cytokine detection
After 6 days of culture, B cells were labeled with CD27(M-T271)-PE. CFSEintCD27- and 
CFSElowCD27high were isolated on an ELITE cell sorter (Beckman-Coulter). Human 
IL-1β, IL-2, IL-4, IL-6, IL-10, IFNγ and TNFα were determined in the supernatant of 
these B-cell cultures using a human cytokine multiplex kit (Invitrogen) according 
to the manufacturer’s instructions. Before cytokine measurement, B cells (2.5-5 x 
104 cells per well) were stimulated overnight with PMA (12.5 ng/ml) plus ionomycin 
(500 ng/ml; Sigma-Aldrich). Supernatants were collected and stored at -20˚C until 
analysis. 
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In vitro T-cell proliferation assay
B cells harvested at day 6 of culture were washed, counted and added to 5 x 104 
CFSE-labeled allogeneic CD4+CD25- T cells
 
in a 1:1 ratio for an additional 6 days of 
culture. CD4+ T
 
cells were analyzed by fl ow cytometry.
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5.03 (GraphPad Software 
Inc., La Jolla, CA, USA). Data in box-and-whisker plots represent the median, lower 
and upper quartiles, and minimum and maximum values. Paired t-tests were used 
to compare results obtained with cells cultured in the presence or absence of RTX. 
The Wilcoxon matched-pairs signed rank test was used for non-normally distributed 
data. P-values <0.05 were considered statistically signifi cant and are indicated with 
asterisks.
Results
RTX inhibits B-cell proliferation, without apoptosis induction
In order to mimic the in vivo situation in lymphoid organs, where B cells are 
exposed to RTX but not depleted, we fi rst characterized a non-depleting in vitro 
B-cell stimulation model. Freshly isolated B cells were incubated in the presence 
or absence of RTX for 30 min, followed by an additional 60 min in the presence 
or absence of complement. Next, cell viability was assessed by fl ow cytometry 
using AnxV and PI staining. RTX alone did not increase the frequency of apoptotic 
 (AnxV+PI-) or necrotic (AnxV+PI+) cells (Figure 1A). The addition of complement 
to the RTX-treated cells resulted in a dose-dependent necrosis of B cells, while 
complement alone had a negligible e# ect on the percentage and absolute number 
of viable cells (AnxV-PI-; Figure 1B). Notably, the phenotype of the viable B cells 
that remained after exposure to RTX and complement was largely similar to that of 
the cells that were exposed to RTX only (Figure 1C). 
To assess the e# ect of RTX on the proliferative capacity of B cells, fresh B 
cells were stimulated with αCD40 mAb and IL-21, in the presence or absence of 
RTX. Dose-response kinetics, using 0, 2.5, 5, and 10 μg/ml RTX revealed optimal 
inhibition of proliferation at a concentration of 5 μg/ml (data not shown). In the 
absence of RTX, about 70% of the cells had divided at day 6 of culture, whereas in 
the RTX-treated condition this percentage was signifi cantly lower (60%, P<0.01) 
(Figures 1D and 1E, upper and middle panels). The same experiment was repeated 
with the small proportion of B cells that remained after incubation with RTX and 
complement as starting population. In this case a similar inhibition of proliferation 
by RTX was observed (Figures 1D and 1E, lower panels). As the e# ects of RTX on the 
total B-cell population and on the fraction remaining after exposure to RTX 
88
Chapter 4
W/O   RTX
W
/O
c
o
m
p
le
m
e
n
t
7
290
1 6
389
2
8
585
2 82
12
1
BA
P
I
Annexin V
10
4
10
3
10
2
10
1
10
0
10
0
10
1
10
2
10
3
10
4
10
4
10
3
10
2
10
1
10
0
10
0
10
1
10
2
10
3
10
4
10
4
10
3
10
2
10
1
10
0
10
0
10
1
10
2
10
3
10
4
10
4
10
3
10
2
10
1
10
0
10
0
10
1
10
2
10
3
10
4
C
5
W/O RTX
0 10 20 30
conc. complement (%)
AnxV-PI- (viable cells)
0
100
RTX - + - +
- - + +complement
%
 p
o
si
ti
v
e
 c
e
ll
s
0
100
- + - +
- - + +
0
20
20
100
- + - +
- - + +
*
D
0 10 20 30
0
100
* **
%
 p
o
si
ti
v
e
 c
e
ll
s
0
60
* *
A
b
so
lu
te
n
u
m
b
e
rs
 (
*1
0
3
)
E
IgD+ CD27+ CD38+
E
v
e
n
ts
CFSE
CFSE-labeled 
B cells
+ RTX
+ RTX
+ complement
wash
+ RTX
90 min 6 days
CD40 mAb + IL-21
+ RTX
CD40 mAb + IL-21α
αCD40 mAb + IL-21
CFSE analysis
0 100
ns
Proliferated cells (%, n=4)
**
**
medium
α
 Characterization of an in vitro nondepleting system to establish the 
functional e! ects of RTX on B cells. 
(A) Freshly isolated CD19+ B cells were incubated with (bottom row) or without (top row) 
20% rabbit HLA-ABC/DR complement in the presence (right panel) or absence (left panel) 
of 5 μg/ml RTX. Annexin V (AnxV) and propidium iodide (PI) staining were analyzed using 
Figure 1.
89
Rituximab e# ects on B-cell phenotype and function
4
and complement appeared similar, we continued to use the non-depleted B-cell 
population in further experiments for practical reasons (cell numbers).
B-cell stimulation in the presence of RTX results in a population shift 
toward an activated naive phenotype
Following the fi nding that RTX inhibited B-cell proliferation, we studied the 
phenotype of the RTX-treated B cells by means of CFSE-based multiparameter 
fl ow cytometry. Typically, stimulation of B cells with αCD40 mAb and IL-21 for 6 
days resulted in the loss of IgD, and the gain of CD27 expression during sequential 
cycles of cell division (Figure 2A, middle panels). The inhibition of cell division by 
RTX resulted in a relative increase of IgD+CD27- cells. Based on the CFSE content 
and the expression of CD27, IgD, and CD38, we defi ned four B-cell subsets after 
αCD40 mAb and IL-21 stimulation: undivided CFSE++CD27-IgD+CD38- cells (from 
here on referred to as subset I), undivided CFSE++CD27+IgD-/+CD38- cells (subset 
II), cells that underwent one or two cell divisions (CFSE-/+CD27-IgD+CD38-/+; subset 
III) and cells that underwent three or more cell divisions (CFSE-CD27++IgD-CD38++; 
subset IV). A similar subset distribution was observed when the fraction of B 
cells remaining after incubation with RTX and complement was used as starting 
population for stimulation with αCD40 mAb and IL-21 (data not shown). The 
presence of RTX during B-cell stimulation resulted in a relative increase of both the 
percentage and absolute cell numbers in subset III and a decrease of cells in subset 
IV (Figure 2B and 2C). 
Next, the phenotype of the four di# erent subsets was assessed in more detail. 
Freshly isolated B cells were positive for BAFF-R and the majority of these cells 
expressed CD24 and CD62L. Approximately half of this population expressed IgD, 
around 25% expressed CD27 and IgM, whereas expression of CD38, CD138, CD25, 
CD69, CD95, CD70, CD80, and CD86 was virtually lacking (Figure 3, left panel). 
fl ow cytometry. The percentage of viable (AnxV-PI-), apoptotic (AnxV+PI-) and necrotic 
(AnxV+PI+) cells is  indicated. One representative experiment of 4 is presented. (B) The 
percentages and absolute numbers of viable cells (AnxV-PI-) are shown after 30 min 
incubation in the absence (W/O; open) or presence of RTX (grey) with subsequent addition 
of various concentrations of complement for 60 min. Shown are the results for 4 di# erent 
donors. (C) The proportions of IgD+, CD27+ and CD38+ B cells within the population of viable 
cells harvested after incubation with RTX and 20% complement. Shown are the results for 
4 di# erent donors. (D) CFSE-labeled CD19+ B cells were incubated fi rst in the absence 
(W/O) or presence of RTX and complement. After washing, the cells were stimulated with 
αCD40 mAb and IL-21 in the presence or absence of RTX. Histograms show the CFSE 
division patterns at day 6 of total B-cell population (top) or the remaining B cells after RTX 
and complement mediated lysis (bottom). (E) Summary plot showing the percentages of 
proliferated B cells (data from 4 independent experiments, using 4 di# erent blood donors); 
*P<0.05; **P<0.01; ns: not signifi cant. W/O: without addition of RTX or complement. 
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Upon stimulation there was an increased expression of the activation marker CD25 
in all subsets, and CD69 was expressed in subsets I, II, and III (Figure 3). Subset II 
was characterized by a relatively low expression of IgD. CD138 was most strongly 
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Figure 3. Phenotypic characterization of RTX-treated B cells. 
The expression of various markers on freshly isolated CD19+ B cells (start) and on B cells that 
were CFSE-labeled and stimulated with αCD40 mAb and IL-21 in the presence or absence 
of 5 μg/ml RTX. Data are shown from 6-8 independent experiments, with di# erent donors; 
*P<0.05, **P<0.01. W/O: without addition of RTX.
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expressed by cells in subset III, while CD38 and CD95 were typically expressed by 
cells in subset IV. 
Addition of RTX resulted in a signifi cantly higher percentage of IgD+ cells in 
all subsets, except for subset IV, which lacked IgD+ cells. Furthermore, there was 
a lower percentage of CD24+ cells in subsets I and II. The expression of other cell 
surface markers was less markedly changed in the presence of RTX (Figure 3).
RTX inhibits the proliferation of  CD19+CD27- naive, but not of 
CD19+CD27+ memory B cells
As we noticed that the starting population of freshly isolated B cells consisted 
of both naive CD27- and memory-type CD27+ cells, we examined which of these 
populations was most a# ected by RTX. Sorted CD19+CD27- and CD19+CD27+ B cells 
were labeled with CFSE and cultured with αCD40 mAb and IL-21 in the presence 
or absence of 5 μg/ml RTX for 6 days (Figure 4A). In this system, the CD27+ cells 
proliferated much stronger than the CD27- cells (Figure 4B). The same gating 
strategy as in Fig. 2B was then used to defi ne four B-cell subsets. Upon stimulation, 
part of the CD19+CD27- B cells divided and di# erentiated into subset III, and to a 
lesser extent into subset IV type cells, whereas the majority of memory CD19+CD27+ 
B cells rapidly turned into subset IV-type cells. So, RTX inhibited the proliferation 
and di# erentiation of naive CD19+CD27-, but not of memory CD19+CD27+ B cells. 
As for the total CD19+ population, we also examined the detailed phenotype of 
isolated CD19+CD27- and CD19+CD27+ B cells before and after stimulation, in the 
presence or absence of RTX (Figures 4C and 4D, respectively). The main fi nding 
was that in the presence of RTX, stimulation of CD19+CD27- B cells resulted in a 
larger fraction of IgD+ cells in subsets I and III, similarly as previously observed 
for the total CD19+ population. Similar to CD19+ B cells, subset III, di# erentiated 
from CD19+CD27- B cells, expressed signifi cantly less CD69 and more CD95 
after exposure to RTX , which resulted in a heterogeneous activation status. 
As expected, RTX had no e# ect on the phenotype of subset IV, di# erentiated 
either from CD19+CD27- or from CD19+CD27+ B cells. Again, RTX increased the 
percentage of IgD positive B cells in all subsets, except subset IV. Thus, RTX inhibits 
the proliferation of naive CD19+CD27-, but not memory of CD19+CD27+ B cells, with 
a population shift into a more naive (IgD+) phenotype.
RTX has no major e! ects on the B-cell-cytokine profi le
We wondered whether the RTX-induced B-cell population shift was associated with 
changes in cytokine production. At day 6 of culture, CFSEintCD27- (subset III) and 
CFSElowCD27high (subset IV) cells were sorted, restimulated with PMA/ionomycin 
and cytokines were measured in the supernatant. TNFα, IL-2, IL-6, and IL-10 were 
exclusively produced by CFSEintCD27- cells, but not by CFSElowCD27high cells. RTX 
slightly increased the production of IL-6 by CFSEintCD27- cells, but did not change 
the production of TNFα, IL-2, and IL-10 (Figure S1A).
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We also measured the intracellular cytokine production of TNFα, IFNγ, IL-2, 
IL-4, IL-6, and IL-10 in the B-cell subsets. After exposure to RTX, the fraction of 
TNFα-producing cells in subsets I+II was slightly enlarged, while the fraction of IL-4 
producing cells was smaller (Figure S1B). RTX had no e# ect on the percentage of 
IL-2 or IL-6 expressing B cells. 
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Figure 4. E! ects of RTX on sorted CD27- naive and CD27+ memory B cells. 
(A) CD19+ B cells were sorted into a CD27- (naive) and CD27+ (memory) B-cell fraction. 
(B) CFSE expression profi le of these cells is presented after 6 days of culture with αCD40 
mAb and IL-21 in the presence (grey fi lled histogram) or absence (black line histogram) 
of RTX. Percentages of the di# erent B-cell subsets as defi ned in Figure 2B are shown. 
One representative experiment of 6 is presented. CFSE-labeled naive CD19+CD27- (C) 
and memory CD19+CD27+ (D) B cells were cultured as described in A. The expression at 
day 0 (start) and after 6 days of culture of the indicated molecules was assessed by fl ow 
cytometry. Data are shown from 6-7 independent experiments, with di# erent donors; 
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B cells exposed to RTX enhance CD4+ T cell proliferation and induce a 
more Th2-like phenotype
Next, we studied the e# ect of RTX on the antigen-presenting function of B cells, 
after having established that RTX had no e# ect on HLA-DR expression (Figure S2). 
B cells stimulated with αCD40 mAb and IL-21 for 6 days in the presence or absence 
of RTX were added to CFSE-labeled allogeneic CD4+CD25- T cells for an additional 
6 days of culture. B cells that were stimulated in the presence of RTX induced 
considerably stronger T cell
 
proliferation than B cells stimulated in the absence of 
RTX (Figures 5A and B).
T cells that proliferated after
 
stimulation with RTX-treated B cells contained 
a smaller fraction of CD27+ cells and a larger fraction of CD70+ cells, however 
T-cell proliferation 
upon stimulation 
with B cells. 
(A) CFSE division patterns 
of CD4+CD25- T cells after 
coculture with αCD40 mAb 
and IL-21 prestimulated B cells 
in the presence or absence 
of RTX. Numbers denote the 
percentage of proliferated cells. 
(B) Summary plot showing the 
percentage of proliferated cells 
from 8 di# erent donors; **P<0.01 
(C) The surface expression of 
the indicated molecules, the 
intracellular expression of several 
transcription factors, and the 
intracellular cytokine staining 
within the proliferated T cell 
population were analyzed on day 6 
of culture. (D) The Th1/Th2 ratio of 
the proliferated T cell population, 
represented as IL-2/IL-4 and T-bet/
GATA3 ratios. Shown are the 
results of 4-5 di# erent donors; 
*P<0.05. W/O: without addition of 
RTX.
10
4
10
3
10
2
10
1
10
0
10
0
10
1
10
2
10
3
10
4
10
4
10
3
10
2
10
1
10
0
10
0
10
1
10
2
10
3
10
4
A B
CFSE
C
D
4
RTX
αCD40 mAb + IL-21 
prestimulated B cells
C
8% 19%
W/O RTX
0
75
**
P
ro
lif
e
ra
te
d
 T
 c
e
lls
 (
%
)
D
0
100
CD25 CD69 CD62L CD27 CD70
*
*
*
0
100
CXCR3 CCR4 CCR6
*
T-bet GATA3 RORJt
0
100
IL-2 IL-4 IL-17 IFNJ TNFDIL-21
*
*
IL-2/IL-4
W/O RTX
0
6
T
h
1/
T
h
2
 r
a
ti
o
T-bet/GATA3
W/O RTX
0
0.6 *
%
 p
o
si
ti
v
e
 p
ro
lif
e
ra
te
d
 T
 c
e
lls
W/O
RTX
W/O
Figure 5.
95
Rituximab e# ects on B-cell phenotype and function
4
there was no e# ect on T cell activation (CD25 and CD69) or the ratio of naive/
memory T cells (CD62L; Figure 5C). Interestingly, after stimulation of T cells with 
RTX-treated B cells, the proliferated T cells showed an increased expression of 
the Th2-associated chemokine-receptor CCR4, transcription factor GATA3, and 
increased production of cytokine IL-4. The expression of Th1-associated (CXCR3, 
Tbet, IL-2, IFNγ, TNFα) and Th17-associated (CCR6, RORγt, IL-17) markers in these T 
cells was not infl uenced by exposure of the B cells to RTX prior to their use as T cell 
stimulators. Consequently, the proliferated T cells displayed a decreased Th1/Th2 
ratio, as represented by decreased IL-2/IL-4 and T-bet/GATA3 ratios (Figure 5D).
Discussion
In this study, we showed that RTX inhibited the proliferation of stimulated human 
B cells, which was associated with a relative increase of B cells with an activated 
naive phenotype. Aside from this population shift, there were no major changes 
in phenotype or cytokine profi le of the various B-cell subsets as such. B cells 
stimulated in the presence of RTX induced stronger T-cell proliferation, compared 
to B cells stimulated in the absence of RTX. Moreover, the resulting T-cell population 
showed a more Th2-like phenotype. 
Studies on the immune processes involved in transplant rejection have 
been mainly focused on T-cell-mediated mechanisms. Accordingly, most 
immunosuppressive drugs especially target T cells. Interestingly, anti-B-cell 
therapy appears to be of additional value in ABO-incompatible transplantation, 
desensitization protocols, and for treatment of antibody-mediated rejection (11-
13). Moreover, renal transplant patients treated with a single-dose of RTX as an 
induction therapy, together with standard immunosuppressive treatment, showed 
a tendency toward fewer and milder rejection episodes compared to the placebo-
group (29). However, the relative contribution of B cells in these conditions, and 
the exact mechanism of action of RTX remain to be elucidated. In renal transplant 
patients, a single dose of RTX e# ectively depleted all peripheral B cells, as well 
as B cells in the renal allograft, but spared up to 50% of B cells in lymph nodes 
(26). Notably, RTX appeared to be bound to these B cells (26). Also in patients 
with RA, the number of synovial B cells was signifi cantly decreased at 4 weeks 
after RTX-treatment, but there was no complete depletion (30). These important 
observations suggest that treatment with RTX may a# ect the phenotype or 
function of a residual population of B cells. Our in vitro culture system mimicked 
this scenario, since B cells were exposed to RTX, but survived when no complement 
was added to the culture medium. Moreover, the small fraction of B cells that 
remained after complement mediated lysis, resembled the total B-cell population 
with respect to phenotype and e# ects of RTX. To imitate the in vivo stimulation of 
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B cells in the lymph nodes, we added αCD40 mAb and IL-21 to the culture medium. 
Furthermore, the culture medium was supplemented with pooled human serum, 
resulting in IgG1 concentrations of about 500-1000 μg/ml. We therefore consider 
the observed e# ects of RTX (used in a concentration of 5 μg/ml) specifi c for its 
CD20 binding property and not a consequence of non-specifi c binding of the IgG1 
molecule. 
CD20 is a tetraspanin-like protein involved in lipid raft formation (31). Binding 
of RTX to CD20 interferes with B-cell receptor (BCR) signaling by preventing 
BCR relocalization into the lipid rafts and inhibition of the downstream BCR 
signaling cascade (32). These e# ects of RTX can explain the inhibition of B-cell 
proliferation that we observed. Interestingly, we found that the antiproliferative 
e# ect of RTX was limited to the CD27- naive B-cell population. In agreement with 
these fi ndings, it has been reported that RTX administered in vivo as part of a 
desensitization protocol decreased the number of splenic naive B cells, but had 
no e# ect on the number of CD27+ memory B cells (33). These discordant e# ects 
of RTX on naive and memory B cells do not seem to be directly related to the 
level of CD27 expression, since Franke et al. found no relationship between the 
RTX induced changes in gene expression and the surface expression of CD27 in 
various B-cell lines (34). The antiproliferative e# ect of RTX during stimulation of 
the B cells was accompanied by a shift in the distribution among B-cell subsets, as 
defi ned by the CFSE content in combination with the expression of CD27, IgD, and 
CD38. After 6 days of culture in the presence of RTX, there was an enrichment 
of CD27-IgD+CD38-/+ cells representing an activated naive phenotype. These cells 
underwent only one or two cell divisions (subset III), but did not go into apoptosis 
which can be explained by the lack of cross-linking of the Fc parts of RTX in our in 
vitro culture system (31).
A striking fi nding was that B cells stimulated with αCD40 mAb and IL-21 in the 
presence of RTX induced stronger T cell proliferation than B cells stimulated in the 
absence of RTX. Since the phenotype and cytokine profi le of the various B-cell 
subsets only marginally di# ered, we believe that the altered distribution among 
the B-cell subsets was mainly responsible for this observation. There was a relative 
increase of activated naive B cells (subset III) and a decrease of plasmablast-like 
cells (subset IV). Plasmablasts (and plasma cells) are terminally di# erentiated B 
cells specialized in producing antibodies while activated B cells can have antigen 
presenting functions (35). A relative increase of these latter cells after B-cell 
stimulation in the presence of RTX can explain the stronger induction of T-cell 
proliferation. 
The enhanced T-cell proliferation induced by RTX-treated B cells might 
implicate that anti-B-cell therapy can also have deleterious e# ects, as has been 
reported for renal transplant patients (36). On the other hand, we observed that the 
proliferated T cells displayed a di# erentiation toward a Th2-like phenotype, which 
is usually associated with graft acceptance rather than rejection (37). Interestingly, 
a recent study showed the accumulation of B cells with an inhibited profi le in a rat 
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model of allograft tolerance (38). This changed B-cell profi le was accompanied by 
a deviation toward the Th2-related IgG1 isotype alloantibodies. A similar shift in the 
B-cell population has also been observed in renal transplant patients with stable 
kidney graft function in the absence of immunosuppression (39). 
In summary, we have demonstrated that RTX can a# ect B-cell proliferation 
and di# erentiation, leading to an altered distribution among defi ned B-cell subsets. 
Exposure of B cells to RTX has e# ects on subsequent interaction between B and 
T cells in vitro. In organ transplantation, anti-B-cell therapy should therefore be 
applied with caution, and preferably be accompanied by additional studies that give 
more insight into the e# ects of RTX on the alloimmune response in vivo.
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Supplementary Figure 1.
E! ects of RTX on the cytokine 
profi le of stimulated B cells. 
(A) CFSE-labeled B cells were 
stimulated with αCD40 mAb and 
IL-21 in the presence or absence 
of RTX On day 6, CFSEintCD27- 
(subset III) and CFSElowCD27high 
(subset IV) cells were sorted 
and re-stimulated with PMA plus 
ionomycin. Culture supernatants 
were analyzed for the production 
of IL-1β, IL-2, IL-4, IL-6, IL-10, 
IFNγ, and TNFα by Luminex. 
IL-1β, IL-4, and IFNγ remained 
undetectable. Data are shown 
from 5 independent experiments, 
with di# erent donors. (B) 
Intracellular expression of TNFα, 
IFNγ, IL-2, IL-4, IL-6, and IL-10 was 
measured in the B-cell subsets 
as defi ned in Fig. 2B at day 6 of 
culture. Intracellular expression 
of IFNγ and IL-10 remained below 
0.1% and are therefore excluded 
from this analysis. After the fi x and 
perm treatment, CD27 expression 
was changed in such a way that 
subsets I and II could no longer be 
distinguished from one another. 
Therefore, these subsets were 
taken together for intracellular 
cytokine measurement. Data 
are shown from 5-8 di# erent 
experiments with di# erent donors. 
W/O: without addition of RTX.
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Supplementary Figure 2. HLA-DR expression of stimulated B cells. 
Expression of HLA-DR by αCD40 mAb plus IL-21 stimulated B cells in the absence (W/O) or 
presence of RTX for 6 days. The percentage positive cells (A) and the mean fl uorescence 
intensity (B) are depicted.
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Abstract
A single dose of the anti-CD20 monoclonal antibody rituximab induces a nearly 
complete B-cell depletion in peripheral blood, but not in secondary lymphoid 
organs. Modulation of this remaining B-cell population due to rituximab treatment 
may contribute to the therapeutic e# ects of rituximab. To assess the in vivo e# ects 
of rituximab we used lymph nodes collected during renal transplant surgery in 
patients who had received rituximab four weeks earlier in preparation for an ABO-
incompatible transplantation. Rituximab treatment resulted in a lower percentage 
of naive (IgD+CD27-) and a higher percentage of switched memory (IgD-CD27+) 
B cells. Remarkably, transitional (CD24++CD38++) B cells were virtually lacking in 
the lymph nodes of rituximab-treated patients. Moreover, lymph node-derived B 
cells from rituximab-treated patients produced di# erent amounts of various Ig-
subclasses after anti-CD40/IL-21 stimulation ex vivo. Finally, after stimulation of 
allogeneic T cells with lymph node-derived B cells from rituximab-treated patients, 
the proliferated T cells showed a decreased production of IL-17. In conclusion, after 
treatment with rituximab there remains a B-cell population with di# erent functional 
capacities. Consequently, the e# ect of rituximab on the immune response will not 
only be determined by the extent of B-cell depletion, but also by the functional 
properties of the remaining B cells.
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Introduction
After transplantation of a solid organ graft, B cells can play a major role in graft 
rejection via the production of alloantibodies, but they can also induce an immune 
response by acting as professional antigen presenting cells, or by the production of 
various cytokines (1). It has recently been shown that a subset of human B cells can 
display regulatory function (B
REG
). This subset, which is predominantly found within 
the CD24++CD38++ B-cell population and produces IL-10, is very small in healthy 
individuals but was found to be increased in patients with autoimmune diseases 
(2, 3) and in tolerant transplant patients who had stable graft function despite 
receiving no immunosuppression for at least one year (4). Since B cells can play 
such a variety of roles in the immune response, the e# ects of anti-B-cell therapy 
have to be analyzed carefully.
The chimeric anti-CD20 monoclonal antibody rituximab (RTX) triggers B-cell 
lysis through antibody-dependent cellular cytotoxicity, complement-dependent 
cytotoxicity, or apoptosis induction (5, 6). RTX is used to reduce autoantibody levels 
in various autoimmune disorders (7). However, RTX can also ameliorate chronic 
infl ammatory diseases mediated by T and B cells, such as rheumatoid arthritis (8) 
and multiple sclerosis (9), suggesting that the therapeutic e# ect of RTX not solely 
depends on inhibition of antibody production. In renal transplantation, RTX is used 
successfully in ABO-incompatible (ABOi) transplantation (10), in desensitization 
protocols (11), and for treatment of antibody-mediated rejection (12). 
Although a single dose of RTX induces a nearly complete B-cell depletion in 
peripheral blood, there often remains a residual B-cell population in secondary 
lymphoid organs (13-15). We have previously shown that exposure of human 
peripheral blood B cells to RTX in an in vitro nondepleting stimulation model 
a# ects B-cell phenotype and function, resulting in an altered outcome of B-T-
cell interaction (16). This triggered us to study the functional properties of the 
nondepleted but potentially modulated B cells that remain present in secondary 
lymphoid organs after treatment with RTX. To this end, we collected lymph nodes 
(LNs) during renal transplant surgery in patients who had received RTX four 
weeks earlier in preparation for an ABO-incompatible renal transplantation (17). 
The phenotypic and functional properties of B cells isolated from these LNs were 
compared with B cells isolated from LNs collected from renal transplant patients 
not treated with RTX.
Materials and Methods
Collection and preparation of samples
Peripheral blood (PB) samples were obtained before renal transplantation and bu# y 
coats from healthy donors were purchased from Sanquin Blood Bank (Nijmegen, The 
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Netherlands). Peripheral blood mononuclear cells (PBMCs) were isolated by density 
gradient centrifugation using Lymphoprep (Lucron, Dieren, The Netherlands). Iliac 
LN were obtained during transplant surgery. Spleen cells (SPL) were obtained 
from deceased organ donors. LN and SPL samples were fi rst homogenized and 
subsequently forced through 75 µm netwell fi lters (Costar, Corning International, 
Amsterdam, The Netherlands) to obtain single-cell suspensions. Mononuclear LN 
and SPL cells were isolated by density gradient centrifugation using Lymphoprep 
(Nycomed Pharma, Roskilde, Denmark). All samples were cryopreserved in liquid 
nitrogen until analysis.
Patients scheduled for an ABO-incompatible renal transplantation received 
a single dose of 375 mg/m2 RTX (Mabthera, Roche Pharma AG, Grenzach-
Wyhlen, Germany) intravenously four weeks before transplantation. Prior to RTX 
administration,  25 mg prednisolone was given intravenously. Two weeks before 
transplantation, treatment with tacrolimus (0.2 mg/kg/day), mycophenolate 
mofetil (2 g/day) and prednisolone (10 mg/day) was started. Intravenous 
immunoglobulin (IVIG, Nanogam, Sanquin, Amsterdam, The Netherlands; 0.5 g/
kg) was administered the day before surgery. Patients scheduled for a regular, 
ABO-compatible living donor kidney transplantation were used as controls. 
Table 1 summarizes the characteristics of all patients. None of the patients had a 
systemic auto-immune disease as cause of renal insu"  ciency and none of them 
received any immunosuppressive drug during the last three months prior to 
transplantation (or the administration of RTX in the ABO-incompatible group). The 
study was performed in accordance with the regulations set by the Medical Ethics 
Committees of the participating hospitals. Informed consent was obtained from all 
participants.
Cell isolation
B cells were purifi ed from SPL and LN cells by negative selection using monoclonal 
antibodies directed against CD3(UCHT1), CD8(RPA-T8), CD14(M5E2), CD16(3G8), 
CD33(P67.6), CD56(B159), and CD235a(GA-R2(HIR2)) (BD Biosciences, 
Erembodegem, Belgium) combined with sheep anti-mouse Ig-coated magnetic 
beads (Dynal, Denmark). This resulted in a CD19+ B-cell enrichment of more 
than 90%. CD3+ T cells were positively selected from PBMCs of healthy donors 
using anti-CD3 magnetic microbeads (Miltenyi Biotec, Utrecht, The Netherlands) 
resulting in a purity of more than 95%.
Culture conditions
For functional studies, 5 x 104 cryopreserved LN and SPL cells were cultured in 
RPMI-1640 medium supplemented with pyruvate (0.02 mM), glutamax (2 mM), 
penicillin (100 U/ml), streptomycin (100 μg/ml) (all from Gibco, Paisley, United 
Kingdom), and 10% heat-inactivated pooled human serum (HPS) in 96-well round 
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bottom plates (Greiner, Frickenhausen, Germany) in a 37°C, 95% humidity, 5% CO
2
 
incubator. In selected conditions, 5 µg/ml RTX was added to the culture medium.
Flow cytometry and CFSE labeling
For cell surface staining, the following fl uorochrome-conjugated mAbs were 
used: CD19(SJ25C1)-PeCy7, CD20(2H7)-PeCy7, CD25(M-A251)-PE (BD 
Biosciences), CD3(UCHT1)-ECD, CD4(13B8.2)-PeCy5, CD5(BL1a)-APC Alexa 
Fluor 700, CD8(SFCI21Thy2D3)-ECD, CD19(J3-119)-ECD, CD19(J3-119)-APC 
Alexa Fluor 750, CD24(ALB9)-APC, CD27(1A4-CD27)-PeCy5.5, CD38(LS198-4-
3)-PeCy7, CD45(J.33)-FITC, CD45(J.33)-Krome Orange, CD45RO(UCHL1)-ECD, 
CD56(N901)-PeCy5, IgD(IADB6)-FITC, IgM(SA-DA4)-PE (Beckman-Coulter, 
Mijdrecht, The Netherlands), CD127(EBIORDR5)-PeCy7 (eBioscience, Uithoorn, 
The Netherlands), CD8(DK25)-PE and CD27(M-T271)-PE (Dako, Glostrup, 
Denmark). Isotype-matched antibodies were used to defi ne marker settings. 
Intracellular analysis of IL-2(MQ1-17H12)-PE (BD Biosciences), IL-4(8D4-8)-PeCy7, 
IL-17(EBIO64CAP17)-PE, and IFNγ(4S.B3)-PeCy7 (eBioscience) was performed 
after fi xation and permeabilization, using Fix and Perm reagent (eBioscience). 
Before intracellular cytokine measurement, the cells were stimulated for 4 hours 
with PMA (12.5 ng/ml), ionomycin (500 ng/ml) and Brefeldin A (5 μg/ml; Sigma-
Aldrich, Zwijndrecht, The Netherlands).
To study cell division by fl ow cytometry, 8 x 106 cells were labeled with 0.5 μM 
CFDA-SE (Molecular Probes, Leiden, The Netherlands) prior to stimulation. The 
cell phenotype was analyzed by fi ve-color fl ow cytometry (FC500) or ten-color 
fl ow cytometry (NaviosTM), and data were analyzed using CXP or Kaluza® software, 
respectively (all from Beckman-Coulter). 
Immunoglobulin isotyping assay
CD19+ LN B cells (5 x 104 cells) were cultured in the presence of anti-CD40 
monoclonal antibody (αCD40 mAb, 1 μg/ml, Bioceros, Utrecht, The Netherlands) 
and recombinant human IL-21 (100 ng/ml, ZymoGenetics, Seattle, WA) for 8 days 
in culture medium supplemented with 10% fetal bovine serum (FBS). Supernatants 
were stored at -20˚C until analysis. Human IgG1, IgG2, IgG3, IgG4, IgM, IgA, and 
IgE were determined using a human Bio-Plex ProTM immunoglobulin isotyping 
assay (BioRad, Veenendaal, The Netherlands) according to the manufacturer’s 
instructions. 
Real-time quantitative PCR of activation-induced cytidine deaminase 
(AID)
CD19+ SPL B cells (5 x 104 cells) were cultured in the presence or absence of 5 µg/
ml RTX with or without addition of 1 μg/ml αCD40 mAb and 50 ng/ml IL-21. After 
4 days of culture, total RNA was extracted, cDNA was synthesized and transcripts 
were quantifi ed as described previously(18). Probes with the following identifi cation 
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number were used: AID, Hs00757808_m1 (Applied Biosystems, Foster City, CA, 
USA). Results were normalized using the human HPRT1 Endogenous Control 
(4333768T; Applied Biosystems) and expressed as the relative fold change 
compared to the control condition.
In vitro T-cell proliferation assay
CD19+ LN B cells were added to 5 x 104 CFSE-labeled allogeneic CD3+ T cells in a 
1:1 ratio. Intracellular cytokine production by proliferating (CFSElow) CD3+CD4+ and 
CD3+CD8+ T-cells was analyzed by fl ow cytometry at day 7.
Statistical analysis 
Statistical analysis was performed using GraphPad Prism 5.03. Paired  t-tests were 
used to compare results obtained with SPL cells cultured in the presence or absence 
of RTX. To test di# erences between both patient groups, a Mann-Whitney U-test 
or an unpaired t-test was performed. P-values <0.05 were considered statistically 
signifi cant and are indicated with asterisks. 
Table 1. Patient characteristics.
Group  ID Sex Age 
(years)
Cause of renal failure Type of 
dialysis
Re-Tx Count at Tx (109/L)
Leukocyte Lymphocyte 
Control 
(Tx RTX –)
1 M 68 Hypertension HD no 4.8 1.7
2 F 55 ADPKD - no 6.3 1.1
3 M 43 Glomerulonephritis* PD no 9.3 1.4
4 F 38 Glomerulonephritis* HD yes 6.2 1.4
5 M 32 Alport syndrome - no 8.2 1.0
6 M 43 FSGS PD yes 9.8 2.5
ABOi 
(Tx RTX +)
1 M 68 Hypertension PD no 16.2 1.6
2 M 37 TIN - no 10.1 0.5
3 M 42 IgA nephropathy HD no 10.8 1.0
4 M 67 Vascular and 
hypertension
HD no  8  NA
ADPKD = autosomal dominant polycystic kidney disease; FSGS = Focal segmental 
glomerulosclerosis; HD = hemodialysis; PD = peritoneal dialysis; RTX = Rituximab; TIN = 
tubulo-interstitial nephritis; Tx = transplantation;
*= not further specifi ed. NA = not available
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Results
 A single dose of RTX induces a nearly complete B-cell depletion in PB, 
but not in LNs of renal transplant recipients
RTX treatment resulted in a nearly complete depletion of B cells from the peripheral 
lymphocyte population (CD19+; 0.12±0.05% versus 4.9±1.1%; P=0.002) while T-cell 
and NK-cell percentages were not a# ected by RTX (Figure 1A). Importantly, the 
percentage of CD19+ B cells in LNs of RTX-treated patients did not di# er from 
that of the untreated patients (35.1±8.5% versus 40.3±11.0%; P=0.61; Figure 1A). 
Likewise, RTX treatment had no e# ect on the percentages of other lymphocyte 
populations in the LNs.
To exclude that LN B cells were not depleted by RTX treatment because they 
lack CD20 expression we fi rst demonstrated that CD19+ LN B cells of untreated 
patients express CD20 (Figures 1B and 1C). Remarkably, LN B cells of RTX-treated 
patients were CD19+ but CD20- suggesting that RTX infl uenced detection of CD20 
on LN B cells. However, we were unable to detect RTX on the surface of the LN B 
cells of RTX-treated patients using an anti-idiotype antibody (19; Figure S1).
B cells remaining in the LNs after RTX treatment are predominantly of 
an IgD-CD27+ switched memory phenotype associated with an altered 
Ig-isotype production
Since RTX treatment failed to deplete CD19+ B cells in the LNs, we examined the 
remaining CD19+ LN B cells in more detail. RTX treatment resulted in signifi cant 
reduction of the percentages of naive B-cells (IgD+CD27-, 1.9±1.0% versus 
31.0±14.7%; P=0.01), transitional B-cells (CD24++CD38++, 0.1±0.05% versus 2.3±1.4%; 
P=0.01) and CD24+CD38+ (mature) B-cells (8.4±4.4% versus 28.6±16.5%; P=0.02), 
and in an increase in the percentages of switched memory B-cells (IgD-CD27+, 
86.1±8.2% versus 53.0±17.0%; P=0.02) percentages and CD24++CD38- (memory) 
B-cells (85.5±6.2% versus 67.5±17.2%; P=0.07). Accordingly, the percentage of B 
cells positive for the naive B-cell markers CD5 and IgM was also reduced after 
RTX treatment (1.3±0.5% versus 9.1±4.5%; P=0.01 and 13.5±5.9% versus 70.3±12.4%; 
P=0.01, respectively; Figures 2A and 2B). Plasma cells (CD19lowCD20-CD38high) were 
virtually lacking in the LNs, irrespective of treatment with RTX (data not shown). 
Similar results were obtained after 3 days exposure of human SPL B cells to RTX in 
vitro (Figure S2).
To defi ne whether the RTX-induced shift of LN B cells from a naive to a switched 
memory phenotype infl uenced Ig-isotype production, LN B cells were stimulated 
ex vivo with αCD40 mAb and IL-21 to mimic the in vivo help of follicular helper CD4+ 
T cells (20). After 8 days Ig-isotypes were measured in the culture supernatant. LN 
B cells from RTX-treated patients produced lower amounts of IgM (0.6±0.2 µg/
ml versus 14.1±7.8 µg/ml; P=0.01) and IgG2 (0.9±0.3 µg/ml versus 2.3±1.5 µg/ml; 
P=0.02), with a trend toward a higher IgG1 production compared to LN B cells from 
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untreated patients (77.8±33.0 µg/ml versus 44.3±15.7 µg/ml; P=0.17; Figure 3A). 
The production of IgA, IgE, IgG3, and IgG4 was not a# ected by RTX treatment.
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Distribution of the lymphocyte population in peripheral blood (PB) and 
lymph nodes (LNs) of renal transplant recipients after RTX treatment. 
(A) Shown are the percentages of T helper cells (CD3+CD4+), cytotoxic T cells (CD3+CD8+) 
and NK cells (CD3-CD56+) within the total lymphocyte (CD45+) population of renal 
transplant patients treated with RTX (Tx RTX+; grey bars) and untreated control patients 
(Tx RTX-; white bars) in PB (n=3) and LNs (n=4-6). (B) Expression of CD19 and CD20 in 
peripheral blood (PB) and lymph nodes (LNs) of renal transplant recipients after RTX 
treatment. Shown are the results of two representative patients. (C) Summary plot showing 
the percentages CD19 and CD20 positive cells within CD45+ lymphocytes in PB and LNs 
of RTX-treated (Tx RTX+; n=3-4; grey bars) and untreated (Tx RTX-; n=3-6; white bars) 
patients; Signifi cant di# erences are indicated by asterisks: **P<0.01.
Figure 1.
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In vitro exposure to RTX enhances the mRNA expression of activation-
induced cytidine deaminase in stimulated human splenic B cells
To determine whether the RTX-induced population shift from a naive to a switched 
memory phenotype was accompanied by class-switch recombination (CSR), we 
studied expression of activation-induced cytidine deaminase (AID) which plays a 
key role in CSR (21). CD19+ SPL B cells were cultured in the presence or absence of 
RTX with or without addition of αCD40 and IL-21. After 4 days of culture AID mRNA 
expression was determined by quantitative PCR (Figure 3B). AID mRNA expression 
levels tended to be higher when SPL B cells were stimulated with αCD40/IL-21 and 
exposed to RTX compared to the control condition (P=0.07). 
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Figure 2. Phenotypic and functional characterization of lymph node (LN) B cells. 
(A) A representative example of naive (IgD+CD27-), unswitched memory (IgD+CD27+), 
switched memory (IgD-CD27+), memory (CD24++CD38-), mature (CD24+CD38+), transitional 
(CD24++CD38++), CD5+ and IgM+ B cells within the total CD19+ B-cell population of RTX-
treated (Tx RTX+, right panel) and untreated (Tx RTX-; left panel). (B) Shown are the results 
from RTX-treated (grey box-plots; n=4) and untreated (white box-plots; n=6) patients. 
Signifi cant di# erences are indicated by asterisks: *P<0.05, **P<0.01.
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T cell stimulation with LN B cells from RTX-treated patients resulted 
in a weaker Th17 response
Based on our previous fi nding that in vitro exposure of human PB B cells to 
RTX altered the B-T-cell interaction (16), we analyzed the intracellular cytokine 
production by T cells after stimulation with LN B cells. LN B cells from RTX-treated 
or untreated patients were added to allogeneic CFSE-labeled CD3+ T cells. After 
7 days of culture, we measured the intracellular cytokine production of IL-2, IL-4, 
IL-17, and IFNγ by proliferating (CFSElow) T cells. Interestingly, the percentage of 
CFSElow CD4+ T cells that produced IL-17 was lower upon stimulation with LN B 
cells from RTX-treated patients as compared to LN B cells from untreated patients 
(2.6±0.6% versus 4.6±1.4%; P=0.003; Figure 4). 
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(A) Production of IgM, IgA, IgE, IgG1, IgG2, IgG3 and IgG4 in the supernatant by lymph 
node (LN) B cells of renal transplant recipients after ex vivo stimulation with αCD40 mAb 
and IL-21 for 8 days. Shown are the results for RTX-treated (Tx RTX+; n=4; grey bars) and 
untreated patients (Tx RTX-; n=6; white bars); *P<0.05, **P<0.01. (B) . Real-time quantitative 
PCR of the AID mRNA expression in human splenic CD19+ B cells after 4 days of culture 
in the presence or absence of RTX with or without addition of 1 μg/ml αCD40 mAb and 
50 ng/ml IL-21. Results were normalized using the human HPRT1 endogenous control and 
the expression in unstimulated control condition was set at 1.0. Shown are the relative fold 
changes in B cells obtained from 3 di# erent donors.
Figure 3.
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node (LN) B cells from renal transplant recipients 
(A) The intracellular cytokine production of IL-2, IL-4, IL-17 and IFNγ within the proliferated 
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and CD8+ T cells after stimulation with CD19+ LN B cells of RTX-treated (Tx RTX+; grey box-
plots) and untreated (Tx RTX-; white box-plots) from 8 to 12 di# erent donors; Signifi cant 
di# erences are indicated by asterisks: **P<0.01.
Figure 4.
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Discussion
In this study, we showed that at four weeks after administration of a single dose 
of RTX there is a nearly complete B-cell depletion in PB, but not in LNs of renal 
transplant recipients. Exposure of human B cells to RTX resulted in a lower 
percentage of naive (IgD+CD27-) and a higher percentage of switched memory 
(IgD-CD27+) B cells. Concomitantly, there was a change in the production of Ig-
subclasses after ex vivo stimulation with αCD40 mAb and IL-21. Finally, CD4+ T cells 
showed lower IL-17 production upon stimulation with LN B cells from RTX-treated 
patients as compared to LN B cells from untreated patients in an in vitro stimulation 
assay.
The observed persistence of B cells in lymphoid tissues after RTX treatment, 
has been reported by others before (8, 13, 15, 22-26).  However, in contrast to 
our fi nding of una# ected numbers of LN B cells, these studies described at least 
some degree of B-cell reduction in synovial tissue, spleen or lymph nodes. Renal 
transplant recipients treated with RTX for antibody-mediated rejection, showed a 
complete depletion of circulating B cells with a 50% reduction of B cells in tertiary 
lymphoid organs (24). RTX therapy of patients with autoimmune thrombocytopenia 
resulted in complete B-cell depletion in PB and in a reduction in SPL B cells (13). 
In patients with rheumatoid arthritis, the number of synovial and bone marrow B 
cells were decreased after RTX treatment, but there was no complete depletion 
(8, 22, 23). Genberg et al. (15) reported an average of 50% reduction of the 
percentage of CD19+ B cells in LNs after treatment with RTX as induction therapy 
in renal transplant patients. The variation in B-cell depletion might be explained by 
di# erences in RTX treatment regimen, choice of immunosuppressive agents, and 
heterogeneity of the patient populations. The majority of the patients were treated 
with at least two doses of 375 mg/m2, or 1000 mg for RA patients, with di# erent 
time intervals before obtaining secondary lymphoid tissue (8, 22-24), while our 
patients only received a single dose of 375 mg/m2 four weeks before collecting the 
lymph nodes. Notably, there is a trend to use less intensive dosing regimens of RTX 
for auto-immune diseases, and like in our study, a single dose of RTX is currently 
applied in several conditions (27, 28). 
Why there is such a wide discrepancy between depletion of B cells in PB and 
LN after RTX treatment is an intriguing question. A possible explanation could be 
an inability of RTX to reach the B cells in the LNs. However, we clearly demonstrate 
that LN B cells that remain after RTX treatment were CD19+CD20-, probably due 
to modulation of CD20 by the binding of RTX (29-32), which indicates that the LN 
B cells had been exposed to RTX. Exhaustion of the complement system is another 
possible explanation, which could not be further addressed in the current study 
(33). Finally, a high concentration of the B-cell activation factor (BAFF) in LNs, 
might favor the survival of B cells (24). 
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Although treatment with RTX had minimal e# ect on the proportion of LN 
B cells, it induced a striking population shift from a naive to a switched memory 
phenotype, which can be the result of two non mutually exclusive processes. First, 
RTX might selectively deplete and/or inhibit naive but not memory B cells leading 
to a relative increase of memory B cells. Second, binding of RTX to naive B cells 
might induce di# erentiation into memory B cells. Using an in vitro nondepleting 
B-cell stimulation model, we have previously shown that RTX inhibited the 
proliferation of CD27 naive, but not of CD27+ memory B cells (16). In agreement 
with these fi ndings, it has been reported that RTX administered in vivo as part 
of a desensitization protocol in kidney transplantation decreased the number of 
splenic naive B cells, but had no e# ect on the number of CD27+ memory B cells 
(14). In general, as compared to naive cells, memory B cells are characterized by 
a high expression of activation and prosurvival molecules, which allows them to 
respond quickly during an immune response and to persist for long time (34). These 
properties may also result in a relative resistance of memory B cells to depletion by 
RTX. In summary, these observations suggest that selective inhibition of naive, but 
not of memory B cells can indeed contribute to the observed shift from a naive to a 
switched memory B-cell phenotype. Next to its e# ect on the phenotype of B cells, 
RTX also a# ected the Ig-isotype production with a decrease in IgM production. 
Combined with a trend towards increased AID mRNA expression, this suggests 
that the population shift might be accompanied by class-switch recombination 
(CSR). Taken together, the LN B-cell population shift from a naive to a switched 
memory phenotype after treatment with RTX might be due to both a selective 
depletion of naive B cells and a direct e# ect on signaling cascades resulting in CSR 
and transition from a naive to a switched memory phenotype.
Treatment with RTX can be e# ective in chronic infl ammatory diseases, such 
as rheumatoid arthritis (8, 35) and multiple sclerosis (9). The improvement of 
these conditions by RTX has been associated with a reduced Th17 response (35). 
In the current study, we found that LN B cells obtained from RTX treated patients 
resulted in a weaker Th17 response when used as stimulators in an allogeneic 
mixed lymphocyte reaction. Likewise, it has been observed that RTX reduces the 
IL-17 production by PBMCs after stimulation with Candida albicans in vitro (35). 
Moreover, the Th17-cell frequency has been shown to correlate with the frequency 
of both switched memory B cells and serum BAFF levels (36). These fi ndings suggest 
a close relationship between Th17-cell homeostasis and B-cell maturation which 
can be a# ected by RTX. In a previous study, we observed that B cells that were 
treated with RTX in vitro, were able to induce a Th2-like shift in proliferating T cells. 
However, it should be noted that in the present study we investigated lymph node 
derived B cells, whereas in the previous study peripheral blood B cells were used. 
The B-cell subset distribution between the two is clearly di# erent, which might 
explain a di# erent T-cell response regardless of any further treatment (e.g. RTX), as 
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was observed by comparing CD27- and CD27+ B cells to stimulate allogeneic CD4+ 
T cells (37).
We acknowledge that the changes in the B-cell repertoire that we observed 
at four weeks after RTX treatment, could theoretically also have been caused by 
steroids that were given at the time of RTX administration, or by the treatment with 
immunosuppressive drugs (tacrolimus, mycophenolate mofetil, and prednisone 
from 2 weeks before transplantation), or IVIG (1 day before transplantation). 
However, none of these drugs directly targets B cells. It has been shown that IVIG 
does not a# ect B-cell responses in vitro (38), and treatment with IVIG as part of 
desensitization protocols had no e# ect on B cells in the spleen (14). In SLE patients 
treated with mycophenolate mofetil, the number and phenotype of B-cells were 
similar to that in controls without immunosuppressive therapy (39). Tacrolimus had 
minimal e# ect on B-cell proliferation and survival after stimulation in vitro (38). 
Finally, treatment of healthy volunteers with a single dose of prednisolone (30 
mg) resulted in a decrease of the absolute counts of total  lymphocytes, B cells, T 
cells and NK cells, but the counts returned to baseline levels within 13 to 26 hours 
after administration (40). Moreover, the only di# erences between RTX-treated and 
untreated patients were those found in the B-cell compartment. The fact that LN 
B cells from treated patients were negative for CD20, strongly indicates that RTX 
was involved in the observed changes in B-cell phenotype and function.
In summary, we have demonstrated that a single dose of RTX depletes B cells 
in PB, but not in LNs at four weeks after administration. Exposure of human B cells 
to RTX results in a relative increase of B cells with a switched memory phenotype. 
Consequently, the e# ect of rituximab on the immune response will not only be 
determined by the extent of B-cell depletion, but also by the functional properties 
of the remaining B cells.
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Anti-RTX antibody MB2A4 for the detection of RTX on 
the surface of cells. 
Lymph node (LN) cells from RTX-treated (Tx RTX+) and untreated patients (Tx RTX-) were 
stained for the expression of CD19, CD20 and the presence of RTX (anti-idiotype antibody 
MB2A4) on the surface of the cells. Isotype control for the anti-RTX antibody was used to 
defi ne gate settings. As a positive control condition, spleen cells from organ donors were 
fi rst incubated in the presence (+ RTX) or absence (- RTX) of 5 µg/ml RTX for 30 min in vitro. 
Subsequently, cells were stained for the expression of CD19, CD20 and the presence of 
RTX. In this control setting all CD19+ cells were CD20- and anti-RTX+, indicating that RTX 
was bound to CD20 and blocked binding of the staining anti-CD20 antibody. In contrast, LN 
B cells from patients who were treated with RTX four weeks earlier, were also negative for 
CD20, but the presence of RTX on these cells could not be detected.
Supplementary Figure 1.
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Human splenic B-cell subsets at day 3 of culture after 
exposure to RTX in vitro. 
Cryopreserved spleen (SPL) cells were incubated with or without RTX in the presence or 
absence of CpG for 3 days. A representative experiment showing fl ow cytometric analysis 
of IgD and CD27 expression (A) within the CD19+ SPL B-cell population. (B) Summary plot 
showing the percentages of naive (IgD+CD27-), unswitched (IgD+CD27+) and switched 
memory (IgD-CD27+) cells within the CD19+ SPL B-cell population with (grey box-plots) or 
without (white box-plots) RTX in the absence (n=9) or presence (n=6) of CpG. Signifi cant 
di# erences are indicated by asterisks: *P<0.05, ***P<0.001. 
Supplementary Figure 2.
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Abstract
Background. Treatment with rituximab may be accompanied by a systemic cytokine 
release. We studied the e# ects of a single dose of rituximab on cytokine levels in 
transplant patients and examined the underlying mechanism.
Methods. Twenty renal transplant recipients (10 rituximab-treated, 10 placebo-
treated) were recruited from a randomized clinical trial. Rituximab or placebo was 
infused during surgery and blood samples were taken before, during, and after 
surgery and analyzed for IL-2, IL-6, IL-10, IL-12, IL-17, TNFα, IFNγ, and MIP-1β. In vitro, 
healthy donor peripheral blood mononuclear cells, purifi ed B cells, monocytes, NK 
cells, or combinations thereof were incubated with rituximab, rituximab-F(ab’)
2
, or 
medium and MIP-1β, IL-10, IFNγ, and TNFα levels were measured in the supernatant. 
Results. Rituximab-treated patients had higher serum levels of IL-10 (101±35 pg/
ml versus 41±9 pg/ml; P<0.01) and MIP-1β (950±418 pg/ml versus 125±32 pg/ml; 
P<0.001) compared to placebo-treated patients at 2 hours after start of infusion. 
There was no di# erence in the level of other cytokines. In vitro, signifi cant levels 
of MIP-1β were only detected when rituximab was added to a co-culture of B and 
NK cells. Incubation with rituximab-F(ab’)
2 
did not result in increased MIP-1β levels. 
Levels of MIP-1β were higher in patients with a high a"  nity Fc-receptor compared 
to those with a lower a"  nity FcγRIIIa (1356±184 pg/ml versus 679±273 pg/ml; P 
<0.01).
Conclusions. Next to B-cell depletion, rituximab can modulate the immune 
response by inducing cytokine secretion, especially IL-10 and MIP-1β. NK cells 
appear to be responsible for the MIP-1β secretion in a B-cell and Fc-receptor 
dependent manner.
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Introduction
Monoclonal antibodies (mAbs) are widely used in the treatment of malignancies, 
transplant rejections, as well as a range of autoimmune diseases. For several of these 
mAbs, administration has been associated with acute infusion reactions, caused 
by various mechanisms, including systemic infl ammatory response syndrome (1). 
Rituximab (RTX), a chimeric anti-CD20 mAb, is an e# ective treatment for malignant 
lymphomas and various autoimmune diseases (2). It is also used in organ transplant 
patients for desensitization and treatment of antibody-mediated rejection (3). 
RTX can deplete B cells via antibody-dependent cellular cytotoxicity (ADCC), 
complement-dependent cytotoxicity (CDC), and apoptosis (4). The observation 
that polymorphisms in the FcγRIIIa gene a# ect the e# ectiveness of RTX, indicates 
that ADCC plays an important role (5). NK cells express the Fc-receptor FcγRIIIa 
(CD16) which has a high a"  nity for binding to IgG1 (6), the isotype of RTX. FcγRIIIa 
appears in two allelic forms that di# er by the amino acid on position 158. FcγRIIIa 
homozygous for valine (VV) has a higher a"  nity for IgG1 than FcγRIIIa with 
phenylalanine at that position (VF or FF) (7). Patients with the high a"  nity receptor 
show a better clinical response to RTX (8-10). 
However, administration of RTX can be followed by acute infusion reactions due 
to the release of cytokines (1), especially in patients with high B-cell counts like 
lymphoma patients (11), although not every patient with elevated levels of cytokines 
develops clinical symptoms (12, 13). After stimulation, B cells can produce virtually 
any cytokine (14). Although the role of these cytokines in the regulation of other 
cell types is not completely understood, a rise in the level of (proinfl ammatory) 
cytokines could lead to activation of the immune system and therefore be of 
clinical relevance. When using RTX as induction therapy to prevent acute rejection, 
a cytokine release could potentially contribute to the risk of rejection. 
Currently, it is unknown to which extent cytokine release occurs in patients 
with normal B-cell numbers, and the cell type responsible for the cytokine release 
has not been identifi ed. In a double-blind placebo-controlled study, we measured 
the release of various cytokines after administration of RTX to renal transplant 
recipients. In addition, we studied the mechanism of this cytokine release in vitro. 
Materials and Methods
Patients
For this study, patients were recruited from the RTX in Renal Transplantation trial 
(ClinicalTrials.gov, NCT00565331), which evaluated the e"  cacy and safety of 
RTX (MabThera, Ho# mann-La Roche, Basel, Switzerland) when added to standard 
immunosuppression in renal transplant recipients. At the start of transplant surgery, 
patients received 1000 mg acetaminophen, 100 mg prednisolone and 2 mg 
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clemastin i.v. next to the standard treatment with 2000 mg ceftriaxone as antibiotic 
prophylaxis. After 30 minutes, RTX (375 mg/m2) or placebo was administered at an 
increasing infusion rate. The total infusion time was approximately 4 hours. 
For logistic reasons, only recipients of a living donor kidney were selected for 
this study. Peripheral blood samples were collected from 20 patients (10 RTX-
treated, 10 placebo-treated) a few hours before the transplantation (baseline), at 2 
and 4 hours after starting the RTX infusion (t=2 h and t=4 h), and the next morning 
(t=24 h). Sera were stored at -80˚C until analysis. Table 1 summarizes the patient 
characteristics.
Healthy donors and cell isolation
For in vitro experiments, peripheral blood samples were obtained from healthy 
donors after written informed consent. Peripheral blood mononuclear cells (PBMCs) 
were isolated by density gradient centrifugation (Lymphoprep; Nycomed Pharma, 
Roskilde, Denmark). CD14+ Monocytes and CD19+ B cells were positively selected 
using specifi c-magnetic microbeads, and NK cells were negatively selected using 
the NK-cell isolation kit II (all from Miltenyi Biotec, Bergisch Gladbach, Germany) 
resulting in a purity of more than 95% for all lymphocyte subsets. 
Culture conditions
Whole blood culture was used to determine the cytokine production in vitro. 
Therefore, whole blood was diluted 1:5 with culture medium in 24-well plates 
(Greiner Bio-One, Frickenhausen, Germany). To study the cytokine production by 
di# erent lymphocyte subsets, 2 x 105 PBMCs, B cells, NK cells, and/or monocytes 
were cultured in RPMI-1640 medium supplemented with pyruvate (0.02 mM), 
glutamax (2 mM), penicillin (100 U/ml), streptomycin (100 μg/ml) (all from Gibco, 
Paisley, United Kingdom), and 10% fetal bovine serum (FBS) in 96-well round 
bottom plates (Greiner Bio-One) in a 37°C, 95% humidity, 5% CO
2
 incubator. In 
selected conditions, 250 µg/ml RTX (MabThera, Ho# mann-La Roche) or 250 µg/
ml RTX-F(ab’)
2
 (provided by Genmab, Utrecht, The Netherlands) was added to the 
culture medium. Supernatant was collected after 14 hours and/or 24 hours and 
stored at -20˚C until analysis. 
Cytokine measurements
Serum and culture supernatant levels of IL-2, IL-6, IL-10, IL-12, IL-17, TNFα, IFNγ 
(eBioscience, San Diego, CA), and MIP-1β (Invitrogen, Carlsbad, CA) were 
determined by ELISA according to the manufacturer’s instructions.
FcγRIIIa-158 genotype analysis
DNA was extracted from peripheral blood of 10 RTX-treated patients using a DNA 
isolation kit (Qiagen, Valencia, CA). Genotyping of FcγRIIIa-158 (rs396991) was 
performed using the TaqMan-Allelic discrimination method with a specifi c probe 
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for rs396991 designed for single nucleotide polymorphism (SNP) of FcγRIIIa and 
results were analyzed using the Allelic Discrimination software program according 
to the manufacturer’s instructions (all from Applied Biosystems, Foster City, CA). 
Statistical analysis
Cytokine concentrations are presented as mean ± SD. Nonparametric tests were 
used to compare variables. One-way ANOVA was used to compare the di# erent 
groups over time, followed by Dunn’s multiple comparison test for post-testing. To 
test the di# erence between the cultured cells with rituximab or without (culture 
medium) the Wilcoxon signed rank test was performed. P<0.05 was considered 
statistically signifi cant. Statistical analysis was performed using GraphPad Prism 
5.03 (GraphPad Software Inc., La Jolla, CA, USA).
Results .
RTX infusion is associated with specifi c cytokine release
The infusion of RTX induced a temporary rise in the levels of IL-10 and MIP-1β. At 
2 hours after the start of the infusion, the serum levels of these cytokines were 
signifi cantly higher in RTX-treated patients than in placebo-treated patients (IL-
10 (101±35 pg/ml versus 41±9 pg/ml; P<0.01) and MIP-1β (950±418 pg/ml versus 
125±32 pg/ml; P<0.001; Figure 1). However, RTX infusion did not increase the levels 
of IL-2, IL-6, IL-12, IL-17, IFNγ, or TNFα levels as compared to placebo treatment, 
suggesting that RTX infusion is associated with a specifi c cytokine release. None of 
the patients experienced any clinical symptoms associated with cytokine release.
Table 1. Patient characteristics*.
Patient groups
Rituximab 
(n=10)
Placebo       
(n=10)
Age; mean ± SD 46.7 ± 12.5 44.7 ± 12.5
Sex; Male : female, n 6 : 4 9 : 1
HLA mismatches; mean ± SD 2.9 ± 1.3 3.3 ± 1.3
Immunosuppression before transplantation; n 0 1
Patients with panel reactive antigen > 6%; n 1 3
Renal replacement therapy 
none / hemodialysis / peritoneal dialysis; n 3 / 6 / 1 2 / 7 / 1
* There were no statistical di# erences 
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Exposure to RTX induces a B-cell dependent secretion of MIP-1β by 
NK cells
Using in vitro studies with blood from healthy donors, we next analyzed which cells 
were responsible for the cytokine production after exposure to RTX. We used whole 
blood cultures next to PBMC, to stay as close to the in vivo situation as possible 
(15). In a 24 hours whole blood culture as well as isolated PBMC culture, addition 
of RTX induced elevated MIP-1β levels as compared to the medium alone (whole 
blood culture: 592±218 pg/ml versus 79±68 pg/ml; P=0.06 and PBMC culture: 
500±450 pg/ml versus 23±6 pg/ml; P<0.05), whereas IL-10, IFNγ, and TNFα were 
not detectable in this system (Figure 2A). 
To pinpoint the cells that produced MIP-1β after RTX administration, MIP-1β 
levels were measured in the culture supernatant of freshly isolated PBMC, B cells, 
NK cells, or monocytes that were exposed to RTX for 14 hours. In addition, MIP-1β 
was measured in co-cultured B-NK-cells and co-cultured B-cell-monocytes upon 
RTX treatment. RTX did not increase the MIP-1β levels in cultures of B cells, NK cells 
or monocytes alone, nor in co-cultures of B cells-monocytes. In contrast, RTX-
placebo
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Figure 1. In vivo cytokine release after RTX infusion. 
Serum levels of IL-2, IL-6, IL-10, IL-12, IL-17, IFNg, MIP-1β and TNFα in patients who underwent 
renal transplantation. 20 patients received a single dose of RTX (375 mg/m2) or placebo 
during transplant surgery. Concomitant immunosuppression consisted of tacrolimus, 
mycophenolate mofetil (MMF) and steroids. Blood samples were taken a few hours before 
transplantation (t=baseline), 2 and 4 hours after the start of infusion of RTX or placebo, 
and the next morning after transplantation (t=24 hours). Results are depicted as mean ± 
SD. Signifi cant di# erences between placebo and RTX-treated patients at the di# erent time 
points are indicated by asterisks: **P<0.01, ***P<0.001.
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treated co-cultures of B cells and NK cells revealed signifi cantly enhanced MIP-1β 
levels as compared to the medium control (597±321 pg/ml versus 30±23 pg/ml; 
P<0.05; Figure 2B). Taken together, this suggests that after exposure to RTX MIP-
1β is secreted by NK cells in a B cell-dependent manner.
MIP-1β secretion after exposure to RTX is Fc-receptor dependent
To establish if the MIP-1β secretion caused by exposure to RTX is Fc-receptor 
dependent, PBMCs were incubated with RTX, RTX-F(ab’)
2
 or in culture medium 
alone. PBMCs cultured with RTX-F(ab’)
2
 did not show increased MIP-1β secretion 
(Figure 2C), indicating that MIP-1β secretion is Fc-receptor dependent. 
It is known that single nucleotide polymorphisms (SNP) of the FcγRIIIa gene at 
position 158 result in an altered Fc-receptor function, where FcγRIIIa homozygous 
for valine (VV) has a higher a"  nity for IgG1 than FcγRIIIa with phenylalanine at 
that position (VF or FF) (7). We therefore wondered whether the MIP-1β secretion 
after treatment with RTX in vivo could be correlated to the genotype of the Fc-
receptor FcγRIIIa (CD16) present on NK cells. To this end, we determined the SNP 
at position 158 in 10 RTX-treated renal transplant patients. Interestingly, RTX-
treated patients in the high a"  nity group (VV) revealed higher serum levels of 
MIP-1β as compared to the lower a"  nity group (VF/VV) at 2 hours after the start 
of the RTX infusion (1356±184 pg/ml versus 679±273 pg/ml; P<0.01; Figure 2D). 
Although not signifi cant, a similar trend was observed for IL-10 levels (288±111 pg/
ml versus 184±35 pg/ml; P=0.17). These fi ndings support our conclusion from the in 
vitro studies that the cytokine release is Fc-receptor dependent.
Discussion
In this study, we showed that RTX infusion leads to a specifi c cytokine release in 
renal transplant recipients. At 2 hours after the start of the infusion, IL-10 and MIP-
1β serum levels were signifi cantly higher in RTX-treated patients as compared to 
placebo-treated patients, whereas the levels of IL-2, IL-6, IL-12, IL-17, IFN and TNFα 
remained una# ected. Additional in vitro data revealed that NK cells were largely 
responsible for the MIP-1β release in a B-cell and Fc-receptor dependent manner. 
Although RTX is usually well tolerated, the fi rst infusion may be accompanied by 
severe side-e# ects, which are correlated with complement activation (16) and with 
the number of circulating B cells (11), as more side-e# ects occur in patients with 
high B-cell counts, like lymphoma patients. There is limited data on the cytokine 
releasing e# ects of RTX in patients with B-cell counts in the normal range, like renal 
transplant recipients or patients with autoimmune diseases. In our study cohort, we 
found elevated cytokine levels after RTX infusion. The type of cytokines secreted 
was di# erent from that observed in other cohorts treated with distinct monoclonal 
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antibodies (6, 17). The cytokine release syndrome associated with OKT3 treatment 
is characterized by the release of the infl ammatory cytokines IL-2, TNFα, and 
IFNγ (17), while treatment with the humanized anti-CD52 mAb alemtuzumab was 
accompanied with elevated levels of IL-6, TNFα, and IFNγ (18). In these cases, it is 
believed that the release of infl ammatory cytokines is due to direct T-cell activation 
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Figure 2. Cytokine release after exposure to RTX is Fc-receptor mediated.
(A) Production of MIP-1β, IL-10, TNFα and IFNγ from whole blood cultures (n=5) and 
PBMCs of healthy donors (n=4) incubated with medium or 250 μg/ml RTX for 24 hours. 
(B) Production of MIP-1β by PBMCs, isolated CD19+ B cells, CD3-CD56+ NK cells, CD14+ 
Monocytes, and a co-culture of B cells with NK cells or Monocytes of healthy donors (n=6) 
incubated with medium or 250 μg/ml RTX after 14 hours. (C) Production of MIP-1β by 
PBMCs of healthy donors 24 hours after incubation with medium, 250 μg/ml RTX or RTX-
F(ab’)
2
. (D) Shown are the serum levels of MIP-1β and IL-10 in patients with the high a"  nity 
receptor SNP-158VV (n=4) and the low a"  nity receptor SNP-158VV/VF group (n=6) 2 
hours after the start of the RTX infusion. Signifi cant di# erences are indicated by asterisks: 
*P<0.05, **P<0.01.
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(17) or dependent on Fc-receptor ligation on phagocytic cells, such as monocytes, 
macrophages, and NK cells (19). We found that exposure to RTX, without further 
stimulus, only led to signifi cant MIP-1β levels in co-cultures of purifi ed B and NK 
cells. As single NK-cell cultures did reveal some, albeit limited, MIP-1β production, 
and the levels of MIP-1β secreted by B cells alone were below detection level, we 
suggest that the cytokine release observed was coming from NK cells and largely 
dependent on the binding of these cells to RTX-coated B cells. Finally, incubation 
of PBMCs with RTX-F(ab’)
2
 did not lead to an increased MIP-1β secretion, indicating 
that the cytokine release is indeed Fc-receptor dependent.
NK cells express the Fc-receptor FcγRIIIa (CD16) which has a high a"  nity for 
binding to IgG1 (6), the isotype of RTX. FcγRIIIa appears in two allelic forms that 
di# er by the amino acid on position 158. Single nucleotide polymorphisms (SNPs) 
at position 158 result in an altered Fc-receptor function. FcγRIIIa homozygous for 
valine (VV) has a higher a"  nity for IgG1 than FcγRIIIa with phenylalanine at that 
position (VF or FF) (7). Interestingly, we found that MIP-1β levels in patients treated 
with RTX correlated to the FcγRIIIa-158 SNP. Patients with the high a"  nity SNP 
produced higher levels of MIP-1β. This observation fi ts with previous data showing 
that the degree of NK cell activation and the clinical response upon RTX treatment 
are infl uenced by the FcγRIIIa-158 SNP (20). 
The observed rise in IL-10 and MIP-1β could be of clinical relevance, since it may 
well modulate the (allo)immune response infl uencing the transplantation outcome. 
IL-10 is a well known anti-infl ammatory cytokine which plays an important role 
in immune regulation (21). In a mouse model, MIP-1β was shown to be the most 
potent chemoattractant for regulatory T cells within a range of chemokines (22), 
suggesting that increased secretion might down modulate the immune response. 
On the other hand, MIP-1β can be produced by lymphocytes that are involved in 
inducing immune reactivity, including NK cells and B cells. (23). Moreover, MIP-1β 
recruits monocytes, T cells, and dendritic cells to the site of injury or infl ammation 
via the chemokine receptor CCR5, which is highly expressed by monocytes and has 
a lower expression on T cells and dendritic cells. Therefore, in renal transplantation 
increased MIP-1β levels might contribute to activation of the immune response, 
and thus graft injury. Indeed, in a previous study with RTX as induction therapy 
in renal transplantation, an increased rate of acute rejection was associated with 
elevated levels of proinfl ammatory cytokines in some of the patients (24). In that 
report no data are provided on MIP-1β levels.
In summary, results from this study indicate that RTX does not only lead to B-cell 
depletion, but also results in the release  of cytokines, especially IL-10 and MIP-1β, 
which might modulate the immune response. NK cells appear to be responsible for 
MIP-1β secretion in a B-cell and Fc-receptor dependent manner. 
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Organ transplantation is the preferred treatment for patients with end-stage 
renal disease. It improves quality of life and increases life expectancy compared 
to dialysis treatment. The short term transplantation outcome is greatly increased 
over the last 50 years, mainly due to the introduction of potent immunosuppressive 
drugs. However, the long-term success of renal transplantation is limited by 
chronic allograft dysfunction (1, 2). This term refers to a clinical syndrome of slowly 
deteriorating graft function due to multiple causes, of which chronic rejection is 
probably the most important. 
T cells play an important role in the pathogenesis of rejection via the recognition 
of alloantigens, resulting in T-cell activation, proliferation, and di# erentiation into 
CD4+ T helper cells and CD8+ cytotoxic T cells (3). Therefore, the most commonly 
used immunosuppressive drugs in transplantation are directed against T cells to 
inhibit these processes (4). Next to T cells, B cells can be involved in graft rejection 
via the production of alloantibodies, but they can also induce an immune response 
by acting as professional antigen presenting cells, or by the production of various 
cytokines (5). The presence of anti-HLA antibodies before or after transplantation, 
as well as the presence of B-cell clusters in renal grafts during acute rejection, are 
associated with poorer graft survival (6-8). Therefore, depletion of B cells in renal 
transplant recipients might help to prevent allograft rejection. On the other hand, B 
cells with regulatory functions have been described in tolerant transplant patients 
who had stable allograft function despite not receiving immunosuppression for at 
least one year (9). Since B cells can play such a variety of roles in the immune 
response, the e# ects of anti-B-cell therapy have to be analyzed carefully. 
In the studies included in this thesis, we aimed to gain more knowledge on anti-
B-cell therapy in renal transplantation. The basis of these studies was formed by a 
randomized clinical trial, in which the e# ects of a single dose of the B-cell depleting 
monoclonal antibody rituximab (RTX) added to standard immunosuppression 
in renal transplant recipients were evaluated (chapter 2). In a selected subgroup 
of participants of this clinical trial, we analyzed the phenotypic and functional 
characteristics of peripheral T and B cells before and after transplantation (chapter 
3). Although RTX leads to a nearly complete B-cell depletion in peripheral blood, B 
cells do remain in secondary lymphoid organs after RTX treatment. Therefore, we 
wondered whether RTX had any direct e# ects on B cells besides inducing B-cell 
depletion. In chapter 4, we studied an in vitro non depleting model to establish 
the e# ects of RTX on the proliferation, activation, and di# erentiation of purifi ed 
B cells. In chapter 5, we assessed the in vivo e# ects of RTX on B cells in secondary 
lymphoid organs. Additionally, we showed that RTX infusion leads to a specifi c 
cytokine release in renal transplant recipients (chapter 6).
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Targeting B cells in renal transplantation
Current immunosuppressive regimens consisting of steroids, a calcineurin-inhibitor, 
and MMF reduce B-cell function directly by inhibition of their proliferation and 
indirectly via the inhibition of T-cell help. An alternative approach is specifi c B-cell 
depletion by treatment with RTX. 
In chapter 2, we evaluated the safety and e"  cacy of RTX when added to a 
standard immunosuppressive drug regimen consisting of tacrolimus, MMF, and 
steroids. We showed that induction therapy with a single dose of RTX at the time 
of transplantation is safe, but ine# ective to reduce biopsy-proven acute rejection 
(BPAR) in the total population of renal transplant recipients. Our data also indicate 
that in immunologically high risk patients, RTX induction therapy may reduce the 
incidence of acute rejection to a level comparable to that in immunologically low 
risk patients. Therefore, induction therapy with RTX might improve the long-term 
graft survival in this specifi c group of transplant patients. However, this hypothesis 
needs to be confi rmed in a multicenter clinical trial focused on immunologically 
high risk patients. In addition, it is important to monitor mortality rates of RTX-
treated patients in the future, since increased mortality has been reported in long 
term follow-up of renal transplant recipients treated with RTX (10-11). 
Interestingly, we found that immunologically high risk patients had more memory 
B cells before transplantation compared to immunologically low risk patients. It is 
tempting to speculate that a protective e# ect of RTX in the immunologically high 
risk patients could be explained by the higher pre-transplant levels of memory B 
cells in these patients, which may then be depleted after RTX treatment. Upon 
re-exposure to antigen after transplantation, these memory B cells could quickly 
di# erentiate into anti-HLA antibody-producing plasma cells (12). Indeed, an 
increase in circulating memory B cells has been associated with acute rejection 
in paediatric renal transplant recipients (13), while heart transplant recipients with 
higher percentages of naive B cells had a lower risk of acute rejection (14). It should 
be noted however that memory B cells appear more resistant to depletion by RTX 
than naive B cells, especially in secondary lymphoid organs (15), which leaves the 
possibility that the protective e# ect of RTX might rather be due to the depletion 
of the naive donor antigen-specifi c B-cell pool, thus preventing further expansion 
and di# erentiation of these cells into memory B cells and/or antigen-presenting 
cells.
In general, B-cell repopulation in autoimmune disease patients treated 
with RTX starts within 6 to 9 months (16, 17). However, in our cohort of renal 
transplant recipients a single dose of RTX added to triple immunosuppressive 
drug regimen resulted in a long lasting B-cell depletion in peripheral blood 
(chapter 3). The majority of the RTX-treated patients had lower B-cell numbers, 
as compared to pre-transplant levels, up to 24 months after transplantation. Our 
fi ndings, combined with previously published studies on renal transplant recipients 
(18), suggest that the delayed repopulation of B cells might be related to the 
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maintenance immunosuppression. However, also in the absence of maintenance 
immunosuppression, in sensitized patients awaiting renal transplantation and 
treated with a single dose of RTX, B-cell repopulation was slower compared to 
autoimmune disease patients (19) :at 12 months after treatment, B-cell numbers 
were lower compared to pre-treatment levels, but returned to baseline after 24 
months. Therefore, the type of underlying condition may also infl uence the rate of 
B-cell recovery.
Although RTX does not target antibody-producing plasma cells, but rather 
their B-cell precursors, prolonged B-cell depletion might lead to a decrease in 
the concentration of donor-specifi c anti-HLA antibodies (DSA), which have been 
associated with poorer kidney graft survival (8). To determine whether the higher 
pre-transplant levels of memory B cells in immunologically high risk patients can 
be correlated to DSA and long-term graft survival several issues remain to be 
resolved. There is still controversy on which type of plasma cells (short or long-
lived) is responsible for the DSA production (12), what the precursors are of those 
DSA-producing plasma cells, and whether or not anti-B-cell therapy might be 
e# ective in the prevention of pre-existing and/or de novo DSA production. So far, 
RTX has been successfully used in the treatment of antibody-mediated rejections 
(2), which in some (20, 21), but not all (5) cases was associated with decreased 
DSA levels. Although this might suggest that DSAs are produced by short-lived 
plasma cells, it cannot be excluded that additional IVIG treatment was responsible 
for the observed reduction. In sensitized patients treated with RTX it was observed 
that the repopulation of memory B cells was more delayed for donor-specifi c B 
cells than those specifi c for third-party HLA (22). In the near future, the e# ect 
of RTX treatment on the titers of pre-existing DSA and on the formation of de 
novo DSA will be measured in sera collected from patients who participated in our 
prospective clinical trial. 
Prevention of rejection after renal transplantation requires treatment 
with immunosuppressive drugs that inhibit the function of alloreactive T and B 
cells. In spite of the wide use of immunosuppressive drugs, there is limited data 
available regarding their in vivo e# ects on the peripheral T and B cells after renal 
transplantation. In chapter 3, we performed a longitudinal analysis of T- and B-cell 
phenotype and function in a homogeneous patient population consisting of CMV 
seronegative patients who received a kidney from a CMV seronegative donor and 
did not experience a rejection episode up to 24 months after transplantation. This 
strict selection criteria were chosen to exclude any potential e# ects on the immune 
system of a CMV infection or rejection. Our main fi nding was that renal transplant 
recipients treated with the combination of tacrolimus, MMF and steroids showed 
an altered memory T- and B-cell compartment as compared to pre-transplantation, 
without changes in the total numbers of peripheral T and B cells. 
Recent data indicate that the composition of the B-cell compartment is related 
to the clinical outcome of transplantation. Tolerant renal transplant recipients, who 
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have stable graft function despite not receiving immunosuppression for at least 
one year, show a higher number of total B cells, of which especially the naive and 
transitional B cells are increased (9). It has been suggested that this increase might 
lead to tolerance induction, since regulatory B cells, which produce the regulatory 
cytokine IL-10, can be found within the transitional B-cell compartment (23). In 
addition, in animal models naive B cells have been shown to be tolerogenic for naive 
T cells (24) and to induce a regulatory phenotype in naive T cells upon stimulation 
(25). Interestingly, in patients with autoimmune disease higher numbers of memory 
B cells were associated with worse clinical outcome (26, 27). Also, in pediatric renal 
transplant recipients increasing counts of circulating memory B cells were seen at 
time of acute rejection (13). This could imply that in transplantation patients the 
balance between naive and memory B cells might be associated with the degree of 
acceptance of the graft.
 Currently, there is limited data on the course of B-cell subset distribution after 
renal transplantation. It is also unclear whether maintenance immunosuppression 
or the presence of an allograft has an e# ect on the B-cell phenotype. We found 
that under triple immunosuppressive drug regimen renal transplant recipients 
showed a shift toward a more memory-like phenotype in the B-cell population 
(chapter 3). The explanation for this phenomenon is not obvious yet. In vitro, 
steroids and MMF, but not tacrolimus have been found to inhibit B-cell activation 
and proliferation (28-30). However, none of these studies described an e# ect 
on the B-cell subset distribution. Alternatively, the presence of an allograft and 
therefore the introduction of novel antigens, might induce an immune response 
resulting in the di# erentiation of antigen-specifi c naive B cells into memory B cells. 
Also, viral infections can have a pronounced e# ect on the immune system (31) 
However, we tried to avoid that e# ect by analyzing only CMV seronegative patients 
who received a CMV seronegative donor (and thus did not develop CMV infection).
In our patients, addition of induction therapy with RTX to the standard 
immunosuppressive treatment resulted in long term B-cell depletion, but eventually 
in the enrichment of CD24hiCD38hi transitional B cells in the reconstituted B-cell 
compartment. In several conditions, a preferential repopulation of transitional and 
naive B cells after RTX treatment has been associated with better clinical response 
and outcome, due to the relative increase of regulatory B cells present in the 
transitional B-cell compartment (13, 26, 32-34). Although we did not fi nd a clinical 
e# ect of RTX in our patient cohort, this observed change in the B-cell compartment 
might be benefi cial for the long term outcome. However, for the short term, B-cell 
depletion and thus the removal of B cells with regulatory properties may have 
adverse e# ects. In an autoimmune disease animal model, depletion of regulatory 
B cells was associated with disease progression (35). Therefore, future anti-B-cell 
therapies should focus on reducing or blocking e# ector B-cell activation rather 
than depleting all B cells, including regulatory B cells. Another possibility might 
be enhancing the number of regulatory B cells by specifi c therapeutic antibodies 
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or by cell therapy with regulatory B cells. First, further research is needed on the 
characterization of regulatory B cells in humans since there is still controversy 
about the exact phenotype of these cells. 
E! ects of RTX beyond B-cell depletion
Upon activation, B cells are able to proliferate, produce various cytokines and process 
antigen for presentation to T cells (36-38). All these processes can be a# ected by 
RTX, resulting in an altered immune response after treatment with RTX. To study 
the direct e# ects of RTX on B cells, we used an in vitro non depleting stimulation 
model. In chapter 4, we describe that in vitro RTX treatment can a# ect B-cell 
phenotype and function, resulting in an altered outcome of B-T-cell interaction 
upon stimulation in a mixed lymphocyte reaction. However, similar changes in 
the T cell phenotype were not observed ex vivo in our renal transplant recipients 
treated with RTX (chapter 3). This is remarkable, as several studies on patients with 
autoimmune disease revealed that the T-cell compartment was indeed a# ected 
upon RTX treatment (39-41). Systemic lupus erythematosus patients had relatively 
decreased percentages of memory T cells 2 years after RTX treatment (39), 
and patients with idiopathic thrombocytopenic purpura, particularly responders 
showed increased levels of regulatory T cells upon treatment. Also, B-cell depletion 
in patients with multiple sclerosis resulted in diminished Th1 and Th17 responses 
(41). This is of interest as in an in vitro stimulation assay, we did observe a lower 
IL-17 production in CD4+ T cells upon stimulation with B cells from RTX-treated 
patients compared to B cells from untreated patients. However, in most of these 
autoimmune disease patients the cumulative dose of RTX was higher than in our 
patients, who received only a single, relatively low dose (39). Another explanation 
might be that the immune system in the patients with autoimmune disease is reset 
after treatment with RTX by depleting autoreactive B cells, while renal transplant 
recipients have in general a less a# ected immune system compared to patients 
with autoimmune disease, which is likely to be less infl uenced by depleting (some 
of the) B cells. It should also be noted that we were only able to analyze peripheral 
blood T cells. We have demonstrated that in renal transplant patients a single dose 
of RTX leads a to nearly complete B-cell depletion in peripheral blood, but not 
in secondary lymphoid organs, and that these remaining B cells have di# erent 
functional capacities (chapter 5). The B cells remaining in the lymph nodes after 
RTX treatment were predominantly of a switched memory (IgD-CD27+) phenotype. 
It appeared that this population of mostly memory type B cells residing in lymphoid 
organs did not noticeably a# ect the peripheral blood T-cell compartment. Notably, 
lymph nodes from RTX-treated patients contained no transitional B cells, including 
B cells with a regulatory phenotype, which contrasts with the enrichment of 
transitional B cells after repopulation of the peripheral blood. Theoretically, this 
relative increase of memory B cells and lack of regulatory B cells in lymph nodes 
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might contribute to an enhanced alloimmune response and thus be undesirable in 
transplant patients.
Even though the majority of studies report an e# ective B-cell depletion in 
peripheral blood, it remains remarkable why there are such discrepancies between 
di# erent studies on the percentage of remaining B cells in lymphoid organs (18), 
bone marrow (42), or synovial tissues (43) after RTX treatment.  In contrast to our 
fi nding of una# ected percentages of lymph node B cells (chapter 5), the previous 
studies described at least some degree of B-cell reduction. There are several 
theoretical explanations for this lack of complete B-cell depletion in lymphoid 
organs. First, RTX may not be able to reach the B cells in the lymph nodes. This seems 
to be unlikely, because CD19 positive B cells in lymph nodes of transplant recipients 
that did not receive RTX were all CD20 positive, while the CD19 positive B cells 
that remain in the lymph nodes of renal transplant recipients after RTX treatment 
were all CD20 negative, indicating that RTX was bound to these cells. Next, there 
may be an exhaustion of complement dependent cytotoxicity (CDC), antibody-
dependent cell cytotoxicity (ADCC), or both (44). Also, the microenvironment in 
the lymphoid organs may play a crucial role in determining the chances of survival 
versus depletion of B cells upon RTX treatment. For instance, increased expression 
of B-cell activating factor (BAFF) in lymphoid tissues may provide a survival signal 
for the B cells (45). Finally, the di# erences in RTX treatment regimen, choice of 
immunosuppressive drugs and heterogeneity of the patient population might also 
explain the variation in B-cell depletion across di# erent studies. 
Based on the considerations above, we exposed B cells in vitro to RTX in the 
absence of complement (chapter 4), which mimics the in vivo situation insofar that 
B cells are exposed to RTX but are spared from cytotoxic e# ector mechanisms, 
whatever the reason(s) for the latter might be. Addition of complement to the 
in vitro system resulted in an increase of the proportion of dying cells, however 
there were no clear di# erences in the expression of relevant cell surface markers 
between the cells remaining after incubation with RTX and complement versus the 
cells exposed to RTX only. Taking into account that an in vitro model can never 
fully mimic the in vivo environment, our in vitro non depleting model gave us the 
opportunity to study the direct e# ects of RTX on B cells more in depth compared 
to the in vivo situation. 
The fi ndings described in chapters 4 and 5 demonstrate that RTX especially 
a# ects naive, but not memory B cells. The relative resistance of memory B cells to 
RTX has also been reported by others (15), but the exact reasons for this di# erence 
remains to be determined. An obvious explanation would be a variation in the 
level of CD20 expression, however this was similar in both subsets and therefore 
does not seem to be involved. Remarkably, peripheral blood B cells stimulated in 
the presence of RTX induced stronger T-cell proliferation, compared to B cells 
stimulated in the absence of RTX. Although this might suggest that anti-B-cell 
therapy could have adverse e# ects in renal transplant recipients by enhancing T cell 
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alloreactivity, in our study the resulting T-cell population showed a more Th2-like 
phenotype, which is usually associated with graft acceptance rather than rejection 
(46). In contrast in chapter 5, we described that lymph node B cells obtained from 
RTX treated patients resulted in a weaker Th17 response when used as stimulators in 
an allogeneic mixed lymphocyte reaction. It should be noted that this di# erence in 
the T-cell responses might be due to the di# erent origin of the B cells; in one study 
we used lymph nodes obtained from renal transplant recipients while in the other 
study we used peripheral blood from healthy donors. The B-cell subset distribution 
between the two clearly di# ers with the majority of peripheral blood B cells being 
naive (IgD+CD27-), while lymph node B cells are predominantly of an IgD-CD27+ 
switched memory phenotype. This di# erence in B-cell subsets potentially leads 
to a di# erent T-cell response regardless of any further treatment (e.g. RTX), as 
was described using CD27- and CD27+ B cells to stimulate allogeneic CD4+ T cells 
in vitro (47). Importantly, we showed that RTX inhibits specifi cally naive, but not 
memory B cells. 
Finally, another e# ect of RTX beyond B-cell depletion is that administration of 
RTX can be followed by an acute infusion reaction due to the release of cytokines 
(48), especially in patients with high B-cell counts, like lymphoma patients (49). 
In chapter 6, we studied the e# ect of RTX infusion on the cytokine levels in renal 
transplant recipients, who exhibit B-cell counts in the normal range. RTX infusion 
led to a specifi c cytokine release, with increased IL-10 and MIP-1β serum levels in 
RTX-treated patients as compared to placebo-treated patients at 2 hours after 
start of the infusion. Using in vitro cultures with blood from healthy donors, we 
found that the highest MIP-1β levels were measured in the RTX-treated co-cultures 
of B cells and NK cells. MIP-1β was most likely produced by NK cells after binding 
to RTX-coated B cells via Fc-receptors. Single nucleotide polymorphisms (SNP) 
in FcγRIIIa (CD16) at position 158 are known to a# ect the binding a"  nity for IgG1, 
the isotype of RTX. Notably, the MIP-1β release was more pronounced in patients 
with a high a"  nity Fc-receptor compared to those with a lower a"  nity FcγRIIIa. 
The observed rise in cytokines could be of clinical relevance, since it may modulate 
the (allo)immune response infl uencing the outcome of renal transplantation. For 
instance, the temporary increase of IL-10 might dampen the infl ammatory response 
during the early post transplant period. In this respect, it would be interesting 
to compare the clinical outcome in RTX-treated patients with SNP-158VV (high 
a"  nity receptor) and those with the low a"  nity receptor. 
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Concluding remarks
The long term success of renal transplantation depends on tricking the immune 
system into thinking that the kidney is not harmful, preferably by inducing 
tolerance. The role of B cells in transplant rejection and tolerance, but also in 
several autoimmune diseases has been increasingly appreciated. The wide use 
of anti-B-cell agents o# ers accumulating evidence for their benefi cial e# ects in 
a wide range of diseases. Even though we have increased our knowledge about 
the role of B cells in renal transplantation, further research is needed. Currently, 
it is still di"  cult to predict whether anti-B-cell therapy will be benefi cial for the 
long term transplantation outcome or not. Also the mechanism of action of RTX 
may not be as straightforward as fi rst was expected. Although RTX depletes B 
cells, the precursors of antibody-producing cells, clinical experience with RTX in 
autoimmune diseases suggests that antibody levels are not always a# ected by 
RTX treatment. Altered T-cell stimulation by the B-cell pool, either by a change 
in antigen presentation or by the production of immunomodulatory cytokines 
might be important mechanisms of action of RTX as well. This would mean that 
the therapeutic e# ects go beyond simple B-cell depletion. In this thesis, we 
described that RTX can directly a# ect B-cell phenotype and function. Therefore, 
the e# ect of RTX on the immune response will not only be determined by the 
extent of B-cell depletion, but also by the functional properties of the remaining 
B cells. Moreover, the relative increase of regulatory B cells in the repopulating 
B-cell compartment after B-cell depletion might potentially promote tolerance. 
Eventually, the therapeutic e# ect of B-cell depletion will depend on the resulting 
balance between e# ector and regulatory B cells next to the timing of treatment 
and the type of disease or condition. Consequently, future therapy should be more 
directed at selective depletion or modulation of the B-cell compartment. 
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Niertransplantatie is de eerste keus behandeling voor patiënten die geen eigen 
nierfunctie meer hebben. Patiënten die een succesvolle niertransplantatie hebben 
ondergaan, leven gemiddeld langer dan patiënten die worden behandeld met 
dialyse. Ook leidt niertransplantatie tot een sterk verbeterde kwaliteit van leven. 
Een transplantatie heeft het beste kans van slagen als de donornier goed past bij de 
ontvanger. Hoe beter de match, hoe minder kans op afstoting. Ons afweersysteem 
(immuunsysteem) is ontwikkeld om op e"  ciënte wijze lichaamsvreemde indringers, 
zoals virussen en bacteriën, op te sporen en ze onschadelijk te maken. Het 
immuunsysteem beschouwt de getransplanteerde nier als iets wat niet in het lichaam 
thuishoort. Als reactie gaan de witte bloedcellen van het immuunsysteem de nier 
aanvallen. De T cellen, die onderdeel uitmaken van de witte bloedcellen, spelen 
een belangrijke rol in de herkenning van lichaamsvreemde indringers. Activering 
van T cellen die specifi ek de getransplanteerde nier herkennen, zogenaamde 
alloreactieve T cellen, leidt tot een snelle vermeerdering (proliferatie) van deze 
cellen en di# erentiatie waarna ze ontstekingseiwitten (cytokines) gaan produceren 
(CD4+ helper T cellen) of direct in staat zijn om andere cellen te vernietigen 
(CD8+ cytotoxische ‘killer’ T cellen). Helper T cellen geven hulp aan andere witte 
bloedcellen, zoals de B cellen die antilichamen gaan maken. Antilichamen kunnen 
een ziekteverwekker of andere lichaamsvreemde indringers herkennen en door er 
aan te binden vormen ze een belangrijke schakel in het onschadelijk maken ervan. 
B cellen worden gedurende het hele leven aangemaakt in het beenmerg, waar ze 
zich ontwikkelen uit bloedstamcellen. Tijdens de voorloper B cel ontwikkeling in 
het beenmerg creëert elke voorloper B cel een uniek antilichaammolecuul, ook 
wel immuunglobuline (Ig) genoemd. Vervolgens verlaat deze B cel het beenmerg 
via de bloedbaan en migreert tussen de verschillende lymfoïde organen, zoals 
de milt en lym lieren, op zoek naar antigenen. Wanneer een B cel zijn specifi eke 
antigeen herkent, zal deze worden geactiveerd en zichzelf vermenigvuldigen. De 
dochtercellen rijpen vervolgens uit tot plasmacellen, die antilichamen produceren, 
of tot geheugencellen, die zeer snel in actie kunnen komen zodra hetzelfde antigeen 
nog een keer het lichaam binnenkomt. Naast de productie van antilichamen zijn B 
cellen in staat om een immuunrespons op gang te zeggen door antigenen aan T 
cellen te presenteren, waardoor de T cellen geactiveerd raken, of door de productie 
van verschillende cytokines.
Om activering van het immuunsysteem en afstoting van de nier te voorkomen, 
moet iemand met een getransplanteerde nier levenslang afweeronderdrukkende 
middelen (immunosuppressiva) gebruiken. Omdat immunosuppressiva het gehele 
immuunsysteem onderdrukken, hebben transplantatiepatiënten een verhoogde 
kans op infecties en het ontwikkelen van tumoren. Om de kans op afstoting te 
verminderen wordt er gekeken naar bloedgroep en weefseltypering (witte 
bloedcellen) om vast te stellen of er sprake is van een goede match tussen donor en 
ontvanger. De kans op afstoting van een donornier is kleiner als de weefselkenmerken 
van donor en ontvanger meer op elkaar lijken. Die kenmerken zijn erfelijk bepaald en 
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worden Humaan Leukocyten Antigenen (HLA) genoemd. Met de zich steeds weer 
verbeterende ontwikkeling op het gebied van immunosuppressiva, is de levensduur 
van een getransplanteerde nier sterk verbeterd. Optimalisering van het gebruik 
van verschillende immunosuppressiva tegelijkertijd, heeft ertoe geleid dat 90% 
van de nieren 1 jaar na transplantatie nog steeds functioneert, terwijl dit na 10 jaar 
ongeveer 60% is. Huidige veelgebruikte immunosuppressiva zijn met name gericht 
om T cel activering te voorkomen, maar zoals eerder genoemd kan B cel activering 
en di# erentiatie ook nadelige gevolgen hebben voor de transplantaatoverleving. De 
aanwezigheid van anti-HLA antilichamen, die geproduceerd worden door B cellen, 
voor en na transplantatie, evenals de aanwezigheid van B cellen in de nier ten tijde 
van een afstotingsreactie, zijn geassocieerd met kortere transplantaatoverleving. 
Daarom zou het verwijderen (depletie) van B cellen bij niertransplantatiepatiënten 
mogelijk kunnen helpen om afstoting te voorkomen. Anderzijds, zijn er B cellen 
met regulerende (afstotingsremmende) functies beschreven bij patiënten die een 
stabiele nierfunctie hebben ondanks dat ze al meer dan een jaar gestopt zijn met het 
gebruik van immunosuppressiva. Omdat B cellen een verscheidenheid van functies 
kunnen hebben bij een immuunrespons, moeten de e# ecten van het verwijderen 
van B cellen (anti-B-cel therapie) zorgvuldig geanalyseerd worden. Een voorbeeld 
van anti-B-cel therapie is het B cel depleterende monoklonale antilichaam 
rituximab. Rituximab bindt aan het CD20 eiwit, dat zich aan het oppervlak van B 
cellen bevindt. Na binding van rituximab aan de B cellen worden deze laatste door 
het eigen afweersysteem herkend en vernietigd. Er worden weer nieuwe B cellen 
gevormd uit de stamcellen in het beenmerg, maar het kan maanden tot jaren duren 
totdat weer normale aantallen in het bloed aanwezig zijn. Omdat het CD20-eiwit 
alleen voorkomt op B cellen zal rituximab niet aan andere cellen in het lichaam 
binden. 
B cellen als doelwit bij niertransplantatie 
Het doel van het onderzoek beschreven in dit proefschrift is het verkrijgen van 
meer kennis over anti-B-cel therapie bij niertransplantatie. De basis werd gevormd 
door een gerandomiseerde, dubbelblinde, placebogecontroleerde klinische studie 
waarin de e# ecten van rituximab gegeven aan niertransplantatie patiënten werden 
geëvalueerd (hoofdstuk 2). In deze studie werden twee patiëntengroepen met 
elkaar vergeleken. De ene groep kreeg rituximab in de operatiekamer gedurende de 
niertransplantatie, de andere een placebo (nepmiddel, in dit geval zoutoplossing). 
De toewijzing van patiënten aan één van beide groepen gebeurde willekeurig 
(gerandomiseerd) en daarnaast wisten zowel de onderzoeker, als de patiënt niet 
wie welk middel kreeg (dubbelblind). Beide patiënten groepen kregen de standaard 
immunosuppressieve behandeling bestaande uit tacrolimus, mycofenolaat mofetil 
en steroïden. Uit de resultaten bleek dat één dosis van rituximab veilig is, maar niet 
leidt tot verminderde afstoting in de totale populatie niertransplantatiepatiënten. 
Bij geïmmuniseerde patiënten, zij die een eerdere transplantatie en/of anti-HLA 
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antilichamen vóór transplantatie hadden, lijkt rituximab het aantal afstotingen te 
verminderen tot een niveau dat vergelijkbaar is met dat bij niet geïmmuniseerde 
patiënten (geen eerdere transplantatie en geen anti-HLA antilichamen). Een 
verklaring voor het beschermende e# ect van rituximab in de geïmmuniseerde 
patiënten kan zijn dat deze patiënten meer geheugen B cellen hebben vóór de 
transplantatie in vergelijking met niet geïmmuniseerde patiënten. Na herkenning 
van het specifi eke antigeen, bijvoorbeeld in de nier, kunnen deze geheugen B cellen 
snel di# erentiëren in antilichaamproducerende plasma cellen. Door deze B cellen 
te verwijderen met rituximab kunnen er geen antilichamen geproduceerd worden, 
waardoor een afstoting voorkomen kan worden.
Om afstoting na niertransplantatie te voorkomen moeten patiënten levenslang 
immunosuppressiva gebruiken die de functie van T en B cellen remmen. Ondanks 
het veelvuldige gebruik van immunosuppressiva is er niet veel bekend over de 
e# ecten van deze medicijnen op de aantallen en functies van T en B cellen in 
het bloed van niertransplantatiepatiënten. In hoofdstuk 3 hebben we in een 
groep niertransplantatiepatiënten een aantal karakteristieken van T en B cellen 
in het bloed onderzocht. Behandeling met combinatietherapie van tacrolimus, 
mycofenolaat mofetil en steroïden leidt tot een verandering in de geheugen T en 
B cellen in vergelijking met vóór de transplantatie. Toevoeging van rituximab naast 
de standaard combinatietherapie resulteerde in een langdurige afwezigheid van 
B cellen in het bloed. Wanneer na verloop van tijd nieuwe B cellen in het bloed 
terugkomen, zien we een verrijking van CD24hiCD38hi transitionele B cellen. In 
bepaalde situaties wordt de aanwezigheid van relatief meer transitionele en naïeve 
B cellen na rituximab behandeling geassocieerd met een beter klinisch resultaat, 
waarschijnlijk omdat er B cellen met regulerende functie aanwezig zijn binnen de 
transitionele B cellen.
E! ecten naast B cel depletie
B cellen hebben verschillende functies. Na activering kunnen B cellen prolifereren 
en di# erentiëren in cellen die verschillende ontstekingseiwitten kunnen produceren, 
antigenen kunnen presenteren aan T cellen of antilichamen produceren. Al deze 
processen kunnen door rituximab beïnvloed worden. Om de directe e# ecten van 
rituximab op B cellen te bestuderen, hebben we in hoofdstuk 4 B cellen geïsoleerd 
uit bloed van gezonde vrijwilligers en gekweekt met of zonder rituximab. Uit de 
analyses bleek dat rituximab de proliferatie van naïeve maar niet van geheugen 
B cellen remt, waardoor de verhoudingen tussen de verschillende B cellen 
veranderen. Wanneer de aan rituximab blootgestelde B cellen gebruikt werden om 
antigenen te presenteren aan T cellen, waren er meer geactiveerde T cellen die 
het cytokine IL-4 produceerden dan wanneer onbehandelde B cellen antigenen 
presenteerden aan T cellen. Uit eerder onderzoek was al bekend dat behandeling 
van rituximab de B cellen in het bloed goed kan depleteren, maar dat er in lymfoïde 
organen B cellen overblijven. Hoofdstuk 5 beschrijft het e# ect van rituximab op de 
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B cellen in lymfeknopen van niertransplantatiepatiënten.. De overgebleven B cellen 
in de lymfeknopen waren met name geheugen B cellen. Na stimulatie van allogene 
T cellen met B cellen uit lymfeknopen van rituximab-behandelde patiënten, waren 
er minder geactiveerde T cellen die het cytokine IL-17 produceerden. Er blijven dus 
na behandeling met rituximab B cellen over die andere functionele eigenschappen 
hebben. Dit betekent dat het e# ect van rituximab op de immuunrespons niet alleen 
bepaald zal worden door de mate van B cel depletie, maar ook door de functionele 
eigenschappen van de overgebleven B cellen. 
Een bijwerking na behandeling met rituximab van patiënten met B cel kanker 
kan zijn dat er kort na de infusie grote hoeveelheden van bepaalde cytokines 
geproduceerd worden. Deze verhoging kan tot een immuunreactie kunnen 
leiden, wat nadelige gevolgen zou kunnen hebben. In hoofdstuk 6 is dit voor 
niertransplantatiepatiënten geëvalueerd. Toediening van rituximab leidde tot een 
specifi eke cytokine productie, met verhoogde concentraties van het regulerende 
cytokine IL-10 en het cel-aantrekkende eiwit MIP-1β. Deze eiwitten kunnen de 
immuunrespons beïnvloeden. 
In hoofdstuk 7 worden de bevindingen samengevat en bediscussieerd vanuit 
een breder oogpunt. De resultaten besproken in dit proefschrift tonen aan dat 
rituximab direct de B cellen kan beïnvloeden. Hierdoor zal het e# ect van rituximab 
op het immuunrespons niet alleen bepaald worden door de mate van B cel depletie, 
maar ook door de functionele eigenschappen van de overgebleven B cellen. De 
relatieve verhoging van het aantal regulatoire B cellen na rituximab behandeling 
kan positieve gevolgen hebben op de lange termijn. Uiteindelijk zal het klinische 
e# ect van anti-B-cel bepaald worden door de balans tussen e# ector en regulatoire 
B cellen. Daarom zou toekomstige therapie zich meer moeten richten op selectieve 
depletie of verandering van de B cel subtypes. 
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Het laatst geschreven, maar het meest gelezen hoofdstuk van dit proefschrift... 
Toch kan ik iedereen aanbevelen om de hoofdstukken hiervoor ook te lezen, of in 
ieder geval door te bladeren om een idee te krijgen waar ik me de afgelopen jaren 
mee bezig heb gehouden ☺.
Meer dan bij alle andere hoofdstukken fl itsen er allerlei gedachten, herinneringen 
en gezichten door mijn hoofd. Allereerst gaat mijn dank uit naar iedereen die direct 
dan wel indirect heeft bijgedragen aan het tot stand komen van dit proefschrift. 
Een aantal mensen wil ik in het bijzonder noemen:
Mijn promotoren: Irma en Luuk, bedankt dat jullie mij de mogelijkheid en vertrouwen 
hebben gegeven om dit promotietraject in te gaan! Irma, door de juiste vragen te 
stellen, wist jij altijd de lijn weer helder te krijgen. Luuk, je scherpe blik, oog voor 
detail en vaak snelle reacties op manuscripten hebben me erg geholpen. Door jullie 
verschillende achtergronden bleef de brede context en de klinische relevantie 
altijd in beeld, wat ik heel prettig vond. Ik heb veel van jullie geleerd. Zonder jullie 
was dit proefschrift er nooit geweest!
Ook Hans en Marije, mijn copromotoren, wil ik ontzettend bedanken voor de fi jne 
samenwerking. Hans, als mijn stagebegeleider, heb je me als eerste enthousiast 
gemaakt over de e# ecten van rituximab. Ik ben heel blij dat Irma, Luuk en jij een 
projectvoorstel bij de Nierstichting hebben ingediend wat heeft geresulteerd tot 
sponsoring van dit promotietraject. Marije, bedankt voor je kritische commentaar 
op onze resultaten en manuscripten. Door jou zijn de manuscripten iets “sexier” 
geworden ☺.
 
Bram en Marina, mijn paranimfen, heel erg bedankt voor jullie ondersteuning. Bram, 
jouw enorme brede kennis heeft me enorm geholpen door de jaren heen, zelfs nu 
ik in Utrecht werk ☺. Daarnaast heb je me ontzettend geholpen in de laatste fase. 
Marina, bedankt voor het opwerken en organiseren van (bijna) alle samples van de 
rituximab-studie. Ook kon ik altijd met een andere (praktische) vragen bij je terecht.
Mijn kamergenoten door de jaren heen: Jorieke, Diana, Sip, Vivian, Xuehui, Claire, 
Clive en mijn (oud) collega’s van het kweeklab: Bram, Marina, Esther van Rijssen, 
Esther Fasse, Ronald, Jos. Bedankt voor de goede sfeer op het lab, alle hulp en de 
gezelligheid!! 
Samenwerken is heel belangrijk om tot een mooi (wetenschappelijk) eindresultaat 
te leiden. Alle coauteurs bedankt voor jullie bijdrage!
Ook dank aan de andere collega’s. Binnen het LMI, in het bijzonder het DNA lab, 
Henk en Kjeld bedankt voor de SNP analyses deels beschreven in hoofdstuk 6. Maar 
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ook alle collega’s van het fl ow cytometrie unit van het hematologie lab. Bedankt 
voor de gezelligheid, hulp en tips tijdens de vele uren die ik achter de FACS heb 
doorgebracht. 
De mensen van afdeling Nierziekten ben ik dankbaar voor het voor mijn onderzoek 
broodnodige patiëntengegevens en -materiaal en in het bijzonder, Martijn. De 
rituximab-studie die (grotendeels) door jou werd georganiseerd is onmisbaar 
geweest voor het tot stand komen van dit proefschrift. Ook de medewerking van 
de patiënten en donoren is hier natuurlijk onmisbaar. 
De masterstudenten die ik heb mogen begeleiden tijdens mijn promotietraject: 
Kyra en Ellen. Het is mooi om te zien hoe enthousiast jullie waren en ik hoop dat 
jullie dat nog steeds zijn. Kyra, je hebt de start gemaakt met het project naar de 
e# ecten van complement en rituximab op milt B cellen, wat uiteindelijk geresulteerd 
heeft in een mooie publicatie. Ellen, ook al staan geen van je stageresultaten in dit 
proefschrift beschreven, heb ik veel van je geleerd over B cel stimulaties. Ik wens 
jullie veel succes met jullie promoties!
Ontspanning is tijdens een promotietraject ook heel belangrijk! Lieve vriend(inn)en 
bedankt voor jullie steun, gezelligheid en ontelbaar veel mooie herinneringen. Dat 
de feestjes, weekendjes weg en andere gezamenlijke activiteiten vooral zo door 
mogen gaan!   
Tot slot wil ik het thuisfront bedanken: mijn familie (in Nederland en Bulgarije) 
en schoonfamilie. Iedereen heeft op zijn eigen manier iets bijgedragen. Bedankt 
voor de interesse en vragen die jullie hadden de afgelopen jaren. Mijn ouders wil 
ik bedanken voor hun steun en vertrouwen. Татко, баба и дядо: въпреки че ви е 
трудно да си представите и разберете с какво точно се съм занимавала последните 
години, винаги се интересувахте зa мен и мойта работа. Благодаря за вашият интерес 
и подкрепа!
Ben, bedankt voor al je steun, liefde en eindeloos geduld! Maar vooral ook voor de 
afgelopen 14 jaar en de leuke momenten die we samen al hebben mogen delen. Dat 
we nog lang samen mogen genieten van het leven. Ik hou van je!

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Elena Kamburova werd geboren op 2 oktober 1984 te Sofi a, Bulgarije. In 1998 
verhuisde ze naar Nederland. Na een jaar Nederlands leren op een internationale 
middelbare school in ‘s Hertogenbosch, ging zij naar het naar het Zwijsen college 
in Veghel. In 2004 behaalde zij haar VWO-diploma en begon zij aan haar studie 
Biologie aan de Radboud Universiteit Nijmegen. In haar bachelorstage, onder 
begeleiding van dr. Waander van Heerde op de afdeling Hematologie van het 
Radboudumc in Nijmegen, onderzocht zij verschillende mutaties in het Annexine 
A2 gen in von Willebrand patiënten. Hiermee behaalde zij in 2007 haar Bachelor 
diploma. Zij vervolgde haar studie met de Master Medische Biologie waarvoor zij 
nog twee onderzoeksstages uitvoerde. Eerst heeft zij tien maanden stage gelopen 
op de afdeling Laboratoriumgeneeskunde - Laboratorium Medische Immunologie 
(LMI) van het Radboudumc in Nijmegen onder begeleiding van dr. Hans Koenen 
en Prof. dr. Irma Joosten waar zij het e# ect van rituximab onderzocht op witte 
bloedcellen. Ter afronding van haar opleiding verrichte zij in 2008/2009 een stage 
van negen maanden op de afdeling Toxicology and Drug Disposition van Organon 
N.V. in Oss. Onder begeleiding van dr. Wim Schoonen en dr. Walter Westerink heeft 
zij een laboratoriumtest ontwikkeld die gebruik kan worden om de toxiciteit van 
potentiële nieuwe medicijnen te testen. Na het behalen van haar Master of Science 
diploma in 2009 begon zij in oktober van dat jaar aan haar promotieonderzoek bij 
het LMI van het Radboudumc in Nijmegen. Onder begeleiding van Prof. dr Irma 
Joosten en Prof. dr. Luuk Hilbrands voerde zij het onderzoek uit wat geresulteerd 
heeft in dit proefschrift. Tijdens haar promotieonderzoek heeft zij verschillende 
bachelor- and masterstudenten begeleid. Aanvullend heeft zij het RIMLS PhD 
programma gevolgd. Daarnaast was zij van eind 2011 tot en met 2013 lid van de RIMLS 
programma commissie en heeft zij, in samenwerking met andere commissieleden, 
tweemaal de jaarlijkse RIMLS PhD retraite georganiseerd.
Vanaf mei 2014 is zij werkzaam op het Laboratorium Translationele Immunologie 
van het Universitair Medisch Centrum in Utrecht als postdoctoraal onderzoeker 
op een door de Nierstichting gesponsord Profi ling Consortium of Antibody 
Repertoire and E# ectorfunctions (PROCARE). Binnen PROCARE werken 
laboratoriumspecialisten en nefrologen van alle Nederlandse transplantatiecentra 
samen om over vier jaar beter te kunnen voorspellen wélke donornier het beste past 
bij wélke nierpatiënt. En daarmee afstoting voorkomen. Die betere match tussen 
donornier en ontvanger maakt dat de donornier langer goed blijft functioneren en 
de wachtlijst korter wordt.
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